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Oligodendrocytes, the myelin-forming cells in the Central Nervous System (CNS) 
of vertebrates, mature through a highly regulated but precisely timed differentiation 
process. The mechanisms underlying this differentiation process are under extensive 
investigations in the past decades. 
Silent information regulator-2 (SIR2) proteins regulate lifespan of diverse 
organisms. In mammals, SIR2 are represented by seven members SIRT1-7, which are 
also collectively called Sirtuins. In the nervous system, though implicated to be 
important by many evidences, Sirtuins are still largely mysterious in their expression 
patterns, functional roles and action mechanisms. In addition, polymorphisms or 
mutations of Sirtuins are well documented, but the significance of these variations for 
health and diseases of the host cell or organism is essentially unknown. 
The current study, on the first hand, shows that Sirtuin 2 (SIRT2) is an 
oligodendroglial cytoplasmic protein enriched in the outer and juxtanodal terminal 
loops in the myelin sheath. Among cytoplasmic proteins of OLN-93 oligodendrocytes, 
α-tubulin was the main substrate of SIRT2 deacetylation. In cultured primary 
oligodendrocyte precursors (OLPs), SIRT2 emergence accompanied elevated 
α-tubulin acetylation and OLP differentiation into the pre-maturity stage. siRNA 
knockdown of SIRT2 increased OLPs’ α-tubulin acetylation, myelin basic protein 
(MBP) expression and cell arbor complexity. SIRT2 overexpression had opposite 
effects, and counteracted the cell arborization-promoting effects of overexpressed 
juxtanodin (JN). Specific SIRT2 mutations concomitantly reduced its deacetylase 
activity and inhibition on OLP arborization.  
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Summary 
On the other hand, our study showed that overexpression of specific rSIRT2 
mutants induced formation of prominent cytoplasmic aggregates containing both the 
mutated rSIRT2 and native cellular proteins including 2’, 3’-cyclic 
nucleotide-3’-phosphodiesterase (CNP) and ubiquitin. But deacetylase activity loss 
could not account for the aggregate formation because siRNA knockdown of 
endogenous rSIRT2 did not replicate similar phenomenon, nor did overexpression of 
some enzymatically defective rSIRT2 mutants. By contrast, the current study 
identified solubility decrease as a direct result of SIRT2 mutations, which are 
inversely correlated to the aggregate formation propensities of rSIRT2 mutant proteins. 
Stabilization of the microtubule network or knockdown of innate histone deacetylase 
6 (in 293T cells) reduced the number of aggregate-positive cells caused by rSIRT2 
mutants. Furthermore, the results showed that a unique 37-residue N terminus domain 
of hSIRT2 (hNter) endowed mutated hSIRT2 or rSIRT2 a protection from solubility 
loss and aggregation; this domain also inhibits the solubility decreases after mutation.  
These results firstly demonstrated a counterbalancing role of SIRT2 against a 
facilitatory effect of tubulin acetylation on oligodendroglial differentiation. Secondly, 
these results suggested contribution of solubility decrease to aggregate formation or 
cytotoxicity of specific SIRT2 mutants. Also, the 37aa hNter domain may be a crucial 
evolutionary improvement from rat to human, enhancing normal protein solubility and 
function. It calls for further investigations to test the role of SIRT2 in myelinogenesis, 
oligodendroglial differentiation and myelin-axon interaction. Future studies will also 
be necessary and important to understand Sirtuins’ polymorphisms and mutations in 
 xviii
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the context of brain aging, neurodegenerative diseases and dys- or demyelination as 
















1. Oligodendrocytes in the central nervous system 
1.1 Cell types in the nervous system 
The nervous system can be divided into Central Nervous System (CNS) or 
Peripheral Nervous System (PNS) based on their distinctiveness in anatomical 
distribution and function. Both at the cellular level consist of nerve cells (neurons) 
and glial cells (glia). Neurons are the main signaling units of the nervous system, and 
typically defined by four morphologically distinct regions: the nerve cell body, the 
axons, the dendrites and presynaptic terminals. Each of these four regions bears 
distinctly different functions in the generation and maintenance of information 
communication in the nervous system. Among these four regions, axons are 
specialized branches extending from neurons, which are long and tubular processes 
acting like antennas to convey signals to target cells. When neurons need to transmit 
signals, electrical signals have to be generated and propagated through axons. These 
electrical signals called action potentials are usually rapid, transient, all-or-none nerve 
pulse.  
The other main class of cells in nervous system is glia. Firstly described by 
Virchow in 1846, gial cells were classically thought to be the connective tissue of 
brain at that time. They represent a large majority of cells in nervous system and 
greatly outnumber neurons by 10 to 50 times in vertebrate CNS. In addition to 
traditional supportive roles, findings in recent years have demonstrated the active 
participation of gila in the physiology of the brain and the adverse consequences of 
their dysfunction (Baumann and Pham-Dinh, 2001). There are four main glial cell 
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types in the nervous system: astrocytes, microglia, oligodendrocytes and Schwann 
cells. As the most numerous glial cells, astrocytes are largely supportive cells in the 
nervous system that are star-shaped and bear long processes. These cells may play 
roles in nourishing neurons, and some astrocytes can employ the endothelial cells of 
blood vessel to form tight junctions, creating the protective blood brain barrier in 
between blood and brain. Meanwhile, astrocytes can help to maintain or regulate 
concentrations of some ions or transmitters to protect neurons and guarantee normal 
neuronal functions (Kandel et al., 2001). Microglias are phagocytic cells residing in 
the nervous system, which can be activated after injury, infection or disease. Though 
these cells function in nervous system, it is still debated as whether microglias are 
physiologically and embryologically related to the other cell types of the nervous 
system because they arise from macrophages outside. Upon activation, microglia will 
extend processes stouter and more branched and may serve as antigen presenting cells 
in the nervous system. They are proposed to be activated in a series of diseases 
ranging from multiple sclerosis (MS) to Parkinson’s disease (PD) and Alzheimer’s 
disease (AD) (Kandel et al., 2001). 
Oligodendrocytes and Schwann cells are two types of insulating cells, which 
function in different parts of nervous system. Oligodendrocytes exist in CNS whereas 
Schwann cells occur in PNS. Both of them work to wrap around axons in a spiral with 
their extended and specialized membranous processes. These processes around axons 
are called myelin sheath and this insulation process was named myelination (Kandel 
et al., 2001). By myelination, nerve impulses generated in excited neurons propagate 
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more rapidly along the shaft of myelinated axons.  
 
1.2 Oligodendrocytes  
Oligodendrocytes are specialized cells to fulfill the myelination function in the 
CNS. The term oligodendrocytes, or its interchangeable synonym oligodendroglia that 
was named by Rio Hortega (Hortega, 1921), are initially used to describe cells in the 
CNS that show few processes in material stained by metallic impregnation techniques. 
Oligodendrocytes are generated from multipotent neuroepithelial cells (Chandran et 
al., 1998), and their specialized myelin-forming function was endowed by a precisely 
regulated differentiation process. Along lineage progression, the sequential and timed 
expression of developmental regulators as well as gradual morphological 
differentiation divides the whole lineage into several distinct genotypic and 
phenotypic stages (Baumann and Pham-Dinh, 2001).  
 
1.2.1 Differentiation of oligodendrocytes  
The end-point of oligodendrocyte differentiation is to be functionally complete 
cells to form myelin sheaths around multiple axons that facilitates saltatory nerve 
conductions (Baumann and Pham-Dinh, 2001; Franklin, 2002). Oligodendrocytes 
experienced several distinct stages of differentiation till maturation in order to 
produce all the specific constituents of myelin sheaths and fulfill the myelination 
function. These stages can be generally divided into precursors, pre-oligodendrocytes, 
pre-maturity oligodendrocytes (immature oligodendrocytes), non-myelinating mature 
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oligodendrocytes and myelinating mature oligodendrocytes. Different stages are 
characterized by different proliferative capacities, migratory abilities and 
morphologies (Barry et al., 1996; Baumann and Pham-Dinh, 2001). The progression 
from precursors to myelinating oligodendrocyte entails a sequence of events, 
including cell cycle exit, cytoskeletal changes and synthesis of myelin components.  
On the one hand, oligodendrocytes undergo striking changes in shapes during 
lineage progression. They develop from mono- or bipolar to multipolar morphology 
as shown in Figure 1.1. The eventual outcome is that the myelinating 
oligodendrocytes appear to be highly branched and complex (sometimes with wooly 
or hairy fine processes or even form lamellipodia structure) that they are able to 
extend their membranes to complete the myelination by wrapping around axons 
(Pfeiffer et al., 1993). On the other hand, a series of molecules are sequentially 
expressed in a timed fashion. The precursors of oligodendrocytes originated from 
distinct locations of CNS during late embryonic development. These cells can be 
stained by the monoclonal antibody (mAb) A2B5, which recognizes several 
gangliosides (Eisenbarth et al., 1979; Fredman et al., 1984). A2B5 immunoreactivity 
was accompanied by the expression of platelet-derived growth factor receptor α 
(PDGFRα, Hall et al., 1996). The mRNA of DM-20 coding a PLP (proteolipid protein) 
isoform can also be detected in this stage (Timsit et al., 1995). Some other markers are 
also used to observe early stage oligodendrocytes, such as NG2 proteoglycan 
(Nishiyama et al., 1996). When the cells further differentiate, they enter the second 
stage—pre-oligodendrocytes. The gene expressions in these cells are significantly 
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changed in comparison to precursor cells. Most cells in this stage cannot be identified 
by A2B5 immunoreactivity, PDGFRα or DM-20 expression. But they are 
immuno-positive to a mAb O4, which designates that these cells remain in their 
proliferative status, whereas the positivity of another mAb O1 is usually considered as 
the exit of proliferation (Sommer and Schachner, 1981; Tang et al., 2001).  
 
Figure 1.1 Oligodendrocytes differentiate in morphology 
 
Table 1.1 Typical gene expression in each oligodendrocyte differentiation stage 
 
Development stages Typical gene expression 
precursors A2B5, GD3, NG2, PDGFRa, DM-20 
pre-oligodendrocytes A2B5, GD3, NG2, O4, PDGFRa, DM-20 
immature oligodendrocytes O4, GalC, CNP, DM-20, JN 
mature oligodendrocytes O4, GalC, CNP, MBP, PLP, MAG, JN 
myelinating oligodendrocytes O4, GalC, CNP, MBP, PLP, MAG, MOG, JN 
 
To acquire maturation, more genes are programmed to be expressed, many of 
which are oligodendrocyte specific molecules, such as CNP, MBP, JN and PLP (Table 
1.1). At the same time, the genes or proteins detected in precursors or 
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pre-oligodendrocytes mostly disappeared.  
 
1.2.2 Molecules and mechanisms controlling oligodendrocyte development 
A proper development program of oligodendrocytes from precursors until 
myelinating mature cells may require successful fate specification, proliferation, 
differentiation and myelination.  
a. Morphological development of oligodendrocytes 
First of all, dynamic arrangements of the cytoskeleton are required to confer cell 
migration, morphological differentiation and cytoplasmic spreading during 
myelination. For example, Fyn tyrosine kinase activity is important for the 
morphological differentiation (Osterhout et al., 1999). Studies also found matrix 
metalloproteinase, such as MMP-9, helps oligodendrocytes to extend their processes 
(Uhm et al., 1998; Oh et al., 1999). A recent report showed that Sec8 is a molecular 
important for oligodendrocyte morphological differentiation (Anitei et al., 2006). Via 
regulation of myosin phosphorylation and actomyosin assembly, Rho kinase functions 
in coordinating the movement of glial membrane to enwrap the axon in the onset of 
myelination (Melendez-Vasquez et al., 2004). Other cytoskeleton-associated 
oligodendroglial proteins are crucially involved in process outgrowth, gene expression, 
and/or myelin–axon interaction, such as CNP, JN, and the kelch-related actin-binding 
protein mayven (Jiang et al., 2005; Lee et al., 2005; Zhang et al., 2005). 
b. Extracellular signals affecting oligodendrocyte differentiation 
During CNS development, oligodendrocytes and other cell types shared the same 
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precursor cells, which are multipotent neuroepithelial cells (Chandran et al., 1998). 
Several molecules are found to be crucial to lead these cells into the program towards 
oligodendrocyte fates. For example, studies have shown that sonic hedgehog protein 
is both necessary and sufficient to induce oligodendrocyte fate specification (Trousse 
et al., 1995; Poncet et al., 1996; Pringle et al., 1996). Neuregulin/GGF at high levels 
was revealed as an inhibitor of lineage commitment of oligodendrocyte precursors 
(Canoll et al., 1996).  
Cell cycle exit is a prerequisite for oligodendrocyte differentiation. Thus after 
adopting an oligodendrocyte lineage fate, these precursor cells either enter 
differentiation or keep proliferating. PDGF and basic fibroblast growth factor (bFGF) 
are two of the factors that play roles against differentiation but favoring proliferation 
of oligodendrocyte precursors (McKinnon et al., 1990; Barres and Raff, 1994). On the 
basis of such properties, these two growth factors are usually used for in vitro cell 
culture to induce a continuously proliferative population of oligodendrocyte precursor 
cells (Bogler et al., 1990). In addition, other growth factors such as insulin-like 
growth factor-1, neuregulin as well as neurotrophins such as brain derived 
neurotrophic factor and neurotrophin-3 are also shown to be mitogenic to promote 
proliferation (Lu et al., 2002; Casaccia-Bonnefil and Liu, 2003). Conversely, diverse 
factors promote oligodendrocyte differentiation, ranging from transforming growth 
factor-β (McKinnon et al., 1993), β-adrenergic receptor agonists (Ghiani et al., 1999) 
and thyroid hormone (Barres et al., 1994; Ahlgren et al., 1997). On controlling the 
proliferation/differentiation axis of oligodendrocyte precursors, the importance of a 
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couple of other elements, including chemokines (Robinson et al., 1998), cytokines 
(Benveniste and Merrill, 1986) are also known. In addition, differentiation of 
oligodendrocytes is greatly affected by the signaling molecules from axons. For 
example, the maturation of oligodendrocytes was promoted by the interaction of its 
surface Notch receptors with F3/contactin, which is expressed by axons (Hu et al., 
2003). LINGO-1 is another oligodendroglial protein that receives signals from axons 
and negatively regulates oligodendrocyte differentiation and maturation (Mi et al., 
2005; Zhao et al., 2007).  
c. Intrinsic mechanisms regulating oligodendrocyte differentiation 
Besides the external cues, oligodendrocytes have a built-in mechanism (also 
called the internal clock) which helps the cells exit from dividing and proceed to 
differentiation at a proper time (Barres et al., 1994; Barres and Raff, 1994). External 
molecules mostly function via modulating this internal clock to control proper 
oligodendrocyte differentiation. 
The internal clock comprises of two aspects, one is a timing component which 
measures the elapsed time or dividing times; the other is effector component working 
to stop cell division and initiate differentiation (Raff et al., 2001). An early study by 
Temple and Raff (1986) showed that the maximum dividing times for an 
oligodendrocyte precursor cell is approximately eight, after which its daughter cells 
simultaneously cease proliferating and differentiate into oligodendrocytes (Temple 
and Raff, 1986). A recent report showed p57kip2 represents one of the molecules 
acting as a part of the timing components (Dugas et al., 2007). p57kip2 belongs to 
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Cip/Kip protein family, which are cyclin-dependent kinase inhibitor proteins that 
inhibit cyclinE-cdk2 complex formation (Cunningham and Roussel, 2001). This 
complex formation relates to G1-S phase checkpoint regulation and cell cycle arrest 
(Ghiani and Gallo, 2001). Dugas et al. (2007) found in vitro, that the levels of p57kip2 
in oligodendrocyte precursors increased over time when the cells proliferate. The 
higher levels of p57kip2 inhibited precursors’ proliferation and finally rendered them 
responsive to external differentiation cues (Dugas et al., 2007).  
Many studies and evidences are reported on the effector component of the 
internal clock. Transcription factors including homeodomain family, bHLH proteins, 
and high-mobility-group (HMG) family proteins are demonstrated to play important 
roles at various stages of oligodendrocyte differentiation and myelination (Qi et al., 
2001; Lu et al., 2002; Zhou and Anderson, 2002; Stolt et al., 2003 and 2004; Sohn et 
al., 2006).  
Homeodomain transcription factors comprise of several subgroups including 
paired-type, Nk-type and POU domain proteins (Wegner, 2000). Nkx2.2 and Nkx6.2 
belong to Nk-subtype are essentially involved in oligodendrocyte differentiation and 
myelination. In Nkx6.2 null mice, proteins in paranodal junction such as Nf 155 and 
contactin/F3 are abnormally expressed and myelinated axons are severely 
disorganized (Southwood et al., 2004). The number of MBP and PLP expressing 
oligodendrocytes dramatically decreased and myelination is delayed in Nkx2.2 
knock-out mice (Qi et al., 2001). Also, POU domain proteins Oct-6 is important for 
myelination onset as its deficiency caused the delay of the later (Bermingham et al., 
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1996; Ghazvini et al., 2002). 
bHLH proteins are important regulators of development in various cell types. In 
oligodendrocytes, Olig1 and Olig2 are two closely related factors that start to express 
in precursor stage. Olig2 is necessary for specification of oligodendrocytes while 
Olig1 may be involved in repairing demyelination in patients with MS (Zhou et al., 
2001; Lu et al., 2002; Zhou and Anderson, 2002; Arnett et al., 2004). 
Sox proteins contain a HMG domain where they can bind DNA to modulate gene 
transcription. Sox10 for example is expressed in both oligodendrocytes and Schwann 
cells (Kuhlbrodt et al., 1998). In Sox10-deficient mice, progenitors of oligodendrocyte 
develop, but the terminal differentiation of the cell is disrupted (Stolt et al., 2002). 
Study also showed Sox10 regulate the transcription of adhesion molecular connexin32 
and connexin47, which are important for myelin formation and maintenance (Schlierf 
et al., 2006). In other studies, Sox8 and Sox9 are identified as crucial determinants 
affecting oligodendrocyte fate specification (Stolt et al., 2003 and 2005).  
Though great progresses have been made, there are still many largely 
undeciphered areas in oligodendrocyte development and the underlying mechanisms. 
In particular, there seems to be a deficiency in knowledge on how the morphological 








1.3.1 Myelination and myelin 
  Myelination is one of the most pivotal natural inventions in nervous system 
during evolution. The first ensheathed axon may have come into being around 400 
million years ago (Baumann and Pham-Dinh, 2001). These sheaths are made up of 
lipid-abundant insulating myelin. Myelin sheaths around axons comprise of many 
discontinuous segments called internodes, in between which there are periodic 
interruptions ---nodes of Ranvier, where axolemma (surface of axon) are bare. These 
nodes are about 0.5 μm in width and are areas where axons are exposed. High lipid 
content of myelin sheaths, low water content as well as unique segmental structures 
enable these myelinated areas of axons to be insulated so that action potentials can 
“jump” from one unmyelinated node to the next rather than transmitting through 
entire axons. This kind of transmission is called saltatory conduction, which largely 
improved the efficiency and velocity of information transmission in the nervous 
system. Myelin sheaths confer three major advantages to the vertebrate nervous 
system: high-velocity conduction, fidelity of signal transduction across long distances 
and economical space-saving. Upon the invention of myelination, organisms are 
enabled to bear long axons. Also based on this feature, vertebrates can evolve and 






Figure 1.2 Periodic structure of myelin sheath 
 
1.3.2 The polarized myelin sheath in morphology 
Myelin sheaths are radially polarized structures. The transactional structure of 
myelin sheath has been well studied by others (as reviewed in Morell et al., 1994). 
These results demonstrated a periodic structure of myelin sheath, with concentric 
electron-dense and light layers. The electron-dense lines called major dense lines are 
formed by closely opposed cytoplasm of expanding myelinating processes of 
oligodendrocytes. The intraperiodic lines represent two fused outer leaflets, in 
between which are extracellular spaces (Fig. 1.2). Another reflection of the radial 
polarization of myelin sheath is the differential expression of myelin components. 
Myelin associated glycoprotein (MAG), for example, is expressed in adaxonal 
membrane (sheath adjacent to axon), but MBP is in compact myelin whereas 
myelin-oligodendrocyte glycoprotein (MOG) in abaxonal (outside layer of the sheath) 
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membrane (Salzer 1995; Buss and Schwab, 2003). 
 
 
Figure 1.3 Axons myelinated by oligodendrocytes in the CNS 
Adapted from Zhang et al., 2005. 
 
Longitudinally, in between two nodes of Ranvier, each segment of myelin sheaths 
or internode measures 150-200 μm in length. A myelinated axon internode is also 
polarized that it could be divided into three distinct domains: juxtaparanodal region 
(JP), paranodal region (PN), juxtanodal region (JN) (Fig. 1.3 and Zhang et al., 2005). 
Longitudinal polarization of myelinated axons is featured by several other 
characteristics. For example, the ion channels, adhesion molecules and other 
associated cytoskeletal elements that express uniformly on axonal surface of 
unmyelinated or demyelinated axons appear to be asymmetrically distributed on 
myelinated axons. Additionally, in different regions such as paranodes in comparison 
to juxtanodes, the velocity of axonal transport, level of neurofilament phosphorylation 
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or accumulation of membranous organelles vary (Salzer, 2003; Edgar et al., 2004).   
In these distinct regions of the myelin, active interactions happen in between 
axons and oligodendrocytes in CNS (or Schwann cells in PNS). These interactions 
between neurons and oligodendrocytes on one hand affect proper differentiation and 
myelination of oligodendrocytes, and regulate the domain organization of axon on the 
other. Axons regulate oligodendrocyte survival, gene expression and the thickness of 
myelin sheath (Smith et al., 1982; Friedrich and Mugnaini 1983; Chakraborty et al., 
1999; Lopresti et al., 2001; Michailov et al., 2004). Reciprocally, myelinating 
oligodendrocytes and Schwann cells regulate axon caliber, axon domain organization 
and clustering of ion channels and cell adhesion molecules (Sanchez et al., 1996; 
Arroyo and Scherer, 2000; Peles and Salzer, 2000; Rasband and Trimmer, 2001; 
Girault and Peles, 2002; Boiko and Winckler, 2006). 
As mentioned in the previous section, myelin sheaths are generated by 
oligodendrocytes in CNS and Schwann cells in PNS. But the two kinds of myelination 
are different from each other in several important features. For example, one typical 
oligodendrocyte can envelop an average of 15 axonal internodes of different axons. 
But Schwann cells envelop just one internode (see below) of only one axon. 
Additionally, the most extremely outside boundary of Schwann cells, but not of 
oligodendrocytes, harbors a basal lamina structure (Bunge et al., 1986). In basal 
lamina, type IV collagen, laminin and heparin sulphate proteoglycan are demonstrated 
to play pivotal roles in completing the ensheathing process of Schwann cells (Bunge, 
1987). Meanwhile, Schwann cells bear interlinked finger-like microvilli which project 
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closely to nodal axolemma. In the CNS, however, perinodal glial processes take the 
place of microvilli to form contacts with nodes (Bjartmar et al., 1994; Butt et al., 
1999).  
 
1.3.3 The chemical composition of myelin sheath 
Myelin is a poorly hydrated structure, which only contains 40% water in contrast 
to gray matter of the brain (80%). Myelin is also peculiar in its high lipids abundance 
that 70% dry weight of myelin attributed to lipid contents while only 30% is protein 
(Morell et al., 1994). Lipids found in myelin also existed in other membrane 
structures, but a discerning characteristic of oligodendrocytes and myelin lipids is that 
they are rich in glycosphingolipids, especially galactocerebrosides. Of all, GalCs are 
the most typical and enriched lipids responsible for ~20% dry weight of myelin 
(Morell et al., 1994). In addition, many oligodendrocyte/myelin proteins are also 
covalently modified that they also possess hydrophobic properties (Agrawal et al., 
1982). All these features including structure, thickness, low water content and wealth 
in lipids together endowed the myelin sheaths with the insulating capability.  
The proteins in myelin have been extensively investigated and some of the 
well-established ones are specifically expressed in myelin. For example, MBP (Kies 
et al., 1965), PLP and its isoform DM-20 (Folch and Lees, 1951) are most abundant 
components, comprising 80% of the total proteins. There are also CNP (Sprinkle, 
1989) and JN (Zhang et al., 2005), which are more recently identified as myelin 
specific proteins. Several glycoproteins are present in myelin, among which are MAG 
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and MOG (Quarles, 1997). These proteins together participated in almost every aspect 
of the cellular activities of myelin/oligodendrocyte, encompassing cellular 
transportation, structural maintenance and differentiation, even affecting neuronal 
survival and axon/myelin interaction (Baumann and Pham-Dinh, 2001). 
 
2. Histone deacetylase (HDAC)  
2.1 Histone deacetylation: an important modification of histones 
Chromatin can be classified into euchromatin and heterochromatin. 
Heterochromatin represents a tightly packed form of hereditary materials, and its 
major characteristic is that transcription of genes is limited. Chromatins comprise of 
nucleosomes, each of which consists of ~146 bp of DNA wrapping around a histone 
octamer. One histone octamer is a complex made up of two molecules of the four core 
histone proteins, H2A, H2B, H3 and H4 (Kornberg, 1977). The amino acid terminals 
protruding from the nucleasomes, that is the N-terminal tail domains of those core 
histone proteins are prone to many different post-translational modifications including 
acetylation, methylation, ubiquitination, glycosylation, ADP ribosylation, 
carbonylation, sumoylation, biotinylation and phosphorylation (Strahl and Allis, 
2000).  
The first piece of investigation linking enhanced histone acetylation with active 
genes dated back to the work by Vincent Allfrey (Allfrey et al., 1964). Accumulated 
evidences in the past 40 years supported this notion that histones in heterochromatin 
are usually poorly acetylated and their acetylation is positively correlated with gene 
 17
Introduction 
transcription activity (Grewal and Elgin, 2002; Clayton et al., 2006). This correlation 
can be illustrated by highly acetylated histone H4 in chromatin near the active chicken 
globin gene (Hebbes et al., 1992), the human platelet-derived growth factor gene 
(Clayton et al., 1993), and the Drosophila male X chromosome (Bone et al., 1994). By 
contrast, for example, histone H4 usually is observed to be hypoacetylated at H4 
lysine 5, 8, and 16 positions in human and yeast heterochromatin, in which gene 
transcription is largely repressed (Braunstein et al., 1993; Jeppesen and Turner, 1993).  
The acetylation reaction happens by adding in an acetyl group to ε–amino group 
of specific lysines in N-terminal histone tails. Certain lysine sites of acetylation are 
particularly important in histone that these site-specific histone acetylation and 
deacetylation is involved in various essential processes including nucleasome 
assembly, chromatin folding, heterochromatin silencing, gene transcription and 
expression (reviewed in Shahbazian and Grunstein, 2007). One of the examples is the 
acetylation and deacetylation of histone H4 lysine 16. Its acetylation is preferentially 
found in the transcriptionally hyperactive X chromosome of Drosophila male larvae 
(Turner et al., 1992; Bone et al., 1994). In addition, chromatin compaction and folding 
was determined by acetylation at histone H4 lysine 16, which also prevents the 
spreading of heterochromatin components (Shogren-Knaak et al., 2006).  
The mechanism by which the histone acetylation influences transcription 
regulation is still under debate. Some early studies proposed that conformational 
changes of chromatin and nucleasome would be the direct results of histone 
acetylation. The positive charge of the histone tails will be neutralized by the 
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acetylation so that the affinity between those tails and negatively charged DNA will 
be attenuated. Such an electrostatic release will result in increased accessibility of 
nucleasomal DNA to transcriptional regulators (Kuo and Allis, 1998). Recently, 
several groups of researchers seem to support a completely different function of 
histone acetylation (reviewed in Zeng and Zhou, 2002; Yang, 2004). Findings showed 
that acetylated lysine residues on histone tails can form binding sites for 
bromodomains, which are 110 amino acid long domains found in many chromatin 
associated proteins. This suggests that acetylation will introduce more binding 
opportunities for related proteins to nucleasome. The two kinds of models are 
different. In the conformation-modifying model, if multiple or all the lysine residues 
of a single histone tail are highly acetylated, the net effect would be much stronger 
than that of a single lysine. Whereas if the bromodomain-binding model is correct 
only adjacent amino acids of acetylated lysine determine binding specificity, increased 
number of acetylated lysine residues or even the hyperacetylation of the whole histone 
tail will not yield further increase to the binding properties and recruitment of 
transcription factors. It is possible that both these two models apply under different 
physiological circumstances. Meanwhile, other influential determinants should also be 
taken into consideration to estimate the mechanisms how acetylation influences gene 
activity, such as other covalent modifications of lysine and/or arginine residues on 
histone tails, including histone methylation and phosphorylation. The overall status of 
histones was a compromise between all those forces presented above. Such a status 
provides signals for recruitment of specific chromatin-associated proteins, which in 
 19
Introduction 
turn alter chromatin states and affect transcriptional regulation (Fuchs et al., 2006). 
But it may be important to note that the acetylation of histones is not a stably 
persisting modification, but rather as suggested by recent investigations undergoes 
rapid turnover upon the action of two counteractive but cooperative partners: histone 
acetyltransferases (HATs) and HDACs (Clayton et al., 2006).  
 
2.2 Histone deacetylase family proteins 
In yeast, a series of HDACs have been well investigated. For example, reduced 
potassium dependency protein 3 (RPD3) and RPD1 (also known as SIN3, SD11, and 
UME4) are two of the earliest yeast HDAC members (Vidal et al., 1991; Vidal and 
Gaber, 1991). The recessive mutations of these two proteins are found to augment the 
transcription activity of a subset of yeast genes with various unrelated functions. After 
that, Rundlett et al. (1996) identified Hda1 from transcriptional complexes they 
isolated. Histone deacetylase 1 protein (HDA1) possesses high sequence similarity to 
Rpd3 and affects histone H3 and H4 acetylation to control gene transcription in yeast. 
They also established that Hda1 and Rpd3 represented members of two distinct yeast 
histone deacetylase complexes (Rundlett et al., 1996). 
The correlation between histone deacetylation and repressed gene transcription is 
equally established in mammals. Taunton et al. identified the first mammalian HDAC 
-- HDAC1 with high similarity to Rpd3 in yeast (60% identity at the protein level, 
Taunton et al., 1996). The past decades have witnessed tens of new members being 
enlisted into the HDAC family. On the basis of functional and structural properties, all 
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HDACs are classified into four subgroups or subfamilies----class I, II, III HDACs and 
HD-2 like proteins. But HD-2 like proteins present uniquely in plants and will not be 
discussed in this thesis (Lusser et al., 1997; Chen and Tian, 2007). In mammals, class 
I, II and II HDACs are enzymes respectively homologous to yeast RPD3, HDA1 and 
silent information regulator protein 2 (SIR2, Gray and Ekstrom, 2001). It is 
noteworthy that a common characteristic for almost all HDACs is that their enzymatic 
activity can be inhibited by one or more inhibitors.  
2.2.1 Class I HDACs  
As mentioned above, HDAC1, as the first mammalian member identified, 
possesses high homology to yeast RPD3 (Taunton et al., 1996). After that, several new 
members similar to RPD3 were successively reported by different groups and they are 
named HDAC2, -3, -8 and -11 (Yang et al., 1997; Zeng et al., 1998; Hu et al., 2000; 
Gao et al., 2002;). In addition to the structural similarity, class I HDACs are 
predominantly nuclear proteins expressed in most tissues and cell lines. All these five 
homologues of yeast RPD3 seem akin to each other on the basis of their functions. 
For example, all these five members are found to form protein complex with 
corepressors to inhibit gene-specific transcription. Two core complexes they formed 
are Sin3 and Mi-2/Nurd complex (reviewed in Knoepfler and Eisenman, 1999). Many 
other repressor complexes were also reported to contain one or several members of 
these four, such as TGIF/Smads (Wotton et al., 1999), glucocorticoid receptor (Ito et 
al., 2000), Groucho (Choi et al., 1999), Hus1/Rad9 (Cai et al., 2000), Retinoblastoma 
protein (Brehm et al., 1998), N-CoR (Li et al., 2000) and DNA methyltransferase 1 
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(Robertson et al., 2000). Class I HDACs also interact with a variety of other important 
proteins, such as Snail (Peinado et al., 2004), β–catenin (Billin et al., 2000), HOXB7 
(Chariot et al., 1999), MBP-1 (Ghosh et al., 1999) and p65 (Ashburner et al., 2001).  
Class I HDACs are crucial and versatile regulators of cell growth, differentiation 
or apoptosis in both physiological and pathological conditions. For example, the 
abnormal downregulation of HDAC3 and other class I HDAC members were found in 
human colon cancer cell lines (Wilson et al., 2006). Corepressor complexes 
containing HDAC1 and other class I HDACs play important roles in adipogenesis 
(Wiper-Bergeron et al., 2003; Lagace and Nachtigal, 2004). More recently, HDAC1 
and HDAC2 are found to regulate cardiac morphogenesis, growth and contractility 
(Montgomery et al., 2007).  
2.2.2 Class II HDACs 
As homologues to yeast HDA1, class II HDACs comprise of a total 7 members, 
which are further subdivided into two subclasses, IIa (HDAC4, -5, -7, -9 and HDAC9 
splice variant MITR) and IIb (HDAC6 and HDAC10) (reviewed in Verdin et al., 
2003). A ~420 amino acids C-terminal catalytic domain is shared by all class II 
HDACs. However, their N-terminal domains seem to not have similarity with other 
proteins. One exception is MITR, the HDAC9 splice variant, which only has 
N-terminal domain but not C-terminal deacetylase domain. In analogy to Class I 
HDACs, these class II members incorporate into different corepressor complex to 
regulate gene transcription and expression. In addition to MEF2 family proteins as 
their major binding partners, class II HDACs also form complexes with E1A 
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C-terminal binding protein (CtBP, Chinnadurai, 2002), 14-3-3 proteins (Wang et al., 
2000), calmodulin (CaM, Youn et al., 2000), transcriptional co-repressors SMRT and 
N-CoR (Huynh and Bardwell, 1998), heterochromatin protein HP1a and SUMO 
(Kirsh et al., 2002; Zhang et al., 2002). Distinct from Class I HDACs, the activity of 
class II HDACs is also modulated by their tissue-specific distribution and 
translocation in between nucleus and cytoplasm with the help of14-3-3 proteins 
(Wang et al., 2000). 
Among others, the biological functions of Class IIa HDACs include their 
participation in the transcription inhibition of myogenesis (McKinsey et al., 2001) and 
regulation of thymocytes negative selection and maturation (Verdin et al., 2004). 
Recently, HDAC7 is also suggested to be an influential monitor of vascular integrity 
(Chang et al., 2006). Class IIb HDACs are distinct from traditional histone 
deacetylases which are usually localized in the nucleus to modify histone tails. By 
contrast, both HDAC6 and HDAC10 are mostly detected in the cytoplasm. Till now, 
limited information is available about exact function of HDAC10, though it is found 
to function in pre-mRNA processing and development of hepatocellular carcinoma 
after infection (Park et al., 2007; Shimazu et al., 2007). With regard to HDAC6, it 
may function in regulating protein ubiquitination through forming multi-protein 
complex with cytoplasmic partners, such as HDAC6/p97/VCP complex 
(Seigneurin-Berny et al., 2001). It is worth noting that HDAC6 is reported to be a 
cytoskeleton modifying deacetylase which removes the acetyl group from lysine-40 of 
α-tubulin, thus depolymerizing and destabilizing microtubules (Hubbert et al., 2002). 
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In addition, it is implicated in regulating aggresome formation and interaction with 
SIRT2. 
2.2.3 Class III HDACs---SIR2 family of proteins  
Class III HDACs are also well known as silent information regulator 2 (SIR2) 
proteins in yeast or Sirtuins in mammals. They are specially classified as a subfamily 
because they need a cofactor nicotinamide adenine dinucleotide (NAD) to be active as 
HDACs. SIR2 proteins control transcription silencing at ribosomal DNA, HM mating 
type loci and telomeres (Shore et al., 1984; Schnell and Rine, 1986; Smith and Boeke, 
1997; Imai et al., 2000). It suppresses the generation of toxic extrachromosomal DNA 
circles, and mediates the lifespan extension by CR (Sinclair and Guarente, 1997; Lin 
et al., 2002). In mammals, SIR2 is represented by seven homologs (collectively 
named Sirtuins) and related to various important functions such as cell cycle 
regulation, cell differentiation, CR and aging in rodents and in cultured human cells 
(see below for detailed introduction). 
2.2.3.1 SIR2 in lower animals and mammalian Sirtuins  
Yeast Sir2 is initially found to be required for silencing of repeated sequences in 
yeast, including mating type loci, telomeres and rDNA (Shore et al., 1984; Schnell 
and Rine, 1986). These gene-silencing functions allowed sir2 in yeast as an 
aging-related molecular promoting lifespan extension (Sinclair and Guarente, 1997; 
Lin et al., 2002). Similar effects had been revealed for its ortholog (molecules across 
species but shared ancestry during evolution) in C. elegans (Tissenbaum and Guarente, 
2001). The silencing results in compacted, closed and inaccessible chromatin structure. 
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The lysine residues of the amino-terminal tails of histone H3 and H4 were found to be 
particularly required for the silencing (Thompson et al., 1994). Coincidently, these 
amino-terminal lysines are usually subjected to acetylation modification and are 
preferably deacetylated in silencing status (Braunstein et al., 1996). Another study 
indicated that overexpressed Sir2 resulted in global deacetylation of yeast histones 
(Braunstein et al., 1993). All these early results seemed to implicate Sir2 as a histone 
acetylation modifier. However, the role of the gene product as a histone deacetylase 
was not established until the finding by Imai et al., (2000). The authors successfully 
demonstrated that yeast and mouse SIR2 proteins are NAD-dependent histone 
deacetylases, which deacetylate lysines 9 and 14 of H3 and specifically lysine 16 of 
H4. This conclusion was further supported by their discovery that two mutations of 
SIR2 attenuated the deacetylase activity of this protein (Imai et al., 2000).  
SIR2 is highly conserved across species ranging from archaea to humans 
(Brachmann et al., 1995). In mammals, these families of proteins, with a conserved 
Sirtuin core domain as reported by Frye (Frye, 1999 and 2000), are represented by 
SIRT1-7, also interchangeably named Sirtuin 1-7. In the past several years, extensive 
studies have focused on investigating the functions of these seven members. As a 
consequence, they are found to be expressed widely and have essential functions. In 
addition to histones, Sirtuins possess a dozen of other substrates. For example, 
SIRT1’s substrates include p53, Ku70, nuclear factor-B (NF-κB), Forkhead box class 
O (FOXO) and hypermethylated in cancer 1 (HIC1) (Luo et al., 2001; Vaziri et al., 
2001; Brunet et al., 2004; Cohen et al., 2004; Motta et al., 2004; Yeung et al., 2004). 
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For SIRT2, α-tubulin was identified as another substrate in addition to histone tails 
(North et al., 2003). Recently, FOXO1 and FOXO3a were also shown to be 
deacetylated by SIRT2 (Jing et al., 2007; Wang et al., 2007a). There are also a couple 
of substrates found for other Sirtuin members. Through regulating 
acetylation/deacetylation of these substrates, Sirtuins are known as crucial regulators 
of a diversity of cellular functions, ranging from cell cycle regulation, cell 
differentiation and survival, cell metabolism and calorie restriction (CR) related 
anti-aging (reviewed in Haigis and Guarente, 2006; li-Youcef et al., 2007). Meanwhile, 
they (especially SIRT1 and 2) are also of great pathophisological importance in the 
mechanistic understanding as well as clinical treatment of several diseases, such as 
AD, ALS and type II diabetes (Kim et al., 2007; Milne et al., 2007; Outeiro et al., 
2007). 
2.2.3.2 The biochemistry of SIR2 and Sirtuins 
Though classified as Class III HDACs, both SIR2 and Sirtuins possess a 
distinctive NAD-dependent histone deacetylases activity. Frye for the first time 
showed that Sir2 proteins from bacteria, yeast, and mammals could transfer an 
ADP-ribose group from NAD to a protein carrier (Frye, 1999). Later, yeast SIR2 
protein was revealed as indeed an ADP- ribosyltransferase in vitro, and its activity 
was essential for the silencing function in vivo (Tanny et al., 1999). In the report by 
Imai et al., SIR2 was found to be a histone deacetylase, they also indicated that the 
amino-terminal tails of histone H3 or H4 peptides could accept ADP-ribose from 
NAD, but only if the peptides were acetylated (Imai et al., 2000). Another piece of 
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finding by the authors showed that the relative molecular weight of the product was 
actually smaller than that of the substrate, indicating that the major modification 
catalyzed by Sir2 was deacetylation but not ADP-ribosylation. In the absence of NAD, 
SIR2 exhibited no deacetylase activity, which could not be compensated by addition 
of NADH, NADP or NADPH. Studies by other groups confirmed the conculsion that 
SIR2 is a histone deacetylase depending on NAD as a cofactor to be effective (Landry 
et al., 2000; Smith et al., 2000). 
SIR2 and Sirtuins catalyze a reaction in which NAD and an acetylated substrate 
are converted into a deacetylated protein, nicotinamide, and a novel metabolite 
O-acetyl ADP-ribose (Tanner et al., 2000). In this regard, some literatures also called 
this family NAD-dependent deacetylase (NDAC) in comparison to HDAC. The 
metabolite O-acetyl ADP-ribose is proposed to bear certain unique cellular function 
linked to the gene-silencing effect of SIR2 and Sirtuins (Tanner et al., 2000; Borra et 
al., 2002), which may also be an essential factor in physiology (Grubisha et al., 2006) 
2.3.3.3 Biological functions of Sirtuins 
SIRT1 
SIRT1 is the Sirtuin member that received the most extensive investigations. It 
localizes in nucleus and interacts with diverse partners. It is found to regulate CR and 
aging, cell survival, cell differentiation and metabolism (Anastasiou and Krek, 2006). 
Firstly, SIRT1 is a positive master controlling cell growth and survival. Luo et al. 
and Vaziri et al. reported that SIRT1 interacts with and deacetylates p53 both in vivo 
and in vitro (Luo et al., 2001; Vaziri et al., 2001). The biological consequence after 
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p53 deacetylation is the repression of p53-dependent transcription and apoptosis. 
Confirmative evidence came from another study, where a SIRT1 knockout mouse was 
shown to have hyperacetylated p53 (Cheng et al., 2003). SIRT1 also interacts with 
promyelocytic leukemia protein 4 (PML4), which constitutes nuclear bodies as one of 
the distinct substructures of nucleus implicated in the control of cell growth, gene 
regulation and apoptosis (Seeler and Dejean, 1999; Langley et al., 2002). 
Overexpression of PML4 induces the arrest of cell growth, which could be rescued by 
overexpression of SIRT1 (Langley et al., 2002). Together with the report that SIRT1 
deacetylates NF-κB to affect cell survival (Yeung et al., 2004), SIRT1 obviously 
plays a crucial role in cell growth and survival.  
Secondly, SIRT1 is broadly involved in lifespan extension induced by calorie 
restriction (CR). CR refers to a dietary regime, low in calories without undernutrition. 
CR extends life spans in many organisms ranging from rotifers, spiders, worms, and 
fish to rodents and primates (Weindruch, 1996). Physiology of mammalian CR 
involves increased insulin sensitivity and corresponding reductions in blood glucose 
and insulin levels. In response to glucose, insulin is secreted by pancreatic β-cells to 
maintain glucose homeostasis. In this aspect, SIRT1 was a crucial connector of 
glucose metabolism to CR and aging. SIRT1 positively regulates glucose-stimulated 
insulin secretion in pancreatic β-cells (Moynihan et al., 2005). 
Also, SIRT1 promotes the survival of pancreatic β-cells under stress (Kitamura et 
al., 2005). In the liver, SIRT1 deacetylates and activates PGC-1α, which promotes 
gluconeogenesis following fasting (Rodgers et al., 2005). PGC-1α, upon activation by 
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SIRT1, also promotes mitochondrial function in the skeletal muscle and the brown 
adipose tissue, leading to enhanced energy expenditure, increased exercise 
performance, and protection from diet-induced insulin resistance and hepatosteatosis 
(Baur et al., 2006; Lagouge et al., 2006). All these effects in mitochondria are 
associated with longevity extension.   
In addition, SIRT1 has also been shown to deacetylate cytoplasmic Acetyl-CoA 
synthetase 1 (AceCS1), which is an enzyme that controls acetyl-CoA levels in the 
cytoplasm for fatty acid synthesis (Hallows et al., 2006). Since impaired acetate 
metabolism is usually a typical feature in diabetes and aging, this piece of finding also 
implicates a potential role of SIRT1 in pathophysiology of these diseases. Finally, 
SIRT1 is demonstrated to be a central player in modifying diseases of CNS (see 
below). 
SIRT2 
A point also of broad interest is that SIRT2 was found to possess several different 
substrates in addition to histone and play roles in cell cycle regulation, cell 
differentiation and aging. To date, SIRT2 is the only Sirtuin that is localized mainly in 
cytoplasm (North et al., 2003). Sirtuin-2 or SIRT2 is the second family member of 
Sirtuins, which was firstly identified by Frye as a protein with activity to transfer 
radioactivity from [32P]NAD to other proteins (Frye, 1999). After that two other studies 
found that SIRT2 was an enzyme deacetylating α-tubulin and controlling mitotic exit 
of cell cycles (Dryden et al., 2003; North et al., 2003). Recent progresses also 
illustrated a possible linkage of SIRT2 to neurodegenerative diseases. In a mode of 
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PD, inhibition of SIRT2 activity rescues cellular toxicity mediated through 
α-synuclein (Outeiro et al., 2007). In another piece of study on Wallerian 
degeneration mice, SIRT2 upon activation by resveratrol (a nontoxic molecular 
activator of Sirtuins found in Asian medicinal herbs and red wines, see Zhuang et al., 
2003) abolished the resistance of the animal to axonal degeneration (Suzuki and 
Koike, 2007).   
As addressed in previous sections, the proper differentiation of oligodendrocytes 
requires precisely regulated cell cycle exit from proliferative stage on one hand and 
complex morphological arborizations that involve microtubule network reorganization 
on the other hand. SIRT2 is involved in regulating both cytoskeletal elements and cell 
cycle proteins. SIRT2 regulates mitotic cell cycle exit (Dryden et al., 2003) and its 
overexpression delays cell proliferation (North and Verdin, 2007); SIRT2 is also a 
regulator of tubulin acetylation/deacetylation (North et al., 2003). Importantly, in 
tissues other than brain, by regulating the acetylation/deacetylation of FOXO1, SIRT2 
was an essential controller of adipocyte differentiation (Jing et al., 2007). Moreover, 
two independent groups reported that SIRT2 was expressed in oligodendrocytes and 
myelin sheath (Vanrobaeys et al., 2005; Southwood et al, 2007). All these 
investigations raise the possibility that SIRT2 might be a functional player in 
oligodendrocyte differentiation. A proteomic study further strengthened the possibility. 
Hiratsuka et al. found that the expression level of SIRT2 in gliomas biopsy was 
downregulated (Hiratsuka et al., 2003). Because gliomas may happen due to 
uncontrolled differentiation or growth of glial cells, this piece of evidence might 
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implicate a regulative role of SIRT2. All together, evidences seem to implicate an 
undeciphered important role of SIRT2 in oligodendrocyte differentiation or growth.  
Other Sirtuins 
SIRT3 is a mitochondrial Sirtuin deacetylase (Onyango et al., 2002). One recent 
study also showed its expression in nucleus, which translocates to mitochondria upon 
cellular stress (Scher et al., 2007). SIRT3 is linked to adaptive thermogenesis and 
apoptosis regulation (Shi et al., 2005; Allison and Milner, 2007). 
SIRT4, also as a mitochondrial Sirtuin, seems not to possess deacetylase activity 
but instead functions as an ADP-ribosyltransferase (Ahuja et al., 2007). SIRT4 
downregulates glutamate dehydrogenase (GDH) in pancreatic β-cells and counteracts 
the effects of calorie restriction, which seems to be opposite to that of SIRT1 (Haigis 
et al., 2006). 
Knowledge on SIRT5, the third mitochondrial Sirtuin, is still limited to date. It is 
known to bear NDAC activity and may influence the localization of SIRT3 when the 
two Sirtuins are coexpressed (Schuetz et al., 2007; Nakamura et al., 2008).  
SIRT6 is a broadly expressed but predominantly nuclear-localized 
ADP-ribosyltransferase (Liszt et al., 2005). Mostoslavsky et al. established SIRT6 
knockout mouse and demonstrated that this enzyme is a controller of genomic DNA 
stability and repair (Mostoslavsky et al., 2006). In addition, the phenotype of the 
SIRT6 knockout mice mimics multiple pathologies found in elderly humans. This 
study also suggested an in vitro deacetylase activity of SIRT6 using histones and DNA 




understandings of the exact roles and functional partners of SIRT6 are still required. 
SIRT7 is a nuclear protein that correlates with cell growth. It is expressed with 
vast abundance in highly proliferative tissues but low in nonproliferating tissues (Ford 
et al., 2006). It is yet unknown whether SIRT7 possesses enzyme activities like other 
Sirtuins, but study has suggested that it interacts with RNA polymerase I (Pol I) as 
well as with histones and promotes Pol I transcription (Ford et al., 2006). 



















Families Members  Functions 
1) form protein complex with corepressors to inhibit gene transcription Class I 
HDACs 
  
HDAC1, -2, -3, -8, 
-11 
  
homologue to yeast 
RPD3 
  
2) are crucial and versatile regulators of cell growth, differentiation or 
apoptosis in both physiological and pathological conditions 
IIa: HDAC4, -5, -7, -9 
and MITR 
form protein complex with corepressors to inhibit gene expression and 
transcription Class II 
HDACs IIb: HDAC6 and 
HDAC10 
homologue to yeast 
HDA1 localize in cytoplasm; HDAC6 is α-tubulin deacetylase and HDAC10 
functions in pre-mRNA processing 
SIR2 in yeast 1) homologue to yeast SIR2 extends animal lifespan via silencing genes Class III 
HDACs  




SIRT1: (nuclear) deacetylates p53, FOXO3a, PGC-1α, AceCS1 and 
NF-κB, regulates CR, aging, cell survival, differentiation and 
metabolism 
   SIRT2: (cytoplasmic) α-tubulin deacetylase 
   SIRT3: (nuclear/mitochondrial) functions in adaptive thermogenesis and apoptosis regulation 
   
SIRT4: (mitochondrial) is not a deacetylase but a 
ADP-ribosyltransferase, downregulates GDH in pancreatic β-cells, 
counteracting the effects of CR 
   SIRT5: (mitochondrial) affects localization of SIRT3 when the two were coexpressed 
   SIRT6: (nuclear) controls genomic DNA stability and repair 
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SIRT7: (nuclear) correlates with cell growth; interacts with RNA 
polymerase I (Pol I) as well as with histones and promotes Pol I 
transcription 
Table 1.2 Summary of histone deacetylases 
Introduction 
Introduction 
2.3 Involvement of HDACs and Sirtuins in nervous system functions 
As extensively presented above, histone deacetylation is an important regulatory 
mechanism of the transcription activity of chromatins. On the basis of modifying 
histone acetylation, HDACs participate crucially in controlling gene transcription and 
expression. HDACs are also pivotal regulators of cell cycles. In a variety of different 
cell models, the inhibition of HDACs’ activity resulted in cell cycle arrest (Davis et al., 
2000; Finzer et al., 2001; Ryu et al., 2006; Yamashita et al., 2003), which would be 
embedded with a therapeutic hope to control the growth of and induce the apoptosis 
of cancer cells (Kim et al., 2006).  
HDACs control both cell cycle and gene transcription. This raises a possibility 
that HDACs play pivotal roles in cell differentiation. In the nervous system, such a 
possibility was supported by many elegant studies. For example, HDACs participate 
in the formation of transcriptional complexes to regulate neuronal or glial 
differentiation (Ballas et al., 2001; Ballas et al., 2005). Studies have also shown that 
HDACs played roles in regulating neural/glial fate specification in development. For 
example, inhibition of class I and class II HDACs was discovered to induce adult 
neural progenitors to differentiate toward neurons as opposed to a glia fate (Hsieh et 
al., 2004). In other investigations, delayed oligodendrocyte lineage progression and 
thus prolonged differentiation process was observed in presence of attenuated 
activities of class I and II HDACs (Marin-Husstege et al., 2002; Shen et al., 2005). 
These and many other evidences together implicated that HDACs might act 
essentially in oligodendrocyte differentiation. 
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Sirtuins have also been illustrated as crucial players in a variety of physiological 
functions or diseases in the nervous system. This could be firstly evidenced by the 
finding that a protective role against neuronal death and dysfunction lies in resveratrol. 
Treatment with resveratrol can prevent mutant polyglutamine−specific neuronal death 
(Parker et al., 2005). The studies in animal or cell models implicated resveratrol as an 
effective modulator for pathomechanisms of debilitating neurological disorders, such 
as strokes, ischemia, Huntington's disease (HD) or even AD (Anekonda, 2006). Other 
investigations on Sirtuins-modulating drugs or compounds in nervous system diseases 
also yield dramatic evidence supporting the essential roles Sirtuins have been playing 
(Mattson and Cheng, 2006). 
Sirtuins also function in nervous system through regulating CR. As discussed in 
above sections, SIRT1 plays essential regulative roles in the effects of CR. CR 
improves neuronal health, and some studies suggested that the global beneficial 
effects of CR to the lifespan were crucially mediated via improving nervous system 
function. CR protects against neurodegenerative pathology in mouse models for AD 
(Zhu et al., 1999; Patel et al., 2005) and PD (Duan and Mattson, 1999). Accordingly, a 
recent study showed the preventive effects of CR on β-amyloid accumulation in AD 
could be mediated by SIRT1 (Qin et al., 2006). SIRT1 is found to be upregulated in 
mouse models for AD, ALS and in primary neurons challenged with neurotoxic 
insults and promote neuronal survival in cell models. Direct injection of SIRT1 into 
the hippocampus of disease model or application of SIRT1 activators conferred 
significant protection against neurodegeneration or neuronal damage (Kim et al., 2007; 
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Shindler et al., 2007). Moreover, SIRT1 seemed to have a protective role against the 
delayed Wallerian degeneration and in the peripheral nervous system of C57BL/Wlds 
mouse (Araki et al., 2004; Wang et al., 2005). Because mitochondrial dysfunction is 
commonly observed in many neurodegenerative diseases, SIRT1 is even suggested to 
be a central target for pharmaceutical modulation to combat these diseases since 
SIRT1/PGC-1 interaction has an essential role in regulating mitochondria metabolism 
(Rasouri et al., 2007).  
Other members of Sirtuins were also involved in nervous system functions or 
diseases. For example, pathomechanisms of AD may involve the activities of SIRT2, 
SIRT3 (Anekonda and Reddy, 2006), in addition to SIRT1. The expression of SIRT2 
was downregulated in gliomas (a cancer of glial cells) biopsy (Hiratsuka et al., 2003). 
SIRT5 polymorphisms are possibly associated with schizophrenia (Chowdari et al., 
2007). 
 
3. Protein mutations and cellular aggregates 
3.1 Abnormal aggregation of proteins in CNS diseases 
Abnormal accumulation and aggregation of filamentous proteins is considered as 
one of the important characteristics shared by various neurodegenerative diseases or 
disorders, such as AD, PD, HD, prion diseases and some kinds of dementias (Taylor et 
al., 2002; Selkoe, 2003). During the past decade, a variety of etiologically distinct 
diseases have been linked together by the likelihood that they are resulted from the 
progressive misfolding of specific proteins into aggregates that injure and kill cells. 
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Several physicochemical features are typically observed for almost all these protein 
aggregates: fibrillar morphologies, predominantly beta-sheet secondary structures, 
birefringence upon staining with the dye Congo red, insolubility in common solvents 
and detergents, and protease-resistance (Braun, 2005).  
As the cell types to myelinate axons, Schwann cells in PNS and oligodendrocytes 
in CNS were also found to possess similar intracellular aggregations in diseases. For 
example, aggregation-prone mutations of a series of Schwann cell proteins lead to 
inherited motor and sensory neuropathies (HMSN, Berger et al., 2006). Protein 
aggregation in oligodendrocyte existed in diseases ranging from frontotemporal 
dementias with Parkinsonism linked to chromosome 17 (FTDP-17), corticobasal 
degeneration (CBD) and progressive supranuclear palsy (PSP) (Chin and Goldman, 
1996; Goedert et al., 1998; Komori, 1999; Berry et al., 2001).  
 
3.2 Specific protein mutations and aggregates  
Studies have illustrated mutations of proteins as an important factor inducing 
cellular protein aggregation. Typical examples are β-Amyloid in extracellular plaques 
in AD and Parkin and α-synuclein in Lewy bodies in PD (Taylor et al., 2002); 
mutations of huntingtin are related to protein aggregation and cytotoxicity in HD 
(Bates, 2003); the mutated forms of photopigment rhodopsin and progranulin were 
respectively responsible for autosomal dominant retinitis pigmentosa (RP) and 
tau-negative frontotemporal dementia linked to chromosome 17 (FTDP-17) (Dryja et 
al., 1990; Baker et al., 2006). 
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Among proteins expressed in Schwann cells or oligodendrocytes, PMP22 and 
PLP are two aggregation-prone examples with disease-associated mutations. In the 
primary cultured neurons from mouse carring PMP22 mutations, aggregates were 
observed, which also presented when the mutated PMP22 was overexpressed in 
cultured cells (Ryan et al., 2002). The mutations in coding region of PLP gene are 
found to be responsible for Pelizaeus-Merzbacher disease. The overexpression of 
these mutated PLP proteins caused prominent aggregate formations in primary 
oligodendrocytes (Southwood et al., 2002). 
 
3.3 Aggregates in their two appearances 
On the basis on the distinctive morphologies and cellular localization, aggregates 
can be classified into two types: inclusion bodies (IBs) and punctate aggregates (PAs) 
(Gosavi et al., 2002; Lee and Lee, 2002). Inclusion bodies represent the type of 
aggregation localized juxtanuclearly which usually was highly fibrillar, whereas 
prefibrillar punctate aggregates dispersed more widely and peripherally in the cells 
and may denote the early stage form of inclusion bodies. This kind of inclusion bodies 
mimics in morphology, but are different from those “inclusion bodies” in 
neurodegenerative diseases. However, the abbreviation IBs here is used to describe a 
type of cellular aggregates in cells upon overexpression of mutant proteins or under 
stress. They are actually different from those “inclusion bodies” observed in vivo in 





Aggresome was firstly designated and characterized in cells overexpressing a 
mutant form (ΔF508) of cystic fibrosis transmembrane conductance regulator (CFTR) 
(Johnston et al., 1998). Aggregates of CFTRΔF508 were found to be ubiquitinated, 
localized in the microtubule organization center (MTOC) of the cells and formed in a 
dynein-dependent manner. Inhibition of proteasome activity in cells overexpressing 
wide type CFTR also led to accumulation (Johnston et al., 1998; Johnston et al., 2002). 
Aggresome formation was proposed to be a general cellular mechanism against 
overproduced misfolded proteins exceeding the capacity of degradation machinery. 
Later, another research group reported that cellular aggresomes indistinguishable from 
those observed in CFTR-overexpressing cells were also produced by transfecting cells 
with GFP-250 (GFP-250 designates a protein chimera composed of an entire GFP 
protein fused at its C terminus to a fragment of p115 protein; Garcia-Mata et al., 
1999). In contrast to the former type, the aggresomes in this study were not 
ubiquitinated and independent of proteasome inhibition. These studies established that 
aggresome formation represents a general cellular response to misfolded proteins.  
Aggresomes share both morphological and biochemical similarities with 
inclusion bodies that characterize common neurodegenerative diseases, suggesting a 
close relationship between aggresome formation and neurodegeneration diseases 
mechanisms (McNaught et al., 2002). For example, the overexpression of α-synuclein 
and its interacting partner synphilin-1 caused typical aggresome formation in cultured 
cell lines, which mimicked both morphological and molecular characteristics of Lewy 
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bodies (Tanaka et al., 2004). In Lewy bodies in PD or ‘dementia with Lewy bodies’ 
(DLB), aggresome-related protein α-tubulin and pericentrin were distributed much 
similarly to that in aggresomes (McNaught et al., 2002). HDAC6, which is an 
essential factor for aggresome formation, was also found to be concentrated in the 
Lewy bodies of PD (Kawaguchi et al., 2003). All these evidences suggested that the 
understanding of aggresome formations may provide clues to decipher mysteries of 
neurodegenerative diseases. 
 
3.5 The mechanisms behind protein aggregation 
Although the relationship between mutations of proteins and their aggregation 
seems undoubted, the mechanism by which the aggregates are formed remains 
uncertain.  
Studies suggested several causes of aggregate formation, one of which is the 
perturbation of protein degradation system in the cell. Ubiquitin-proteasome system 
(UPS) is the degradation machine of the cell. Johnston et al., (1999) reported that the 
inhibition of proteasome activity by ALLN resulted in aggresome formation. Studies 
of mutated parkin and other proteins also confirmed the result (Junn et al., 2002; 
Bardag-Gorce et al., 2004; Fratta et al., 2005). The resulted protein aggregations 
further exacerbate the disruption of UPS (Bence et al., 2001). Moreover, the mutations 
or overexpression of the protein may modify the structures or normal interactions of 
the protein. Studies suggested that overproduced proteins are overwhelming in both 
amounts and synthesis rate which would exceed the capacity of normal folding 
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machinery and degradation system in the cell. For example, Golgi apparatus is 
reported as fragmented in an aggregate-containing cell model overexpressing 
α-synuclein (Gosavi et al., 2002), suggesting the interruption of folding machinery.  
Investigations also provided insights into the processes how aggregates are 
formed and the crucial molecules involved. For example, they are thought to form in a 
way depending on the microtubule network (Bauer and Richter-Landsberg, 2006). 
Active transport involving HDAC6 and dynein/dynactin is also reportedly important 
mediators for assembly of aggresomes (Johnston et al., 2002; Kawaguchi et al., 2003).  
 
3.6 Consequences of protein aggregation 
In some cases, protein aggregation represents a necessary and active regulatory 
step in normal cell functions, such as that in dendritic cell maturation (Lelouard et al., 
2002 and 2004). But most aggregation formed because of protein mutations acts as an 
essential factor causing cell death or cellular toxicity in diseases. For example, the 
aggregation status of huntingtin protein determines neuronal loss in HD (Bates, 2003). 
Fibrillar α-synuclein aggregation into Lewy bodies is associated with nigrostriatral 
degeneration in PD (Lee and Trojanowski, 2006). One study suggested that, in protein 
misfolding diseases, the aggregates in host cells bearing them are inherently toxic 
(Bucciantini et al., 2002). They found that in vitro generated proteinaceous aggregates 
formed by various non-disease-associated proteins sharing specific domains are 
equally toxic and suggested the avoidance of protein aggregation is crucial for the 
preservation of biological functions in diseases. In a study on familial-associated 
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mutations of parkin, researchers suggested that the aggregation of parkin sequestered 
the enzyme from its native substrates, which results in accumulation of its substrates 
and cellular toxicity (Sriram et al., 2005).  
Some other studies suggested an interesting interpretation that aggregate 
formation could be a cytoprotective mechanism by which the mutated or misfolded 
proteins could be sequestered so that the cytotoxicity was mostly eliminated. For 
example, aggresomes formed by overexpression of α-synuclein and synphilin-1 are 
found as protective forces against cell apoptosis (Tanaka et al., 2004). Aggresomes 
formed in pancreatic cancer cells are also considered as cytoprotective (Nawrocki et 
al., 2006). However, to date, no consensus has been reached with regards to whether 
aggregation contributes to cell death or plays protective roles. 
 
4. The objectives of the current study 
Though SIRT2 was reported to exist in oligodendrocytes (Vanrobaeys et al., 2005; 
Southwood et al., 2007), its exact distribution in these cells as well as in the whole 
CNS is still mostly unexplored. Equally limited understanding is available about its 
functional roles and its action mechanisms. SIRT2 is involved in stability of 
microtubule network (North et al., 2003), which is also important for aggregate 
formation (Iwata et al., 2005; Bauer and Richter-Landsberg, 2006). Also, SIRT2 is 
reported to interact with HDAC6 (North et al., 2003), a master regulator of aggregate 
formation process (Kawaguchi et al., 2003; Iwata et al., 2005).  
Furthermore, if SIRT2 plays important roles in oligodendrocyte, the abnormality 
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of SIRT2 expression, activity or structure would be possibly correlated to the 
malfunction of the cellular system of oligodendrocyte or even CNS as a whole. It is 
more interesting since single nucleotide polymorphisms (SNPs) or variants/mutants of 
either rat or human SIRT2 are well documented (Table 2.3). The report that SIRT2 
was downregulated in diseases (such as gliomas, Hiratsuka et al., 2003) as well as that 
it is a functional player in cellular cytotoxicity (Outeiro et al., 2007) strengthened the 
possibility. However, with respect of the exact roles of SIRT2 in diseases and the 
underlying mechanisms, very little information is reported.  
The current research will be focused on the ensuing topics: 
1. Mapping SIRT2 expression in CNS;  
2. Investigating the functional roles of SIRT2 in the rat CNS and elucidating the 
molecular mechanisms underlying its effects.  
3. Illustrating, if and how, the SNPs and variants/mutants of SIRT2 would 




























Materials and methods 
 
Figure 2.1 Flow chart of the methodology used in this study 
 
The methodology used in the current study is summarized in Figure 2.1.  
1. Chemicals 
Bovine serum albumin (BSA), 4',6-diamidino-2-phenylindole (DAPI), thyroxine 
(T4), triiodothyronine (T3), nicotinamide (NAM), nicotinamide adenine dinucleotide 
(NAD), 1,4-Dithiothreitol (DTT), formaldehyde, 4-(2-Hydroxyethyl)- 
piperazine-1-ethanesulfonic acid (HEPES), glycine, Tris base, Tween 20, Triton 
X-100, putrascine, NP-40, deoxycholate, gentamicin, platelet-derived growth factor 
(PDGF), nocodazole and taxol were all purchased from Sigma (St. Louis, MO). Basic 
fibroblast growth factor (bFGF), fetal bovine serum (FBS), insulin-transferrin-selenite 
(ITS solution), glutamine, sodium pyruvate and low melting point agarose were all 
purchased from Invitrogen (Carlsbad, CA). All HPLC grade reagents (e.g. methanol 





















Materials and methods 
2. Experimental animals 
All animal uses in this study were approved by the Institutional Animal Care and 
Use Committee at the National University of Singapore. For antibody generation, two 
New Zealand White rabbits were injected with antigen every two weeks (described 
below). Ten days after the sixth injection, blood was withdrawn from the rabbits under 
anesthesia (ketamine 35 mg and xylazine 5 mg/kg body weight). Euthanasia was then 
administered by intracardiac injection of Nembutal (100 mg/kg). For histology, adult 
Wistar rats were anesthetized and euthanized with Nembutal (100 mg/kg of body 
weight), and subsequently perfused with saline and 3% paraformaldehyde (or 4% for 
immunoelectron microscopy). Brain sections of the CNS were then prepared on a 
cryostat (for light microscopy) or vibratome (for immunoelectron microscopy). For 
Western blots or primary cell culture the animals were anesthetized and euthanized 
with Nembutal (100 mg/kg of body weight), and their CNS or cerebra were dissected 
for extracting total protein or preparing primary OLPs. 
 
3. Cloning and in vitro expression of rat SIRT2 
This was described previously (Zhang et al., 2005). Briefly, cDNA clones from a 
rat brain cDNA library (Invitrogen) were sequenced and analyzed by Blast (Altschul 
et al., 1997). Digoxigenin-labeled cRNA probes were synthesized by in vitro 
transcription against 274 unannotated cDNA sequences. In situ hybridization 
histochemistry (ISH) on CNS histological sections was then performed and rSIRT2 
was chosen because of the predominant expression of its mRNA in neuroglial cells. 
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Table 2.1 Primers used for cloning and in vitro expression  
The incorporated sites for restriction digestion as well as the codons subjected to 
mutagenesis are presented in capital cases.  
  Name Sequence (5'-3') Digestion site Remarks 
1 pETrSirt2_ORF_f GGTACC atgcagtcagacttctcaaa KpnI Clone nt625-1053 of 
 pETrSirt2_ORF_r GAGCTC ctagtgttcctctttctctt SacI rSirt2 ORF  
2 pXJ-rSirt2_f CCCGGGc atggacttcctacggaatt SmaI Clone rSirt2 ORF  
 pXJ-rSirt2_r GGTACC ctagtgttcctctttctctt KpnI  
3 pEGFP-rSirt2_f cgGAATTCt atggacttcctacggaatt EcoRI Clone rSirt2 ORF  
 pEFGP-rSirt2_r ggGGTACC ctagtgttcctctttctctt KpnI  
4 rSirt2-S53CΔΔ_f tgggagctggaatctccacaTGCatccctgact  Mutagenesis 
 rSirt2-S53CΔΔ_r tgtggagattccagctcccaccaaacagat   
5 rSirt2-N69A_f catccactggcctctatgcaGCCttggagaaata  Mutagenesis 
 rSirt2-N69A_r tgcatagaggccagtggatggggagcggaa   
6 rSirt2-A80S_f accaccttccatacccagagTCCatctttgaga   Mutagenesis 
 rSirt2-A80S_r ctctgggtatggaaggtggtatttctccaa    
7 rSirt2-K107Δ_f agctctatcctgggcagttcccgaccatct  Mutagenesis 
 rSirt2-K107Δ_r gaactgcccaggatagagctccttagcaag   
8 rSirt2-N131A_f tgctgcgctgctacacgcagGCTattgacactc   Mutagenesis 
 rSirt2-N131A_r ttccccgacg acgacgcgacgatgtgcgtc    
9 rSirt2-D133A_f gctgctacacgcagaatattGCCactctggaacg  Mutagenesis 
 rSirt2-D133A_r aatattctgcgtgtagcagcgcagcagcag   
10 rSirt2-H150Y_f cccaggacctggtggaggccTACggcaccttct  Mutagenesis 
 rSirt2-H150Y_r ggcctccaccaggtcctggggctccagccc   
11 rSirt2-P182L_f agatcttctcagaagcaactCTCaagtgtgaga  Mutagenesis 
 rSirt2-P182L_r agttgcttctgagaagatcttctctttcat    
12 rSirt2-P182K_f agatcttctcagaagcaactAAGaagtgtgaga  Mutagenesis 
 rSirt2-P182K_r agttgcttctgagaagatcttctctttcat    
13 rSirt2-K302Δ_f ctgacctcctgggatggaaggagctggaagacc   Mutagenesis 
 rSirt2-K302Δ_r cttccatcccaggaggtcagcgagagccag    
14 hSirt2_ORF_f cgGGATCC atggcagagccagacccc   BamHI Clone hSirt2 ORF    
 hSirt2_ORF_r ccgCTCGAG tcactggggtttctccc  XhoI  
15 hSirt2_A117S_f accatcttccctacccagagTCCatctttgaga   Mutagenesis 
 hSirt2_A117S_r ctctgggtagggaagatggtacttctctaggtt   
16 hSirt2_R126C_f aggacaaggggctactcctgTGCtgctacacgc  Mutagenesis 
 hSirt2_R126C_r caggagtagccccttgtccttcagcaggcgcat   
17 hSirt2_N168A_f tcctgcgctgctacacgcagGCCatatataccc  Mutagenesis 
 hSirt2_N168A_r ctgcgtgtagcagcgcaggagtagccccttgtc   
18 hSirt2_A198T_f acacatcacactgcgtcagcACCagctgccggc  Mutagenesis 
 hSirt2_A198T_r gctgacgcagtgtgatgtgtagaaggtgccgtg   
19 hSirt2_P219L_f agatcttctctgaggtgacgCTCaagtgtgaag  Mutagenesis 
 hSirt2_P219L_r cgtcacctcagagaagatcttctctttcatcca   
20 hSirt2-K339Δ_f ctgagctccttggatggaaggagctggagg  Mutagenesis 
  hSirt2-K339Δ_r cttccatccaaggagctcagcaagggccag     
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The ORF of rat rSirt2 was cloned from aforementioned cDNA library by 
Polymerase Chain Reaction (PCR) technique. The nucleotides 625-1053 of rSirt2 
ORF, encoding the c terminus fragment of rSIRT2 (rSIRT2c), was amplified by PCR 
(1st pair in Table 2.1) and subcloned into pET41a (Novagen) for in vitro expression of 
GST tagged recombinant protein. The GST-rSIRT2c fusion protein was GST-affinity 
purified and used to immunize adult New Zealand white rabbits (n=2) for the 
generation of anti-rSIRT2 polyclonal antibody (pAb). For expression in mammalian 
cells, ORF sequence of rat Sirt2 was amplified by PCR and cloned in between SmaI 
and KpnI sites of pXJ40-FLAG (Manser et al., 1997) or EcoRI and KpnI sites of 
pEGFP-C1 (Clonetech), creating FLAG-rSIRT2 and EGFP-rSIRT2 overexpressing 
vectors (primers used are the 2nd and 3rd pairs in Table 2.1). Human Sirt2 was 
amplified by standard PCR, for which primers used are the 14th pair in Table 2.1 and 
templates used are plasmids extracted from IMAGE clones 2820929 and 6093541. 
The generated fragment was inserted in between BamHI and XhoI sites of HA tagged 
pXJ40 vector, creating HA-hSIRT2 overexpressing plasmids. All human Sirt2 gene 
and it mutants are tagged with HA, whereas those rat Sirt2 and its mutants are FLAG 
tagged. 
 
4. Mutagenesis and construction of sirt2 variants/polymorphisms 
All mutants of rat or human Sirt2 were generated by GeneTailor™ Site-Directed 
Mutagenesis Kit (Invitrogen) as instructed by manufacturer. Briefly, wild-type 
plasmids were firstly methylated by a DNA methylase provided in the kit. A cycle 
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PCR was then performed with pairs of primers (as listed in Table 2.1), the forward 
one of which was designed to carry the target mutations. These PCRs in this study 
were conducted with Platinum™ Taq DNA polymerase (Invitrogen). Through these 
PCRs, linear double-stranded DNA products would be generated carrying either 
deletions or mutations at the desired points. Subsequently transformation of these 
products into DH5αTM-T1R competent cells was performed. These competent cells 
can circularize the linear mutated PCR products, but at the same time digest to clear 
out methylated original wild-type plasmids because of the presence of McrBC 
endonuclease in the cells. Therefore, the colonies that subsequently arise would only 
be those carrying mutated forms of genes.  
All residues subjected to point mutation in the present study are conserved 
between human and rat Sirt2 except A198T (shown in Table 2.2 and Fig. 3.16), which 
only presents in human Sirt2. Capital case “SIRT2” usually designates the protein 
while lowercase “Sirt2” represents the DNA. Thus rSirt2N131A, for example, is the 
abbreviation for pXJ-FLAG-ratSirt2N131A plasmid, whereas hSIRT2N168A 
designates HA-humanSIRT2N168A protein. Other abbreviations of mutations are: 
rSirt2R/N: rSirt2 with double mutations at R126C and N131A; rSirt2N/H: rSirt2 with 
double mutations at N131A and H150Y; rSirt2N/K: rSirt2 with double mutations at 
N131A and K302Δ; rSirt2R/N/K: sirt2 with triple mutations at R126C, N131A and 
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Table 2.2 Point mutations of human and rat Sirt2 in the current study 
Single- or multiple-point mutated forms of human and rat Sirt2 gene are generated by 
GeneTailor mutagenesis kit and used for transfecting cells in the current study. 
Several of those mutants are documented in SNP or gene/protein databases in NCBI 
or exist in MGC cDNA clones. 
 
human Sirt2 rat Sirt2 multiple-point mutation documentation 
- S53CΔΔ S53C+A54Δ+G55Δ EAW56836 
- N69A  - 
A117S A80S  Gn1/dbSNP/rs 2241703 
- K107Δ  EAW56834 
R163C R126C  - 
N168A N131A  - 
- D133A  - 
- H150Y  - 
A198T -  Gn1/dbSNP/rs 34321258 
P219L P182L  CAD43717 
- P182K  - 
K339Δ K302Δ  MGC: 105900 
- R/N R126C+N131A  
- R/N/K R126C+N131A+K302Δ  
- N/K N131A+K302Δ  
- N/H N131A+H150Y   
 
All together, a total of 15 rSirt2 mutants consisting of rSirt2S53CΔΔ, rN69A, 
rA80S, rK107Δ, rR126C, rN131A, rR/N, rR/N/K, rN/K, rD133A, rH150Y, rN/H, 
rP182L, rP182K or rK302Δ were derived from mutations of codons for 12 conserved 
amino acid residues of rSIRT2. Of the mutants highlighted in bold, in particular, the 
human corresponding point to rA80S (or hA117S) has been reported as a single 
nucleotide polymorphism of human Sirt2 (Gn1/dbSNP/rs 2241703); the human 
counterparts for rS53CΔΔ (NCBI accession: EAW56836), rK107Δ (EAW56834) and 
rP182L (CAD43717) are also found in human Sirt2 DNA/protein sequences in NCBI 
databases. rK302Δ is present in a rat Sirt2 cDNA clone (MGC: 105900). hA198T is 
also documented as a SNP but not conserved between rat and human (Gn1/dbSNP/rs 
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34321258). 
 
5. siRNA knockdown  
Table 2.3 siRNAs used in the current knockdown experiments 
 





1 siSirt2a ggagcgucugcuggacgag dTdT 518-540 +++++ 
2 siSirt2b gggagcaugccaacauaga dTdT 1390-1412 +++ 
3 siSirt2c ggcucugccuccaacaaag dTdT 1927-1949 + 
4 siHDAC6 gggaugacagcuucccggaag dTdT 284-306 +++ 
5 siJN auuuaagacaugccagcagu dTdT 3235-3257 +++ 
 
As shown in Table 2.3, siRNA duplexes against nucleotides 518-540, 1390-1412 
and 1927-1949 of rat SIRT2 (NM_001008368), nucleotides 284-306 of human 
HDAC6 (BC013737) and nucleotides 3235-3257 of rat Juxtanodin (NM_001008311) 
were commercially synthesized (1stBase, Singapore). Expression plasmids were 
transfected into the primary OLPs and immortalized cell lines using either 
electroporation by MP-100 Microporator (Digital Bio Technology, Kyonggi, South 
Korea), or Lipofectamine 2000 (Invitrogen, Carlsbad, CA); siRNAs were transfected 
using RNAiMax (Invitrogen). Nocodazole and taxol (Sigma) was added into the 
culture medium at indicated concentrations 12 h before the cells were fixed or lysed.  
 
6. Antibodies 
For purification of the rabbit anti-rSIRT2 polyclonal antibody, the 
GST-rSIRT2c209-351 recombinant protein was resolved by SDS-PAGE, transferred to 
polyvinylidene difluoride membranes (PVDF, PerkinElmer) and used for affinity 
purification of anti-rSIRT2 antibody. In detail, with the help of ponceau S staining, the 
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membrane slices containing the recombinant protein bands could be visualized and 
excised. These slices were then minced into small pieces and incubated for overnight 
at 40C with the antiserum from aforementioned rabbits after 6 times immunization 
(diluted with equal volume of ice cold PBS). The immunoglobulin bound to these 
slices was eluted down by three times wash with Glycine-HCl (pH 2.5-3.0).  
All other antibodies used in this thesis are commercially available. 
Anti-acetylated α-tubulin 6-11B-1 (ICC 1:1000, IB 1:2000), anti-α-tubulin B-5-1-2 
(ICC 1:1000, IB 1:2000), anti-FLAG M2 (ICC 1:1000, IB 1:5000), anti-β-actin (IB 
1:5000), anti-pan sodium channel (NavP, 1:200), anti-β-COP (ICC 1:500, IB 1:1000), 
and anti-neurofilament 200 (ICC 1:1000) were all purchased from Sigma. Anti-actin 
C4 (IB 1:2000), anti-MBP (ICC 1:200), anti-GFAP (ICC 1:200), and anti-A2B5 (ICC 
1:200) were obtained from Millipore (Billerica, MA). Other primary antibodies 
included anti-CNP (ICC 1:200, IB 1:400, US biological, Swampscott, MA), anti-GD3 
(ICC 1:200, AbCam), anti-OX42 (ICC 1:50, Harlan Sera-lab, Leicestershire, UK) 
anti-EGFP (ICC 1:500, IB 1:1000, Invitrogen), anti-ubiquitin (ICC 1:300, IB 1:1000, 
Santa Cruz biotechnology, Santa Cruz, CA), anti-histone 3 and anti-potassium channel 
Kv1.2 (1:300, Upstate Biotech, Lake Placid, NY). Secondary antibodies consist goat 
anti-rabbit and/or mouse IgG conjugated to alkaline phosphatase (AP, Millipore) or 
biotin (Vector Labs, Burlingame, CA), and Alexa fluro 488 or 568 conjugated goat 
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7. Cell culture 
Cell lines used in the experiments included OLN-93, 293T and HeLa (generous 
gifts from A/P Xiao Zhicheng’s laboratory, Singapore General Hospital), SHEP 
(purchased from The American Type Culture Collection, USA) and B104 (kindly 
provided by Dr. Franca Cambi, University of Kentucky, USA). All these cells were 
routinely cultured in Dulbecco’s modified Eagle’s medium (DMEM, Sigma) 
supplemented with 10% FBS.  
Isolation and culture of primary oligodendrocyte precursor cells (OLP) followed 
previous protocols (McCarthy and de, 1980; Armstrong, 1998). Cerebra of 1-2 day old 
Wistar rats were dissected and minced, and the dissociated cell suspension was 
cultured for 9-10 days in DMEM plus 10% FBS, 1 mM sodium pyruvate and 25 
μg/ml gentamicin before immature OLPs (purity > 90%) were isolated by shaking and 
selective detachment. The OLPs were then maintained proliferating for 3-5 days in 
DMEM plus sodium pyruvate (1 mM), gentamicin (25 μg/ml), insulin (5 μg/ml), 
transferrin (50 μg/ml), selenium (30 nM), glutamine (2 mM), thyroxine (T4, 0.4 
μg/ml), triiodothyronine (T3, 0.3 μg/ml), FBS (2%), platelet-derived growth factor 
(PDGF, 10 ng/ml, Sigma) and basic fibroblast growth factor (bFGF, 10 ng/ml, 
Invitrogen). One to six days before transfection or fixation for immunocytochemistry, 
the mitogens were withdrawn from the medium to allow the cells to differentiate on 
poly-D-lysine (PDL, 10μg/ml) coated Thermanox pre-treated cover slips (NUNC, 
Nalge Nunc International, Rochester, NY) in the culture plates.   
All cell culture plastic wares were purchased from NUNC or Falcon (Becton 
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Dickinson, San Jose, CA).  
 
8. Transfection of cells 
Two kinds of transfection methods were used in the experiments.  
Method 1: All the cell lines or OLPs were grown on coverslips until ~50% 
confluence. They were then transfected by overexpressing plasmids with Effectene 
transfection reagent (Qiagen) or with Lipofectamine 2000 (Invitrogen), or by siRNA 
with Lipofecamine RNAiMax (Invitrogen). The transfection method with Effectene 
was slightly modified that, in comparison to manufacturer’s instruction, we added 
0.16μg plasmid instead of 0.2μg into each well of 24-well plate, and the buffer 
volumes for each well were also proportionally decreased. The transfection with the 
other two kits was carried out according to the manufacturers’ instructions.  
Method 2: In the studies to test rat and human SIRT2 detergent-solubility and 
aggregation-prone properties, OLN-93 cells or 293T cells were transfected by using 
MP-100 Microporator (Digital Bio Technology, Kyonggi, South Korea). For OLN-93 
transfection, cells were kept in DMEM supplemented with 10% FBS until ~80% 
confluence and detached from flasks by trypsin. Cells were washed twice with 
Ca2+-free PBS and cell densities were calculated with hemacytometer. For one single 
shoot with the 10μl golden tip, 3×105 cells were used, which were resuspended in 
buffer R and combined with 0.5μg plasmids. Three crucial parameters for the 
electroporation were pulse voltage, width and pulse numbers, which were set as1400V, 
20ms and 2 times for OLN-93 cells; the transfection procedures for 293T is mostly 
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same as for OLN-93 cells except the parameters being set as1300V, 30ms and 3 times.  
After transfection, cells were harvested and lysed for western blotting by 
M-PER® Mammalian Protein Extraction Reagent (Pierce, Rockford, IL), or fixed 
with 3% paraformaldehyde for immunocytochemistry. 
 
9. Western blotting 
Samples from animal tissues or cell lysates were generated using T-PER® or 
M-PER® Protein Extraction Reagents (Pierce) supplemented with cocktail protease 
inhibitor (Pierce), following instructions from the manufacturers. These samples were 
resolved by 10% or 12% SDS-PAGE and transferred to PVDF membranes. After 
blocking by PBS-T-NGS-milk [PBS, 0.1% Tween 20, 2% normal goat serum and 5% 
non-fat blocking milk (BioRad, Hercules, CA)] for 1hr at RT, membranes were 
probed with designated primary antibodies at RT overnight. The membrane was then 
washed and incubated with alkaline phosphate-conjugated secondary antibody. 
Immunodetection was performed using CDP-Star chemiluminescent reagent (Roche, 
Basel, Switzerland) and X-ray films (Kodak, New Haven, CT). 
 
10. Immunoprecipitation and in vitro tubulin deacetylase assay 
For immunoprecipitation of GFP-rSIRT2 or its mutants, 2-mg transfected 
OLN-93 lysate was firstly pre-cleared with 30 μl protein A-agarose (Amersham 
Pharmacia) at 4°C for 3h, followed by incubating with 6 μg anti-EGFP (Invitrogen) 
for 8h at 4°C and finally 50 μl protein A-agarose for 4h at 4°C. For in vitro α-tubulin 
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deacetylase assay, refer to North et al. (2003). Briefly, we resuspended the 
immunoprecipitate harvested as described above in 150 μl deacetylase buffer (50 mM 
Tris-HCl pH9.0, 4 mM MgCl2, and 0.2 mM DTT) and divided it into three portions of 
50 μl each, to which 40 μg OLN-93 cell lysate was added together with either NAD or 
NAM (as described in Result chapter). Reactions were terminated by adding 
SDS-PAGE sample buffer. 
 
11. Solubility tests of SIRT2 mutants 
To isolate soluble and insoluble fractions of rSirt2 or hSirt2 transfected cells, 
please refer to a previous study (Garcia-Mata et al., 1999). Briefly, OLN-93 or 293T 
cells were transfected with Microporator and seeded onto wells of 6-well plates. 
Transfected cells were harvested by trypsinization at various time points (for 
solubility kinetics analyses), or at 36/48 hours after transfection (for other analyses), 
washed and resuspended with PBS. After centrifugation, the cell pellets were lysed in 
one of the following three lysis buffers of increasing detergent strength for 30 min on 
ice. These buffers are: PBS with 2% Triton X-100, IPB (10 mM Tris-HCl, pH 7.5, 5 
mM EDTA, 1% NP-40, 0.5% deoxycholate, and 150 mM NaCl), and RIPA buffer [50 
mM Tris-HCl, pH 8, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate 
(SDS) and 150 mM NaCl], all supplemented with protease inhibitor cocktail (Pierce). 
The lysates were then passed 10 times through 27-gauge needles, and centrifuged at 
13,000×g for 15 min at 4°C to separate the soluble supernatants from the insoluble 
pellets. Pellets were then resuspended in PBS with 1% SDS (equal volume to the 
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supernatants) and sonicated to dissolve. Equal volumes that represent equal 
percentages of each pellet and supernatant were used for further Western blots 
analysis. 
 
12. In situ hybridization histochemistry  
This is done as previously described (Liang et al., 2000; Zhang et al., 2005). 
Briefly, in vitro transcribed digoxigenin-labeled cRNA probe was generated using the 
same rSirt2 cDNA fragment (as template) as for developing antibody (nucleotides 
625-1053 of the open reading frame). Free-floating histological brain sections 
representing different regions were rinsed sequentially in PBS, 0.75% glycine, 0.3% 
Triton X-100, 1 μg/ml proteinase K and 0.25% acetic anhydride in 0.1 M 
triethanolamine. Following that, sections were washed in saline sodium citrate (SSC) 
and at 60°C in a hybridization buffer omitted probes. The hybridization of sections 
with the probe generated (0.6 μg/ml) was carried on for overnight at 62°C. The 
hybridization buffer consisted of 2× SSC, 2% blocking reagent (Boehringer 
Mannheim, Germany), 50% deionized formamide, and 0.1% N-lauroylsarcosine.  
After the hybridization step, sections were sequentially treated in (all containing 
0.1% N-lauroylsarcosine except ribonuclease A) these solutions: 1) 2× SSC plus 50% 
deionized formamide at 60°C; 2) ribonuclease A buffer (0.01 M Tris-HCl buffer, pH 
8.0, plus 1 mM ethylenediaminetetraacetic acid and 0.5 M NaCl) at RT; 3) 
ribonuclease A(0.02 mg/ml in ribonuclease A buffer) at 37°C; 4) 2× SSC at 60°C; 5) 
0.2× SSC at RT once and then at 60°C once. Finally, the hybridization signals were 
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detected by AP conjugated anti-digoxigenin antibody and the NBT (nitro-blue 
tetrazolium)-BCIP (5-bromo-4-chloro-3´-indolylphosphate) reaction. Rinsed sections 
in 0.1 M Tris-HCl buffered saline (TBS, pH 7.5) were incubated in 1% blocking 
reagent in TBS, and then in alkaline phosphatase-conjugated sheep anti-digoxigenin 
antibody. After three washes in TBS plus 0.1% Tween 20, AP activity was visualized 
by NBT-BCIP reaction. All the reagents and enzymes for RNA in vitro transcription 
and hybridization were purchased from Roche. 
 
13. Immunofluorescent double/triple labeling  
For immunofluorescent double/triple labeling, histological sections of the rat 
CNS or fixed cells were washed with PBS and pre-incubated with PBS-T-NGS [0.1M 
PBS, 0.3% triton X-100 and 6% NGS] to block non-specific binding sites. Primary 
antibodies were then added for overnight incubation at RT. Secondary antibodies 
conjugated with either Alexa fluor 488 or 568 were used for detecting the primary 
antibodies. After washing with PBS, fixed cells were routinely stained for 15 minutes 
with 200ng/ml DAPI solution before being mounted and analyzed, whereas 
histological sections were mounted directly.  
 
14. Immunohistochemistry (IHC) and transmission electron microscopy (TEM) 
For immunoperoxidase (avidin-biotin-peroxidase method) and immunoelectron 
microscopy, refer to protocols described previously (Ling et al., 1992; Liang et al., 
2000). Briefly for IHC, free-floating sections were washed with PBS for 4 times at RT, 
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followed by PBS-T-NGS blocking for 1hr at RT. The sections were then incubated 
with primary antibodies dissolved in PBS-T-NGS at RT for overnight. After 4 times 
wash with PBS, they are incubated with biotinylated secondary antibodies at RT for 
75 minutes with shaking. Again after 4 times wash with PBS, avidin-biotin complex 
(1:100 avidin and biotin in 0.1M phosphate buffer with 0.15% triton X-100 and 3% 
NGS) was used to incubate the sections for 75 minutes at RT. Then sections were 
washed with 0.05M tris buffer (TB) pH 7.4-7.6 for 4 times, followed by washing with 
0.05% ammonium nickel sulphate [(NH4Ni(SO4)2] in 0.05M TB for 3-5 minutes. The 
sections were lastly incubated with 0.05 % DAB dissolved in 0.05M TB plus 0.01% 
H2O2 and 0.05% [(NH4Ni(SO4)2], this step is color reaction step. The reaction was 
stopped when clear signals can be observed (usually ranged from 3-120 minutes), by 
removing the color reaction solution and refilling the wells with 0.05M TB. 
For immuno EM, the immunohistochemical signals were harvested by same 
procedures as IHC. The tissue sections with IHC signals are cut into small pieces (1-4 
mm2) and post fixed in 1% OsO4, pH 7.4 for 1 hour at RT ( perform in fume hood ). 
After that, these small section pieces were dehydrated through an ascending ethanol 
series at room temperature: 
25% Ethanol - 5 minutes    
 50% Ethanol - 10 minutes    
 75% Ethanol - 10 minutes    
 95% Ethanol - 10 minutes    
100% Ethanol - 10 minutes     
100%  Acetone - 10 minutes (2 changes) 
Next, small sections are infiltrated sequentially with: 
a. 100% acetone : resin ( 1 : 1 ) for 30 minutes at room temperature (optional). 
b. 100% acetone : resin ( 1 : 6 ) for overnight at room temperature. 
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c. 1st change of fresh resin --- 20 minutes at room temperature then transfer to 
400C for 30 minutes. 
d. 2nd change of fresh resin --- 1 hour at 450C. 
e. 3rd change of fresh resin --- 1 hour at 500C. 
The tissues were then embed in fresh resin and polymerise at 600C for 24 hours. 
After which the sections could be sliced into ~100nm thickness pieces for observation 
under TEM. 
 
15. Data analyses 
All data were verified by at least two repeats of the experiments. Statistical 
significance between experimental and control groups were calculated by Student’s 
t-test. Immunofluorescent microscopic results were analyzed using a laser scanning 
confocal microscope (Olympus Fluoview FV1000, Olympus). Western films were 
scanned by GS-710 Calibrated Imaging Densitometer (BioRad), and the band density 
was calculated by multiplying the mean OD (after subtracting background) with the 
band area (mm2) using Quantity-One (v3.1, BioRad). Relative expression abundance 
of rat SIRT2 during developmental stages was calculated by dividing the ODs of 
SIRT2 or CNP bands by corresponding β-actin bands of the same stage.  
For complexity analyses, SIRT2 or CNP-positive OLPs were classified as simple 
if they only had 1-3 primary processes, as intermediate if they had over 3 straight 
radial primary branches with small secondary processes, as complex if many tertiary 
and further branches emerged, and as highly complex if the distal processes became 
wooly or fused to form lamellipodia around the cell bodies (see examples in Results; 
Marin-Husstege et al., 2002). 
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The solubility of SIRT2 mutants was calculated by dividing the percentage of 
bands densities in soluble portion with the sum of the soluble and insoluble portions 
together. Aggregate-positive cell percentage represents the percentage of cells 
showing cytoplasmic aggregates relative to total transfected cells from at lease five 


























1. The generation of rabbit polyclonal anti-SIRT2 antibody  
1.1 Expression of recombinant GST-SIRT2c protein 
The rat Sirt2 mRNA contained an open reading frame encoding a 351-amino-acid 
protein. The C terminus of rat SIRT2 (amino acid 209-351, SIRT2c) bears a high 
antigenicity score. Therefore a polyclonal antibody against this part of rat SIRT2 
protein was generated. PCR was first performed using the No.1 pair of primers (Table 
2.1), the product of which was then inserted in between KpnI and SacI sites of the 
pET 41a vector. High level of GST-SIRT2c expression could be observed after the 
generated plasmids were transformed into BL21 (DE3) host cells and induced to 
express recombinant protein by addition of 0.5mM IPTG (Fig. 3.1 A). This 
recombinant protein was used to immunize rabbit and generate polyclonal rabbit 
anti-SIRT2 antibody (refer to Material and methods for details). 
1.2 Specificity tests of the antibody  
The specificity of this recombinant protein was firstly tested by Western blot 
analyses. Recombinant GST-SIRT2c (~44kDa) could be successfully detected by this 
affinity-purified GST-adsorbed anti-SRIT2 antibody; similarly a commercial GST 
antibody did detect a band at the same position (Fig. 3.1 B, lanes 1 and 2). On other 
blots, the antibody detected a doublet band around 37 kDa in adult rat brain protein 
samples (Fig. 3.1 B, lane 4), whereas preimmune serum could not reveal 





Figure 3.1 Molecular features of rat SIRT2 protein 
(A) pET-Sirt2c (625-1053) plasmid was tr nsformed into BL21 (DE3) host bacteria 
tibody. 
s were transiently transfected (Tf) with either pEGFP-C1 vector (lane 
To further determine the specificity of the antibody, we inserted Sirt2 open 
reading frame into pEGFP-C1 mammalian expression vector. OLN-93 (a rat 
oligodendrocyte cell line, Richter-Landsberg and Heinrich, 1996) cells transfected 
with the pEGFP-SIRT2 were lysed, immunoprecipitated using anti-EGFP antibody, 
and then subjected to immunoblots. The band for the recombinant EGFP-SIRT2 
emerged at around 66 kDa, as detected by either the anti-SIRT2 or an anti-EGFP 
antibody (Fig. 3.1 C, lanes 2 and 3). In the lysate of OLN-93 transfected with empty 
pEGFP vector, EGFP was precipitated and migrated to around 29 kDa (Fig. 3.1 C, 
 
a
and recombinant GST-SIRT2c protein was induced to express. Arrowhead points to an 
abundantly expressed protein band, which was proposed to be GST-SIRT2.   
(B) Western blots, showing specificity tests of rabbit polyclonal anti-SIRT2 an
Labels above and below blots indicate the protein sample origins and antibodies used 
for immunoblotting detection (IB), respectively. GST-SIRT2c, recombinant 
GST-SIRT2c (209-351) protein expressed in E. coli; PS, pre-immunization serum 
(rabbit serum before the first time immunization); Double arrows indicate the SIRT2 
doublet band detected by rabbit anti-SIRT2. Arrowhead points to the position of 
GST-SIRT2c.  
(C) OLN-93 cell
1) or pEGFP-Sirt2 (lanes 2-4). Forty-eight hours after transfection, lysates of the cells 
were subjected to immunoprecipitation (IP) using anti-EGFP or irrelevant IgG, 




lane 1). By contrast, irrelevant IgG (anti-FLAG M2, Sigma) cannot precipitate the 
recombinant protein (Fig. 3.1 C, lane 4). Together, the antibody proved adequately 
specific for further experiments. 
 
2. SIRT2 was expressed predominantly in rat CNS  
 
Figure 3.2 Distribution of rat SIRT2 protein in different tissues 
In this multi-tissue Western blot, samples from 8 different tissues were probed with 
rabbit polyclonal anti-SIRT2 antibody or anti-pan-actin antibody. Only in rat brain but 
not in other seven tissues, could significant SIRT2 signal be detected, although there 
seemed a very faint band (around 41 kDa, white arrow) in testis lysate. The pan-actin 
signals in the lower panel work as the loading control. (SkM, skeleton muscle).  
 
To test the overall distribution of SIRT2 protein, we harvested protein samples 
from 7 different rat tissues and identified the expression of SIRT2 by Western blots. 
On the blots probed with this anti-SIRT2 antibody, the 37 kDa SIRT2 doublet band 
was detected in brain protein sample, but not in that of the heart, liver, spleen, lung, 
kidney, testis, or skeletal muscle, although a weak 41 kDa band, which we presumed 









Figure 3.3 Developmental expression of SIRT2 protein in rat CNS 
(A-F) Western blot analyses comparing the expression profiles of SIRT2 and CNP in 
postnatal 0, 3, 7, 10, 14, 21, 28, 60 rat cerebrum, spinal cord and cerebellum, 
respectively. Each lane was loaded with 20 μg of soluble tissue lysate. Signals for 
β-actin served as loading controls. Quantitative analyses of expression levels of 
SIRT2 and CNP relative to β-actin in the different CNS regions are shown on the right 
(panels G, H and I). PD, postnatal day. 
 
To investigate the developmental expression of SIRT2, protein samples of the 
cerebra, cerebella and cervical spinal cords of rats aged 0, 3, 7, 10, 14, 21, 28, and 60 
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postnatal days were subjected to western blots. In the cerebrum, the 37 kDa SIRT2 
was expressed marginally at PD7, clearly visible at PD10, increased sharply at PD14, 
and approximated adult level at PD21 (Fig. 3.3 A). In both cervical spinal cord and 
cerebellum, the signal appeared at PD3, but higher abundance and earlier 
approximation to adult level (PD10) was detected in spinal cord (Fig. 3.3 B and C). 
In comparison, immunoblotting signals for the 42 kDa CNP emerged at approximately 
the same time as SIRT2 in all the three CNS regions, and co-fluctuated with those of 
SIRT2 along the various postnatal ages (Fig. 3.3 D-F). Interestingly, the 41 kDa minor 
band of SIRT2 showed up earlier than the 37 kDa band, and then decreased to very 
low levels in all three regions of PD60 CNS. 
 
4. SIRT2 as a protein of oligodendroglia and myelin 
4.1 In situ hybridization histochemistry (ISH) 
The digoxigenin-labeled cRNA probe for ISH was generated against the same 
fragment as for antibody development, which is the nt625-1053 part of Sirt2 ORF. As 
shown in Figure 3.4, Sirt2 mRNA-positive signals were seen not only in the gray 
matter but also in the white matter throughout most CNS regions. Positive cell bodies 
in the gray matter were typically dispersed, round-shaped and of relatively small sizes, 
whereas those in the white matter were more variable in morphology (Fig. 3.4 A-D). 
The strength of hybridization signals was highest in corpus callosum and hippocampal 
formation, followed by thalamic nuclei, the cerebral and cerebellar cortices, caudate 
puteman and spinal cord. In the neocortex, the Sirt2 mRNA-positive cells distributed 
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more intensely in layer IV and V (Fig.3.4 G). In the cerebellum, staining sometimes 
appeared in proximal processes in addition to cell bodies, suggesting a possibility of 
local translation (Fig. 3.4 E). 
 
Figure 3.4 Distribution of Sirt2 mRNA in rat CNS 
In situ hybridization histochemical photomicrographs showing expression of Sirt2 
mRNA in representative CNS regions, including forebrain (A-C), cerebellum (D, G), 
hippocampal formation (E), parietal cortex (F) and spinal cord (H). Abbreviations: 
AON, anterior olfactory nucleus; Cpu, caudate puteman; cc, corpus callosum; I–VI, 
layers of cerebral cortex; GM, gray matter; Gr, granule cell layer of dentate gyrus (E) 
or cerebellar cortex (G); Hil, hilar region of hippocampal formation; Hipp, 
hippocampus; LV, lateral ventricle; Mol, stratum lacunosum-moleculare of 
hippocampal CA1 (E) or molecular cell layer of cerebellar cortex (G); Or, stratum 
orien; Par, parietal cortex; Pyr, stratum pyramidale; Rad, stratum radiatum; Thal, 
thalamus; WM, white matter. Scale bars: 800 μm in A-D; 200 μm in E and F; 20 μm 
in G and H. 
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4.2 Immunohistochemistry (IHC) 
 
Figure 3.5 Distribution of SIRT2 protein in rat CNS 
Immunohistochemical photomicrographs showing expression of SIRT2 protein in 
representative CNS regions, including olfactory bulb (A), forebrain (B-E), cerebellum 
(F, I), parietal cortex (J) and spinal cord (G, H). Abbreviations: Am, amygdala; cc, 
corpus callosum; Cpu, caudate putamen; III and VI, layers of cerebral cortex; DG, 
dentate gyrus; Fr, frontal cortex; GM, gray matter; Hipp, hippocampus; HT, 
hypothalamus; Mol, molecular cell layer of cerebellar cortex; Olf, olfactory bulb; Par, 
parietal cortex; Thal, thalamus; WM, white matter; Crbll, cerebellum and . Scale bars, 
800 μm in A-H, 20 μm in I and J. 
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IHC with the anti-SIRT2 antibody revealed distribution of SIRT2 protein in 
various regions of the brain (Fig. 3.5 A-H). The expression was most abundantly 
detected in corpus collusum, cerebral and cerebellar cortex, followed by caudate 
puteman, hippocampus and spinal cord. In the cerebral cortex, the histochemical 
signals of of SIRT2 are very low in superficial layer I and II, but become stronger in 
layer V and VI and subcoritcal white matter (Fig. 3.5 J). In the cerebellar cortex, 
SIRT2 immunoreactivity was abundant in the granule and Purkinje cell layers. The 
molecular layer, however, was mostly devoid of SIRT2 signals with the exception of a 
few scattered cells and related processes near the Purkinje cell layer (Fig. 3.5 I). 
These scattered cells with processes are also occasionally observed in other regions of 
the CNS, such as cerebral cortex (Fig. 3.5 J). 
 
4.3 Immunofluorescent double labeling 
Double immunofluorescent study established that SIRT2 expression in the CNS 
was primarily confined to oligodendrocytes. Colocalization between SIRT2 and CNP, 
a well-characterized oligodendrocyte marker in the CNS, was seen in all CNS regions 
examined (Fig. 3.6 A-D). Figure 3.6A shows the cerebellar cortex where SIRT2 
immunoreactive signals overlapped those of CNP in the oligodendroglial processes, 
along myelinated axons in the Purkinje cell and granule cell layers, and in the 
subcortical white matter. The CNP-positive perikarya of oligodendrocytes, however, 
were frequently devoid of detectable SIRT2 (insets in Fig. 3.6 A and K). Similar 
colocalization of SIRT2 and CNP in oligodendroglial processes/along myelinated 
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axons, and absence of SIRT2 in the oligodendrocytic cell bodies were found in, 
among others, the caudate nucleus and in the gray and white matters of cervical spinal 
cord (Fig. 3.6 B-D). Double labeling against SIRT2 and MBP, another group of 
marker proteins for oligodendroglia and myelin sheath, confirmed the above findings. 
Figure 3.5I and J illustrate such examples of SIRT2 colocalization with MBP in 
oligodendroglial processes and along myelinated axons in the cerebral cortex and the 
hippocampal formation, respectively. SIRT2 was not detected in astrocytes marked by 
glial fibrillary acidic protein (GFAP), in microglia marked by OX42, nor in neurons 
marked by neurofilament 200 (NF200) (Fig. 3.6 E-H). It is noteworthy that in certain 
areas such as cerebral and cerebellum cortex, the positivity of SIRT2 usually formed a 
cluster and seemed to present only in bundles surrounding a cell but never in the cell 




Figure 3.6 SIRT2 is predominantly an oligodendroglial protein 
A–H, Double-immunofluorescent labeling of SIRT2 (red in all panels) plus CNP 
(A–D and K), GFAP (E and L), OX42 (F), neurofilament (G,H), or MBP (I, J) in the 
rat cerebellar cortex (A, E), caudate-putamen (B, F), cerebral cortex (layers III and IV 
in I; layers II and III in K and L), dentate gyrus (J), cross (C, G) or longitudinal 
sections (D, H) of cervical spinal white (C, G) or gray (D, H) matter. The inset in A or 
E is the observation of the marked area at a higher magnification. In A–D, note that, 
although it overlapped CNP (green) in most oligodendrocytic processes, SIRT2 (red) 
was undetected or only faintly positive in most oligodendroglial cell bodies that 
showed strong CNP staining (open arrowheads). Gr, Granule cell layer of cerebellar 
cortex (A, E) or the dentate gyrus (J); Mol, Molecular layer of cerebellar cortex; Pur, 
Purkinje cell layer of cerebellar cortex. Scale bars: B, D, F, H–J, 20 μm; A, E, 50 μm; 




5. SIRT2 was localized to juxtanodal area in the myelin sheath 
Under high magnification, in certain axon bundles near the pia surface of 
cross-sectioned cervical spinal white matter, SIRT2 positive profiles, similar to those 
of CNP labeling, were observed in concentric double rings around the NF200-positive 
neuronal axons. The inner rings often seemed in contact with the centrally positioned 
axons, but not with the outer rings. Careful comparison with SIRT2 immunoelectron 
microscopic data (see below) suggested that the concentric rings most possibly 
corresponded to the cytoplasm-containing innermost and outermost layers of myelin 
sheaths, respectively (Fig. 3.6 C and G).  
 
Figure 3.7 SIRT2 localized in the juxtanodal region adjacent to nodes of Ranvier 
On longitudinal sections of cervical spinal white matter, double-immunofluorescence 
labeling (A ) of SIRT2 (red) together with pan-sodium channel (NavP, green), or 
triple labeling (B) of SIRT2 (red) together with NavP (green) and potassium channel 
Kv1.2 (green) showing SIRT2 distribution in the juxtanodal and paranodal domains 
of myelin sheath. The arrows point to examples of the NavP clusters at the nodes of 
Ranvier. The inset in L shows an example from the marked area at a higher 
magnification. Note the SIRT2-positive bands flanking the node of Ranvier and in 
between the strongly Kv1.2-positive juxtaparanodes. Scale bar: 10 μm. 
 
In most other axon bundles of cervical spinal cord, SIRT2 signals could be seen 
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around the NF200-positive axons but mostly did not directly contact or overlap the 
latter, indicating their localization mainly in the outermost layer of myelin sheath. 
To more clearly understand the localization of SIRT2 in the myelin sheath, we 
performed a triple labeling experiment on longitudinal sections of cervical spinal 
white matter. As revealed, SIRT2 was frequently found enriched in the juxtanodal and 
paranodal region in between the sodium channel-clustered node of Ranvier and the 
potassium channel Kv1.2-enriched juxtaparanodal domain (Fig. 3.7 A, B). 
 
 
Figure 3.8 SIRT2 localization in oligodendrocytes and myelin sheaths under electron 
microscope 
(A) Immunoelectron micrograph of cervical spinal cord showing occasional SIRT2 
immunoreactivity in the perikaryal cytoplasm and in marginal heterochromatin 
clumps of nucleus of oligodendrocyte (denoted by an asterisk).  
(B-F) Immunoelectron micrographs of cervical spinal cord (B, C, F) or corpus 
callosum (D, E) showing SIRT2 immunoreactivity in the cytoplasm-containing outer 
layer of myelin sheaths (arrow in D) or the juxtanodal loops of myelin sheaths (open 
arrowheads in B, C, E, F) on the sides of the nodes of Ranvier (marked by “n” in the 
middle of the axons). Scale bars, 0.5 μm (panels A-D, F) and 0.2 μm (panel E). 
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Under the electron microscope, SIRT2 immunoreactivity was mainly found in the 
cytoplasm-containing non-compact portions of myelin sheath such as the abaxonal 
(outer) layer of myelin sheath (Fig. 3.8 A-D), the juxtanodal terminal loops (Fig. 3.8 
B, C, E and F), and in processes of oligodendroglia. Electron-dense immunoreactive 
products were also occasionally found in the perikaryal cytoplasm and in the marginal 
heterochromatin areas of oligodendrocytic nucleus (Fig. 3.8 A). No SIRT2 signal was 
detected in the compact laminae of myelin sheath, and no association of the signals 
with cytoplasmic organelles could be unequivocally established. 
 
6. SIRT2 NAD-dependently deacetylates α-tubulin 
As presented in the “introduction” chapter, SIRT2 is an NAD-dependent histone 
deacetylase. In addition to histones, it can also deacetylate α-tubulin (North et al., 
2003). We sought to identify the candidate SIRT2 substrates in oligodendrocytes as 
the protein is predominantly localized in cytoplasm (Fig. 3.6 and North et al, 2003). 
Western blot analysis showed no endogenous SIRT2 expression in OLN-93 rat 
oligodendroglia cell line (Fig. 3.1 B, lane 5). We then incubated the lysate supernatant 
of pXJ-Sirt2 transfected OLN-93 cells (mainly cytoplasmic proteins) with NAD for 
30 min at room temperature, and subjected them to Western blots probed with an 
anti-acetylated-lysine antibody (AKL5C1, Matsuyama et al., 2002) or a mouse 
monoclonal antibody specific to lysine 40-acetylated α-tubulin (6-11B-1, Piperno et 
al., 1987). The former antibody revealed a predominant positive band at 52 kDa. This 
signal was presumed to be acetylated α-tubulin since 1) anti-acetylated α-tubulin 
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detected a single band at exactly the same position, 2) in comparison with normal 
OLN-93 cell lysate (also treated with NAD for 30 min), the lysate with overexpressed 
FLAG-SIRT2 showed significantly decreased levels of both the acetylated-lysine 
(48% reduction compared to control) and acetylated α-tubulin (57% reduction 
compared to control) immunoreactivities (Fig. 3.9 B). Levels of total α-tubulin were 
not affected by FLAG-SIRT2 overexpression (Fig. 3.9 B). The anti-acetylated lysine 
antibody also stained two other bands in OLN-93 immunoblots, but in comparison 
with acetylated a-tubulin these signals were much weaker, and seemingly not much 
influenced by overexpression of FLAG-SIRT2 (Fig. 3.9 B). Since SIRT2 is also 
reported to deacetylate histones (North et al., 2003; Vaquero et al., 2006), we next 
tested if the acetylation levels of histones in the transfected cells were altered. In 
addition to the supernatant portion mentioned above, the pellet of the cell lysate in 
which most nuclear proteins presented was subjected to Western blots. As shown in 
Figure 3.9 C, almost all the recombinant FLAG-SIRT2 was expressed in the 
supernatant portion. In presence of FLAG-SIRT2 rather than FLAG-SIRT2N131A, 







Figure 3.9 SIRT2 is an NAD-dependent histone deacetylase with as α-tubulin its 
preferable substrate 
(A) OLN-93 cells were transiently transfected as indicated, lysed and 
immunoprecipitated with anti-EGFP. The immunoprecipitates were then added to 
OLN-93 cell lysate (as the source for acetylated α-tubulin) together with various 
combinations of NAD (1 mM) or NAM (5 mM), and incubated for two hours at room 
temperature. Samples after that were subjected to Western blots analyses (5 μg each 
lane). 
(B and C) OLN-93 cells were transiently transfected with indicated plasmids, lysed 
and centrifuged, the supernatant (B, C) and pellet (C) of which were subjected to 
Western blots. Crtl: normal OLN-93 cell lysate. The bar chart on the top of panel B 
represents the densitometric analysis of the bands densities in lanes1-4. The bands 
densities of acetylated-lysine in lane 2 and acTub in lane 4 (white bars) were 
calculated as percentages of the control groups in lane 1 and lane 3 (black bars), 
respectively. 
 
Conversely, the acetylation levels of the histone H3 (acetylated at lysine 14) and 
histone H4 (acetylated at lysine 16) (North et al., 2003; Vaquero et al., 2006) were not 
changed (Fig. 3.9 C). These results suggested that the main substrate for SIRT2 is 
α-tubulin in the cytoplasm of OLN-93 cells. 
To further determine the α-tubulin deacetylase activity of rat SIRT2, 
point-mutated or wildtype forms of SIRT2 with EGFP tag were overexpressed in 
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OLN-93 cells, immunoprecipitated by EGFP antibody and used as enzymes to treat 
untransfected normal OLN-93 cell lysate as a substrate. Western blots were finally 
employed to semi-quantitatively assess the tubulin deacetylase activity of the 
immunoprecipitates. The results showed that, in the presence of NAD (1mM), the 
addition of immunoprecipitated EGFP-SIRT2, rather than EGFP, caused a significant 
decrease of acetylated α-tubulin in the cell lysate (Fig. 3.9 A, lane 8). The 
EGFP-SIRT2 did not influence the level of total α-tubulin, and its tubulin deacetylase 
activity was abolished when NAD was removed or sufficient nicotinamide (NAM, 
5mM) added into the system (Fig. 3.9 A, lanes 7 and 9). Point-mutated SIRT2s, in 
which aspartic acid-133 of SIRT2 was replaced by alanine (SIRT2D133A) or 
histidine-150 by tyrosine (SIRT2H150Y) (Finnin et al., 2001), showed significantly 
diminished deacetylase activity (Fig. 3.9 A, lanes 5 and 6). SIRT2N131A 
(replacement of asparagine-131 by alanine) exhibited similar reduction of deacetylase 
activity (data not shown). These results indicated that SIRT2 could deacetylate 






Figure 3.10 Overexpressed SIRT2 deacetylates α-tubulin in OLN-93 cells 
OLN-93 cells were transfected with plasmids as indicated under each panel column 
after being cultured on coverslips for 24 hours in presence of 1mM NAD. Forty-eight 
hours after transfection, cells were fixed and immunofluorescent staining was 
performed using antibodies indicated in the top of each panel. The results shows that 
overexpressed EGFP-SIRT2 attenuated the acetylated level of α-tubulin, but the 
effects of which could be inhibited by 1mM NAM. Scale bar: 20μm 
 
We further tested the deacetylase activity of overexpressed SIRT2 in vivo in 
OLN-93 cell lines. EGFP-SIRT2 or its point-mutated forms were transfected into cells 
and observation was done 48 hours after that. As shown, overexpressed SIRT2 
specifically abolished the staining of acetylated form of rather than normal α-tubulin 
(Fig. 3.10 A, B). Additionally, in accordance with in vitro data presented above, the 
deacetylase activity of overexpressed SIRT2 can be inhibited by presence of NAM or 






7. Association among SIRT2 expression, tubulin acetylation levels and 
oligodendrocyte maturation in culture 
We next investigated the relations between SIRT2 expression, tubulin acetylation 
and development of oligodendroglia in OLP cells extracted from postnatal day 1-2 rat 
cerebra. After 3-4 days’ differentiation, a quarter of the primary OLPs exhibited 
complex morphology with tertiary processes. Roughly 20% of them started to express 
SIRT2. Surprisingly, abundance of endogenous SIRT2 expression was positively 
correlated with the acetylation levels of α-tubulin in the same cells. Subcellular 
distribution of acetylated α-tubulin and SIRT2 also mostly overlapped. More 
importantly, the process arbors of SIRT2-positive and EL-acTub (elevated acetylation, 
refer to “materials and methods” for morphological scoring criteria) primary OLPs 
were clearly more complex in morphology than those of the surrounding 
SIRT2-negative and BL-acTub (basic level acetylation) cells, and the increase of 
SIRT2 expression and acTub levels was accompanied by the differentiation 
progression of those OLP cells’ arborization (Fig. 3.11 J,L). Similar correlation 
between CNP expression and OLP cells’ arborization differentiation was detected (Fig. 
3.11 K). It was also noteworthy that primary and secondary processes of the 
SIRT-positive/CNP-positive/EL-acTub OLP cells were often tortuous along the way 
and enlarged at the distal end from where many finer processes originated. In contrast, 
processes of the SIRT2-negative/ CNP-negative/BL-acTub OLPs often radiated out 
straight from the cell bodies, and gave rise to relatively fewer further branches. Levels 
of total α-tubulin, however, were not closely correlated with SIRT2 expression (Fig. 
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3.11 C,F,I).  
 
Figure 3.11 Cofluctuation between the morphological complexity of primary OLPs , 
the acetylation levels of α-tubulin and expression of SIRT2 and CNP 
(A-C, E-G and I-K) Double-immunofluorescent photomicrographs showing close 
correlation of SIRT2 expression (A-C) with CNP (D) and levels of α-tubulin 
acetylation (E) in cultured OLPs. Levels of total α-tubulin (F) were, however, not 
closely associated with SIRT2 expression (C). Morphologies of the immuno-negative 
cells could also be appreciated in the respective lower panels of phase-contrast 
photomicrographs (G-I). Note the increased α-tubulin acetylation and 
emergence/increases of SIRT2 and CNP immunoreactivities in the pre-maturity-stage 
oligodendrocytes, as compared with the earlier-stage cells that showed no SIRT2 or 
CNP signals, and low levels of α-tubulin acetylation. Abbreviations: Tub, α-tubulin; 
AcTub, acetylated α-tubulin. Scale bars, 20 μm. 
(J, K and L) Three-D bar charts representing the differentiation progression of cellular 
arborization was accompanied by the emergence/increase of cellular expression levels 
of SIRT2, CNP and elevated levels of acetylated 　-tubulin. “S”, “I”, “C” and “HC” 
are abbreviations for “Simple”, “Intermediate” “Complex” and “Highly Complex” 
hierarchies of cellular arborization. ”BL” “-”, “+”, “++” and “+++” are used to 
designate the levels of expression. Please refer to Material and Methods for detailed 
criteria. “% of OLP cells” on the z-axis represents that, in each of the four expression 





Further double immunofluorescent stainings and statistical analysis proved that 
the concurrent SIRT2 and CNP emergence, α-tubulin acetylation increase and typical 
morphological changes of cultured primary OLPs marked the entry of 
oligodendrocyte differentiation into the pre-maturity stage (Barry et al., 1996; 
Armstrong, 1998; Baumann and Pham-Dinh, 2001; Woodruff et al., 2001). All cells 
positive for SIRT2 became immunoreactive for the oligodendroglial functional protein 
CNP as well, whereas those lacking SIRT2 remained negative for CNP. The two 
enzymes showed overall co-variation in levels, and colocalization at subcellular 
domains (Fig. 3.11 A,E,I). 
The raised α-tubulin acetylation levels in spite of the appearance of SIRT2 tubulin 
deacetylase activities in the pre-maturity-stage oligodendrocytes seemed paradoxical. 
We hypothesized that the heightened α-tubulin acetylation (possibly due to activities 
of certain acetyltransferases) and CNP activity promoted OLP differentiation. The 
concurrent SIRT2 increase functioned as a counterbalance to prevent uncontrolled 
tubulin acetylation, to offset over-differentiation, and to avoid premature myelination 
in the CNS. To test this hypothesis, the following overexpression and siRNA 
knockdown experiments were carried out. 
 
8. SIRT2 overexpression lowered α-tubulin acetylation levels and inhibited OLP 
differentiation 
Two days after Sirt2 transfection, primary OLP cells (in their third or fourth day 
of differentiation) showed retarded morphological differentiation (Fig. 3.12 A, B, F, G) 
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and marked decreases in α-tubulin acetylation levels (Fig. 3.12 A). Many of the 
transfected cells expressed considerable levels of intrinsic CNP, but failed to assume 
the typical morphology of the normally CNP-positive pre-maturity-stage 
oligodendrocytes (refer to Fig 3.11 F). Process arbors of these cells still appeared 
relatively immature, much like those of earlier-stage cells (Fig. 3.12 A,C,F,G). By 
contrast, morphologies of cells expressing EGFP only or FLAG-juxtanodin141 
(FLAG-JN141, Zhang et al., 2005) appeared to be highly complicated, similar to 
untransfected neighboring cells (Fig. 3.12 D,E,H). Overall, at the end of the 3-4 days 
differentiation, the OLP cells untransfected or transfected with control plasmids 
exhibited mostly intermediate or complex morphology, whereas the majority of the 
OLPs transfected by Sirt2 were simple or intermediate in cell arbor complexity (see 
“materials and methods” for morphological scoring criteria). In comparison to the 
JN141 transfected controls, for example, the percentage of simple cells increased by 
three fold in the pXJ-Sirt2 transfected group, whereas those with complex 
morphology dropped from 53.6% to 34.9% (Fig. 3.12 I, average of 3 experiments, 




Figure 3.12 Overexpression of SIRT2 inhibits the morphological differentiation of 
primary OLPs 
(A-H) Sirt2-transfected OLP cells showed decreased α-tubulin acetylation levels 
(arrow in A), and simpler morphology in comparison with neighboring untransfected 
cells (A, C, F and G), with cells transfected with SIRT2H150Y, the deacetylase 
partially inactive form of SIRT2 (B), and with pEGFP-C1 or JN141-transfected 
controls (E, H and D). Total α-tubulin levels in the Sirt2-transfected cells were not 
significantly affected (C). For the visualization of the much higher intensity of 
overexpressed SIRT2 signals in the transfected cells, normal endogenous SIRT2 
signals in the neighboring cells, if any, were underexposed and therefore could not be 
optimally appreciated in some of the panels (A, B, C and G).  
(I) Statistic analyses of morphological maturation of primary OLPs transfected with 
pXJ-Sirt2, pXJ-Sirt2N131A, pXJ-Sirt2H150Y and pXJ-JN141 plasmids. Data are 
from three independent experiments (n>300 transfected cells for each transfection 
group). ***, p<0.001 (Student’s t-tests).  
Plasmids/drugs for transfection/treatment of cultures are indicated on the upper right 
of the panels, and antibodies for immunofluorescence on the lower left. Refer to 
Fig.3.11 for abbreviations. Scale bars, 20 μm. 
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To test if the deacetylase activity of SIRT2 is essential for its inhibitory effect on 
OL arborization, SIRT2H150Y which has largely lost deacetylase activity (Fig. 3.12 
C; Finnin et al., 2001) was used to transfect OLP cells. The results showed that the 
deacetylase activity loss of SIRT2H150Y almost completely abolished the inhibitory 
effect of wild-type SIRT2 on OL arbor complexity (Fig. 3.12 C,I). Transfection of 
another deacetylase-inactive mutant of SIRT2, SIRT2N131A, gave rise to similar 
results (Fig. 3.12 I). 
To further determine the effects of SIRT2 overexpression, we co-transfected 
OLN-93 cells with both pEGFP-Sirt2 and pXJ-JN. Cells overexpressing 
FLAG-tagged JN alone showed marked increases in the process arbor complexity 
(Fig. 3.13 B; Zhang et al., 2005), of which, statistical analysis revealed 43.1% 
exhibited complex morphology while 25.6% were simple. In contrast, cells 
overexpressing both FLAG-JN and EGFP-SIRT2 proteins showed remarkably 
less-developed branches or only rounded-up cell bodies (13.1% and 50.0% of 
transfected cells fell into complex and simple group respectively; Fig. 3.13 C, G), 
much similar to cells overexpressing only SIRT2 (Fig. 3.13 A, G). The simultaneous 
overexpression of SIRT2N131A or EGFP together with JN did not significantly 
counteract the arborization-promoting effect of the latter (Fig. 3.13 D, E and G). 
Addition of 5 mM nicotinamide to the JN-SIRT2 co-transfected culture partly blocked 
the arborization-inhibiting effect of SIRT2 (Fig. 3.13 F,G).  
Together, these results supported the notion that SIRT2 decelerated 





Figure 3.13 Overexpressed SIRT2 counteracts the promotive effects of JN on cell 
arborization in OLN-93 cells 
(A-F) pEGFP-Sirt2 transfected OLN-93 cells showed much fewer cell processes (A), 
in comparison with cells transfected by pXJ-JN alone (B) or pXJ-JN plus pEGFP-C1 
(D). When cotransfected with pXJ-JN, pEGFP-Sirt2 counter-regulated the 
arborization-promoting effect of the former (C), whereas the inhibitory effect of 
pEGFP-Sirt2N131A was much less obvious (E). Addition of nicotinamide (5 mM) to 
the culture medium partly abolished the arborization-inhibiting effect of SIRT2 (F). 
Cells in all groups except panel F were transfected and grown in presence of NAD. 
(G) Statistic analyses showing the counteractive activity of overexpressed SIRT2 on 
cellular arborizations of OLN-93 cells promoted by JN overexpression. OLN-93 cells 
were transfected or treated as indicated in A-F. Data are from two independent 
experiments (n>300 transfected cells for each transfection group). 
Plasmids/drugs for transfection/treatment of cultures are indicated on the upper right 
of the panels, and antibodies for immunofluorescence on the lower left.  
Refer to Fig.3.11 for abbreviations. Scale bars, 20 μm. 
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In agreement with previous results (Marin-Husstege et al., 2002; Liu et al., 2003; 
Hsieh et al., 2004; Shen et al., 2005), addition of trichostatin A (TSA), an inhibitor of 
class-I/II HDACs, to the medium delayed differentiation of all primary OLPs in the 
culture, as evidenced by their much simpler process arbors. This repressive effect of 
the drug was obvious before the onset of endogenous oligodendroglial SIRT2 
expression (data not shown). 
 
9. Knockdown of endogenous SIRT2 by siRNA promotes α-tubulin acetylation 
and accelerates OLP differentiation 
To verify the above SIRT2 effects from a different angle, we used siRNAs to 
interfere with intrinsic SIRT2 expression in cultured primary OLPs starting at 2-4 
days into their differentiation. Transfections by siRNAs for JN or histone deacetylase 
6 (HDAC6), both of which showed no detectable expression within the OLP 






Figure 3.14 Knockdown of endogenous SIRT2 in primary OLPs in early stages of cell 
differentiation 
(A-F) siRNA knockdown of endogenous SIRT2 for 3 days (days 2-5 into 
differentiation) did not significantly alter OLPs’ morphological complexity or 
distribution of acetylated α-tubulin (A), CNP (C) and MBPs (E) as compared to cells 
transfected with JN or HDAC6 siRNAs (B, D, F). OLPs within 10 days into 
differentiation had no JN or HDAC6 immunoreactivity (data not shown). Thus the 
latter two siRNAs served here as negative controls.  
Plasmids/siRNAs for transfection are indicated on the top of the columns, and 
antibodies for immunofluorescence on the lower left of individual panels.  
Scale bars, 20 μm. 
 
All three Sirt2 siRNA duplexes depleted or lowered SIRT2 immunoreactivity in a 
majority of the cultured OLPs. The knockdown effect of the siRNA targeting Sirt2 
nucleotides 518-540 (NM_001008368) was nearly complete and lasted for at least 
eight days. When examined 3-4 days into the knockdown, OLPs showed no obvious 
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changes in the levels and distribution of CNP or MBPs, nor did the cells display 
marked alteration in their process arbors (Fig. 3.14 A-F). After 7-8 days of 
nullified/reduced Sirt2 expression by the siRNAs, however, significantly more OLPs 
in the experimental cultures adopted complex or highly complex morphologies, as 
compared with JN/HDAC6 siRNA-treated or with siRNA-omitted controls. 
Percentage of OLPs with simple morphologies, indicative of less differentiation, 
accordingly decreased in the experimental group (Fig. 3.15 A). Accompanying the 
morphologically enhanced differentiation in the experimental group were the 
decreased deacetylation of tubulin and increased expression of an immature form of 
MBP at around 50 kDa (Ursell et al., 1995). Immunoreactivities for CNP, total tubulin, 
or β-actin in the OLPs, as detected by Western blotting analyses, were not 
significantly altered by SIRT2 siRNAs (Fig. 3.15 B). JN or HDAC6 siRNAs 
transfection gave rise to no significant influence on differentiation or gene expression 




Figure 3.15 Prolonged knockdown of endogenous SIRT2 expression promotes 
differentiation of primary OLPs 
(A and B) siRNA knockdown of endogenous SIRT2 for 6 or 8 days (days 2-8 or 2-10 
into differentiation) promoted the differentiation of OLPs as evidenced by increased 
morphological complexity (A) and upregulation of acetylated α-tubulin and MBP 
expression (B) in comparison with untransfected or JN/HDAC6 siRNA-treated 
controls. No difference was observed in the expression of CNP, total α-tubulin and 
β-actin between the SIRT2 knockdown and the control groups (B). Example 
morphology and CNP expression in cell after 8-day SIRT2 knockdown and in 
untransfected control cell are shown in panels C and D. In panel A, grayscale pictures 
under the graph represent typical examples for the four morphological hierarchies (A). 
Abbreviations: HC, highly complex; NC, untransfected negative control; siJN, JN 
siRNA 3235-3257; siSIRT2a, Sirt2 siRNA 518-540; siSIRT2b, Sirt2 siRNA 
1390-1412; ***, p<0.001; **, p<0.01 (Student’s t-tests).  
Plasmids/siRNAs for transfection are indicated on the top of the columns, and 















Figure 3.16 Schematic diagram showing the mutated residues of rSIRT2 and hSIRT2 
in the current study  
All the 15 rSIRT2 mutants were derived from various combinations of these 12 point 
mutations. Arrows indicate known deacetylase-defective point mutations; asterisks 
denote human Sirt2 SNP point (rA80S/hA117S, hA198T), or mutations found in 
human Sirt2 sequences in NCBI databases or a MGC rat clone (rK302Δ/hK339Δ). 
 
Fifteen different mutants of rSirt2 and six of hSirt2 are included in the current 
study and the positions of these points are shown in Figure 3.16. There is a 37 reside 
N terminus domain that only presents in hSIRT2 but not in rSIRT2. 
OLPs were transfected with rSirt2 mutants or control plasmids 48 hours after the 
start of differentiation, and fixed for immunofluorescent staining after another 48 
hours in culture. Overexpression of rSIRT2R/N mutant resulted in the formation of 
aggregate structures in the cytoplasm of a majority of transfected primary OLPs (Fig. 
3.17 A,D). By contrast, the transfection with wildtype rSirt2 or point-mutant 




Figure 3.17 Overexpression of specific mutants of rSIRT2 induced cellular aggregates 
in primary OLPs 
Primary OLP cells were differentiated for 2 days and transfected with rSirt2R/N (A, B, 
D, E), wildtype rSirt2 (G, H) or rSirt2H150Y (J, K). The cells were then subjected to 
immunofluorescent analyses after 48 hours in culture. Antibodies used for staining are 
indicated in the lower left part of each panel, and DAPI was used to visualize the 
nuclei. Scale bars in F and L: 20µm (the one in F is shared by A-F, and in H shared by 
G-L). rSirt2K302Δ single codon-deletion mutant and rSirt2R126C point mutant 
transfected OLPs also exhibited perikaryal aggregates, although in a relatively 
smaller percent of transfected cells. The clumps or granules of aggregation were 
found mostly in the perikarya and occasionally in the cell processes of OLPs (data not 
shown). By contrast, transfection of OLPs with wildtype rSirt2 or several other rSirt2 
mutant constructs (rN131A, rH150Y, rN69A and rN/H) did not produce overt 
aggregate formation in the host OLPs (such as those in Fig. 3.12).  
 
We next investigated such aggregation induced by overexpression of rSirt2 
mutants in immortalized cell lines. OLN-93, 293T, HeLa, SHEP and B104 cells were 
transfected with wildtype rSirt2 or various rSirt2 mutants. As in the primary OLPs, 
overexpression of rSIRT2R/N, rK302Δ and rR126C caused prominent aggregate 
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formation in all cell lines tested (Fig. 3.18 and data not shown), whereas wildtype 
rSirt2 did not give rise to observable aggregation (Fig. 3.18 E). This result indicated 
that aggregation by the rSirt2 mutants in transfected cells was not specific to any cell 
type or species, but a generalized property of the specific protein mutants. rSirt2N69A, 
rN131A and rH150Y transfection in OLN-93 cells produced occasional aggregates (in 
2.9%, 7.0% and 2.9% of the respectively transfected cells), while rN/H gave rise to 
aggregates in about 15% of the overexpressors. The percentages of 
aggregate-positivity by other rSIRT2 mutants ranged from 3.5±1.4% (S53CΔΔ) to 
99.2±1.0% (R/N/K) of transfected OLN-93 cells (Fig. 3.22 B). Transfection by 
rSirt2A80S, rK107Δ, rP182L and rK302Δ, in particular, resulted in aggregates in 
6.0±1.2%, 9.5±1.9%, 16.1±3.3% and 64.9±5.0% of the transfected cells, respectively, 
whereas the number stood at 72.8±3.3% for rSirt2R126C and 85.4±4.5% for 
rSirt2R/N. The slight discrepancy between primary oligodendrocytes and 
immortalized cell lines in aggregates formation by overexpressed rSIRT2N131A, 
rH150Y, rN69A and rN/H might lie in the different properties, such as the 




Figure 3.18 Cellular aggregates triggered in 293T and OLN-93 cells by 
overexpression of specific SIRT2 mutants 
(A-I) Cellular aggregates were triggered by rSIRT2R/N or rK302Δ overexpression in 
OLN-93 (E, I) and 293T (A-D) cells, in comparison to overexpressors of wildtype 
rSIRT2 (H, 293T cell). The aggregates were found as either larger perinuclear 
inclusion bodies (B-E, and I) or smaller punctuate aggregates dispersed widely in the 
cytoplasm (A, D and I). Normal appearances of α-tubulin and β-COP staining were 
observed in most rSirtN131A transfected OLN-93 cells except very sporadic 
occasions (F, G). Antibodies or DAPI used for staining are indicated in the lower left 
part of each panel. Double immunofluorescent staining show overexpressed 
rSIRT2R/N localized in Golgi apparatus (A, B) and occasionally encaged by the latter 
(arrow in B). Arrows and arrowheads in panel D represent IBs and PAs respectively. 
Panels Ia-c are depictions at higher magnification of marked area in I. All scale bars 
(bar in panel H is shared by panels A-H and Ia-c, bar in I): 20µm. 
 
According to the morphology and distribution, the aggregates appeared either as 
large juxtanuclear inclusion bodies (IB) (Fig. 3.18 B-D, F and I) or as smaller 
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punctate aggregates (PA) that were distributed more diffusely in both the cell body 
and cell processes (Fig. 3.18 A, D, I). Usually one individual transfected cell contain 
only one, though occasionally both, type of the aggregates (Fig. 3.18 I). These two 
types of accumulation resembled previously reported aggregates after mutated 
α-synuclein or GFP-250 overexpression (Garcia-Mata et al., 1999; Gosavi et al., 2002; 
Lee and Lee, 2002). Although distinct in morphologies and distributions, PAs and IBs 
share common characteristics in immunofluorescence for β-COP and ubiquitin. The 




11. Mutated SIRT2 clumps deform Golgi apparatus and coaggregate with 
endogenous cellular molecules 
Next, the subcellular distribution and molecular composition of the rSIRT2 
mutant aggregates were assessed. As revealed by double immunofluorescence, the IBs 
by mutated rSIRT2 in transfected OLN-93 and 293T cells were clearly surrounded by 
immunoreactivity of the Golgi-apparatus marker β-COP (Fig. 3.18 B). Accompanying 
formation of the smaller PA particles in rSIRT2 mutant-transfected cells, 
β-COP-positive Golgi apparatus was usually fragmented, but its close relation with 
the aggregates seemed unchanged (Fig. 3.18 A). This proximity/overlap of β-COP 
with aggregated rSIRT2 mutants differed significantly from the normal distribution 
pattern of β-COP in the untransfected control cells (Fig. 3.18 A, B), and in the 
aggregate-free cells transfected with wildtype rSirt2 or rSirt2N131A (Fig. 3.18 H). On 
 95
Results 
Western blots, however, no β-COP was detected in the insoluble pellets of any 
mutated or wildtype rSirt2 transfected cell lysates (Fig. 3.19), in contrast to the 
insolubility of rSIRT2R/N or rSIRT2K302Δ (Figs. 3.21, 3.22 and 3.23). Together, 
these results suggest that the rSIRT2 mutants did not coaggregate with, but were 
nevertheless related to the Golgi apparatus. The formation of PAs may be 
accompanied by disintegration of Golgi apparatus, a phenomenon also seen in certain 
neurodegenerative diseases or cell models (Sakurai et al., 2000; Fujita et al., 2002; 
Gosavi et al., 2002). 
 
Figure 3.19 The aggregates induced by mutated rSIRT2 overexpression contain 
ubiquitinated proteins 
The OLN-93 cells overexpressing different rSIRT2 mutants were lysed in RIPA buffer 
and divided into detergent-soluble (S) and –insoluble (I) fractions, probed with 
anti-ubiquitin and anti-β-COP. “-”: transfection without plasmid. 
 
The ubiquitin-proteasome system (UPS) has been reported to be involved in 
several cases of cellular aggregate formation (Bence et al., 2001; Bennett et al., 2005). 
To test if the aggregates in the rSIRT2 mutants-expressing cells are ubiquitinated, 
double immunofluorescent staining of ubiquitin and FLAG was first performed. In 
 96
Results 
both 293T and OLN-93 cells, mutated rSIRT2 largely overlapped with ubiquitin 
staining in either IB or PA aggregates (Fig. 3.18 D and data not shown). Though also 
detected in the cytoplasm of control cells, levels of ubiquitin were significantly higher 
in the aggregates (Fig. 3.18 D). Between the soluble and insoluble portions of the 
rSIRT2 mutants-overexpressing cell lysates, the transfection of rSirt2R/N and 
rK302Δ, but not wildtype rSirt2 or rSirt2N131A, resulted in significant increases of 
detergent-insoluble ubiquitin signals although most ubiquitin immunoreactivity was 
detected in the supernatants in all five transfection groups (Fig. 3.19). Combined with 
immunofluorescent colocalization of ubiquitin with both IBs and PAs (Fig. 3.18 D), 
these results suggested trapping of ubiquitinated proteins in the aggregates of specific 
rSIRT2 mutants. However, overexpressed rSIRT2 mutants themselves were most 
possibly not significantly ubiquitinated as judged by the absence of obvious 
polyubiquitinated ladder-like bands with ~7kD intervals (Ward et al., 1995; 
Garcia-Mata et al., 1999) at anywhere near the ~37 kD FLAG-rSIRT2 bands in either 
soluble or insoluble parts (Fig. 3.19). Instead, ubiquitinated intrinsic cellular proteins 
probably coaggregated with overexpressed rSIRT2 mutants. 
In primary OLPs that often began to bear endogenous CNP expression at the end 
of the transfection experiments, rSIRT2 mutant aggregates often immunostained also 
positive for CNP (Fig. 3.17 A-C). The cytoplasmic space surrounding the aggregates, 
in contrast, unusually showed low levels of both rSIRT2 and CNP immunoreactivities. 
This result indicates coaggregation of CNP together with the overexpressed 
aggregation-prone low-solubility rSIRT2 mutants (Fig. 3.17 A-C). 
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The overall distribution of the microtubule network as revealed by 
immunostaining of α-tubulin or acetylated α-tubulin in the transfected cells, was not 
overtly affected by the formation of rSIRT2 mutants aggregates (Figs. 3.17 D and 
3.18 C, F, G, I). Neither IB nor PA clumps colocalized with α-tubulin staining to any 
significant extent (Figs. 3.17 D-F and 3.18 C, F, G, I). Immunostaining of α-tubulin 
in the area of rSIRT2 mutants aggregates, on the contrary, was usually lower in 
comparison to that in other part of the cytoplasm or in cells without aggregates (Fig. 
3.18 C, F, G, I). As compared to that in the wildtype Sirt2-transfected or the 
untransfected controls, solubility of α-tubulin was also not significantly affected by 
overexpression of aggregation-prone rSIRT2 mutants. The majority of α-tubulin was 
consistently detected in soluble portion of cell lysates on Western blots of all 
transfection groups. Figure 3.18B shows such examples with rSirt2, rSirt2N131A, 












12. Cytoplasmic aggregates were not induced by the loss of rSIRT2 deacetylase 
activity 
 
Figure 3.20 rSIRT2 mutant-induced aggregation is not resulted from loss of 
deacetylase activity 
Primary OLP cells were differentiated for 6 days and transfected with siRNA against 
rSIRT2 (C, D, E); they were analyzed after 48 hours in culture. The knockdown effect 
of endogenous rSIRT2 was obvious as judged by either immunofluorescence (C) or 
Western blots (E) in comparison to untransfected controls (A, E). No aggregate 
formation was observed in these rSIRT2-deficient cells. Normal OLP cells in panels A 
and B were presented as controls. β-actin was used as loading control in Western blots 
(E). Antibodies or DAPI used for staining are indicated in the lower left part of each 
panel. Scale bars in all panels: 20µm. 
 
rSIRT2 as an α-tubulin and histone deacetylase could be partially inactivated by 
specific point mutations (Finnin et al., 2001; North et al., 2003). These results were 
confirmed in our previous experiments (Li et al., 2007). We next investigated if the 
present mutation-induced aggregate formation is related to the deacetylase activity 
loss of rSIRT2 mutants in transfected cells. Though both rSIRT2H150Y and rD133A 
are both known to be partially deacetylase-defective, their propensity to cause 
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aggregate formation in transfected cells differed markedly. rSIRT2H150Y triggered 
none or only occasional aggregates formation, whereas rSIRT2D133A caused 
aggregates in over 60% of the transfected OLN-93 cells (Fig. 3.22 B). To further 
clarify the issue, we used three siRNA duplexes of rSIRT2 to transfect and 
knockdown endogenous rSIRT2 activity in primary OLPs. As shown by 
immunofluorescence and Western blots, the knockdown of rSIRT2 mRNA effectively 
diminished native rSIRT2 expression (Fig. 3.20 C,E), but produced no observable 
aggregates in the rSIRT2-depletd cells (Fig. 3.20 D). These results indicated that 
aggregate formation in the transfected cells was unlikely a result of deacetylase 
activity loss of the aggregation-prone rSIRT2 mutants. 
 
13. Solubility decrease contributes to aggregate formation by rSIRT2 mutants  
If not the biological enzyme activity loss, we next questioned whether 
mutation-induced modifications of the protein biophysical properties determined or 
related to aggregates formation. In fact, through quantitative analyses, an obvious 
trend of inverse correlation between solubility and aggregate formation propensity of 
rSIRT2 mutants was established (Fig. 3.22 B). Solubility in RIPA buffer, for example, 
was 80.5±2.9% for rSIRT2, 23.2±6.7% for rSIRT2N131A and 0.6±0.1% for 
rSIRT2R/N (Western blots were at least repeated twice for each sample), whereas 
aggregate formation by the three was in 0.5±1.1%, 7.0±2.3% and 85.4±4.5% of 
transfected OLN-93 cells, respectively. There also seemed a cumulative effect of 
selected point mutations on insolubility and aggregation-prone property. 
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Overexpressed rSIRT2N/H, for example, appeared to be less soluble than either 
rSIRT2N131A or rH150Y, and this rSIRT2 double-mutant gave way to higher 
percentage of aggregate-positive cells. All together, these results suggested that the 





Figure 3.21 Decreased solubility may contribute to aggregate formation by SIRT2 
mutants 
(A) OLN-93 cells transfected with different plasmids as indicated were lysed 48h 
after transfection in three buffers with increasing detergent strength: PBS with 2% 
triton X-100 (TXPBS), IPB, RIPA, divided into detergent-soluble (S) and –insoluble 
(I) fractions and probed with anti-FLAG or anti-α-tubulin antibodies. “-”: transfection 
without plasmid;  
(B) Solubility kinetics of rSIRT2 mutants after overexpression. OLN-93 cells were 
transfected with three representative mutants as indicated. After 12, 24, 36, 48 or 72 
hours, the cell lysates were divided into RIPA soluble and insoluble portion and 
subjected to Western blotting.   
 
Next, we tested the solubility kinetics of selected SIRT2 mutants after 
overexpression in OLN-93 cells. OLN-93 cells were lysed 12, 24, 36, 48 or 72 hours 
after transfection, and subjected to Western blot analyses. From the early stages (e.g., 
12 hours) after overexpression, all SIRT2 mutants tested (H150Y, R/N and P182L) 
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showed decreased solubility in comparison with that of wildtype SIRT2. SIRT2R/N, 
which formed aggregates in most transfected cells (Fig. 3.22 B), was almost 
completely insoluble throughout the course of the overexpression (Fig. 3.21 B). 
Gradual decreases of solubility were observed for both SIRT2 wildtype and two other 
mutants. The attenuations for the SIRT2H150Y and P182L mutants, however, seemed 
accelerated and more significant than for wildtype SIRT2 (Fig. 3.21 B).  
 
 
Figure 3.22 An inverse correlation between aggregate-triggering propensity and 
protein solubility of mutants  
(A) Forty-eight hours after transfection, OLN-93 cells were lysed by RIPA buffer, and 
the distribution of wildtype or 15 mutated SIRT2 proteins in soluble supernatants (S) 
or insoluble pellets (I) of the cell lysates were examined by Western blots.  
(B) Quantitative analysis of the solubility of 15 different SIRT2 mutants according to 
the Western blots immunoreactivities (as in panel D) and the corresponding 
aggregate-positive cell percentages after their transfection in OLN-93 cells. A trend of 
inverse correlation could be clearly observed between solubility and aggregate 
formation propensity of these mutants. Solubility decrease of SIRT2 mutants in 





Consistent with the speculation that solubility decrease contributed to aggregate 
formation, a portion of the transfected cells at early stages after overexpression were 
already aggregate-positive. At 12 hours after transfection, for example, 
aggregate-positive cells were 1.2±1.1% for rH150Y group, 5.2±1.1% for rP182L and 
50±4.8% for rR/N. Accompanying the gradual decreases of solubility along the course 
of overexpression (Fig. 3.21B), the percentages of aggregate-positive cells, by 
contrast, increased gradually, and reached 2.9±1.3% for rSirt2H150Y, 16.1±3.3% for 
rP182L and 85.4±4.5% for rR/N at 48 hours after transfection. Overall, these data 
supports the notion that aggregate formation by rSIRT2 mutants rooted, at least in part, 
from solubility decreases of the mutated molecules. The kinetics of gradual but 
enhanced insolubilization as demonstrated by some of the mutants may implicate 
possibility of delayed or chronic aggregation by mutants of such type (Fig. 3.21B). 
 
14. A protective role of the N-terminus domain of human SIRT2 against 
solubility loss and aggregation 
As mentioned, different from rSirt2, mutations introduced into hSIRT2 only 
attenuate protein solubility but were incompetent to induce prominent aggregate 
formation (Fig. 3.23B). In addition, higher solubility was invariably detected for all 
overexpressed hSIRT2 and mutant proteins in comparison to rSIRT2 with mutations at 
corresponding positions (Figs. 3.21, 3.22 and 3.23). For example, the solubility of 
rK302Δ was 6.2±3.7% as compared to 66.2±1.5% of rSIRT2, whereas that of hK339Δ 
was found to be 32.0±1.6% as compared to 99.2±0.2% of hSIRT2. Similar results 
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were observed for all other 5 mutants (Figs. 3.22B and 3.23B). But the higher 
solubility of hSIRT2 and its mutants may not account for the absence of aggregates in 
OLN-93 overexpressors. The evidence is that some hSIRT2 mutant bears a solubility 
akin to that of rSIRT2 mutants (i.e. hR163C 17.8±4.5% versus rP182L 17.0±7.0%), 
but possesses significantly different ability to cause aggregate formation (hR163C 
~0% versus rP182L 16.1±3.3%).  
 
Fig 3.23 Upon overexpression, hSIRT2 mutants showed solubility decrease but did 
not cause aggregate formation 
(A) OLN-93 or 293T cells transfected with wildtype hSirt2 and its mutants as 
indicated were lysed 48h after transfection in RIPA buffer, then divided into 
detergent-soluble (S) and -insoluble (I) fractions and probed with anti-HA or 
anti-α-tubulin.  
(B) Bar graphs showing the mutant solubility and aggregate-positive cell percentages 
after transfection of different hSirt2 mutants in OLN-93 cells as described in panel A. 
 
We thus sought to understand the mechanisms underlying such a discrepancy 
between these two SIRT2 homologues. Both rSIRT2 and hSIRT2 possesses 
NAD-dependent deacetylase activity and can be inactivated by specific mutations at 
correspondingly same positions (North et al., 2003; Li et al., 2007). The most 
significant structural difference between the two orthologs might be the 37-residue N 
terminus domain (hNter) which only present in hSIRT2 (Fig. 3.16). We questioned 
whether this hNter domain could be the player causing such difference. We firstly 
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tested the effects if this domain was deleted from hSIRT2 (Fig. 3.24). The 
hNter-deletion forms of wildtype and three hSIRT2 mutants (NΔhSIRT2, NΔhA117S, 
NΔhA198T and NΔhK339Δ) were constructed into HA-tagged pXJ40 vector and 
transfected into OLN-93 cells. As shown in Figure 3.25A, 24hrs after transfection, 
the solubility of overexpressed hSIRT2 and its mutants was greatly attenuated after 
hNter deletion. For example, the solubility of hSIRT2 is 95.1±1.0%, whereas that is 
4.7±1.4% for NΔhSIRT2. Solubility of NΔhA117S, NΔhA198T and NΔhK339Δ are also 
significantly decreased in comparison to their counterparts bearing hNter (Fig. 3.25 A, 
B). Consistent with the notion that solubility is one of the determinants of aggregate 
formation, the solubility decrease after hNter deletion was accompanied by increases 




Fig 3.24 Schematic diagram showing four different kinds of human, rat or human-rat 
chimera SIRT2 used in this study 
 
We next investigated if the addition of the hNter to rSIRT2 could change the 
biochemical and cellular properties of rSIRT2 and its mutants (Fig. 3.24). As shown 
in Figure 3.25A and B, 24hrs after transfection, the solubility of rSIRT2 and its 
mutants is 57.9±1.6% (rSIRT2), 48.9±0.7% (rA80S) and 24.6±3.3% (rK302Δ). By 
contrast, the solubility of chimera hNrSIRT2, hNrA80S and hNrK302Δ is greatly 
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improved and reached 95.8±1.1%, 89.6±4.3%, and 37.3±2.9%, respectively. This 
piece of result strongly suggested that hNter of hSIRT2 may prevent the solubility 
decrease of SIRT2 mutants. The aggregate formation percentages in the transfected 
OLN-93 cells were also assessed. The addition of hNter into rSIRT2 inhibited the 
aggregation of the later. Taking rK302Δ as an example, the aggregate percentages 
reduced from 14.7±2.1% to 3.6±0.5% after addition of hNter (data collected 24hrs 
after transfection) or from 61.3±6.2% to 5.4±1.2% (48hrs after transfection). 
As presented above in Figure 3.21B, mutant rSIRT2 proteins exhibited kinetics 
of gradual insolubilization after overexpression. In this regard, the current 
experiments also indicated that the presence of hNter in the overexpressed proteins 
greatly inhibited the time-dependent progression of protein insolubilization. In 
between 24 and 48 hours post transfection, the solubility of rSIRT2 in RIPA buffer 
decreased from 90.4±2.0% to 57.9±1.6%, in sharp contrast to that of hNrSIRT2, the 
change of which is not statistically significant (96.0±0.4% to 95.8±1.1%). Similar 
trends are also observed for rA80S and rK302Δ as compared to their chimera 
counterparts (Fig. 3.25 A, B). Take together, all these results demonstrated that the 
37aa N terminus domain of hSIRT2 may play a role to inhibit the insolubilization of 






Fig 3.25 Protection of hSIRT2 N-terminus domain against solubility loss and protein 
aggregation 
 (A) OLN-93 cells were transfected with different kinds of human, rat or 
human-rat chimera SIRT2 plasmids as indicated. 24 or 48 hours post transfection, the 
cells were lysed and divided into RIPA detergent-soluble (S) and -insoluble (I) 
fractions and probed with anti-HA or anti-α-tubulin. Note the molecular weight 
difference between proteins with and without hNter is around 4kDa. 
(B) Bar graphs showing the mutant solubility and aggregate-positive cell 
percentages after transfection of different kinds of human, rat or human-rat chimera 
SIRT2 plasmids as described in panel D. In each transfection time point, the solubility 
of hSIRT2 or its mutants was compared to corresponding hNter deletion forms; 
similarly, solubility of rSIRT2 or its mutants was compared to their respective forms 
with addition of the hNter domain. The aggregate-bearing transfection cell 
percentages were also assessed. 
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15. Microtubule and HDAC6 functions affect the aggregate formation induced 
by SIRT2 mutants 
Several reports have implicated involvement of both microtubule network (MT) 
and HDAC6 in the formation (Johnston et al., 2002; Kawaguchi et al., 2003; Tanaka 
et al., 2004) or degradation of protein aggregates (Johnston et al., 1998). We hence 
investigated possible roles of MT and HDAC6 in the SIRT2 mutants-triggered 
aggregates formation. These experiments were carried out in 293T cells that bear 
endogenous HDAC6 expression. We first examined the effects of nocodazole and 
taxol, well-established microtubule destabilizing and stabilizing reagents, on SIRT2 
mutants-related aggregates formation.  
After wildtype Sirt2 transfection, both treatments did not cause aggregate 
formation. But as shown in Figure 3.26 B, in all three transfections by rR/N, rK302Δ 
and R126C, the addition of nocodazole significantly increased the aggregate-positive 
cell percentages in transfected cells, whereas taxol treatment exhibited the opposite 
effects (Fig. 3.26 B). In terms of the relative number of IB- and PA-positive cells, 
taxol treatment did not induce obvious change of the ratio between the two as 
compared to the control (Fig. 3.26 C), but nocodazole seemed promoting formation of 
PA aggregates and inhibiting that of IBs (Fig. 3.26 C). Neither of the two drugs 
significantly altered the detergent-solubility of FLAG-tagged SIRT2 mutants (Fig. 
3.26 A). Put together, these results indicated that stabilization of MT may inhibit the 
aggregates formation, and MT destabilization by nocodazole preferably promoted the 




Figure 3.26 Stability of microtubule network influences the formation of aggregations 
but not protein solubility 
(A) Thirty-six hours after transfection with Sirt2R/N, 293T cells were treated for 12 
hours with various concentrations of taxol and nocodazole (Noco) as indicated before 
eventual cell lysis by RIPA buffer. Cell lysates were then divided into RIPA soluble (S) 
and insoluble (I) portion and subjected to Western blots analysis. The result indicated 
that treatment of these drugs, though changed the IB-to-PA ratio (panel C), did not 
significantly affect the solubility of rSIRT2 mutants. “conc.”: concentration of drugs. 
(B) 293T cells were transfected with rSirt2R/N, rR126C or rK302Δ, and treated with 
either taxol (10µM) or nocodazole (10µg/ml) in the culture medium 36 hours after 
transfection. The treatment persisted for 12h before the cells were fixed and subjected 
to immunofluorescent staining. Statistical analysis shows the percentages of 
aggregate-positive cells out of all transfected 293T cells in each transfection group. 
(C) Statistical analysis of the percentages of IB-positive and PA-positive cells out of 
rSirt2R/N transfected cells after treatment by taxol (10µM) or nocodazole (10µg/ml) 
as described in panel B legend.  
 
In 293T cells, when rSirt2R/N was cotransfected with an effective HDAC6 
siRNA duplex that would knockdown endogenous HDAC6 expression of the cells 
(Fig. 3.27 A), the percentage of aggregate-positive cells was significantly reduced 
without obviously altering the IB-to-PA positivity ratio (Fig. 3.27 B), as compared 
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with the rSirt2R/N-JN siRNA cotransfection control group. HDAC6 did not co-pellet 
with FLAG-rSIRT2R/N in detergent-insoluble portion of cell lysates in RIPA buffer 
(Fig. 3.27 C). 
 
 
Figure 3.27 HDAC6 is required for the formation of aggregates triggered by rSIRT2 
mutants 
(A) Western blots showing endogenous HDAC6 was successfully knocked down in 
293T cells; β-actin was used as the loading control. 
(B) 293T cells were transfected with rSirt2R/N only, rSirt2R/N plus siHDAC6, or 
rSirt2R/N plus siJN. Thirty-six hours after transfection, cell counting based on 
immunofluorescent staining indicated percentages of aggregate-positive cells out of 
all transfected 293T cells.  
(C) 293T cells transfected with rSirt2, rSirt2R/N and rK302Δ were lysed in RIPA 
buffer, the soluble (S) and insoluble (I) portions were subjected to Western blot 
















1. SIRT2 as a protein preferentially expressed in oligodendrocytes 
By means of ISH, IHC and double labeling, the present study identified SIRT2 
was preferentially expressed by oligodendrocytes. This result agrees with previous 
proteomics studies that have identified SIRT2 in the myelin sheath (Vanrobaeys et al., 
2005; Southwood et al., 2007). In comparison with various markers of developing and 
mature oligodendrocytes/myelin sheath, spatial and temporal profiles of SIRT2 
expression closely matched those of CNP except in oligodendrocytic cell bodies 
where little SIRT2 was found. In Figure 3.3, SIRT2 and CNP expression levels were 
demonstrated to be co-variants along the progression of oligodendrocyte development 
in vivo. The two molecules colocalize in various regions of the CNS (Fig. 3.6 A-D,K). 
There is also in vitro evidence, such as those in Figs. 3.11, 3.14 and 3.15. In this 
connection, it is noteworthy that CNP, like SIRT2, is also a tubulin-associated 
oligodendroglial protein in the CNS (Bifulco et al., 2002; Lee et al., 2005). 
Unlike the absence of SIRT2 in the majority of oligodendroglial perikarya in the 
adult CNS, clear SIRT2 signals were observed in the cell bodies of cultured primary 
OLPs. This dissimilarity in subcellular distribution of the protein most likely reflected 
differences between mature oligodendrocytes in the adult CNS and oligodendrocyte 
precursors in the culture. 
 
2. SIRT2 as a differentiation inhibitor of oligodendrocytes 
Among others, cytoskeleton-associated oligodendroglial proteins such as CNP, 
JN and mayven, have been recently reported to regulate oligodendrocytic process 
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outgrowth, gene expression and/or myelin-axon interaction (Jiang et al., 2005; Lee et 
al., 2005; Zhang et al., 2005). The present results showed that SIRT2 is yet another 
member of the protein family, but probably functions as a “braking” mechanism in 
oligodendroglial development. Overexpression of SIRT2 significantly inhibited the 
oligodendroglial arborization and tubulin acetylation, indicating retardation of the 
cells’ course of specialization, whereas siRNA knockdown of endogenous SIRT2 had 
the opposite effects. This inhibitory role of SIRT2 is further supported by our finding 
that overexpression of the protein counteracted the facilitatory effects of JN on 
arborization of OLN-93 oligodendrocyte cell line. Interestingly, SIRT2 has been 
implicated in regulating adipocyte differentiation (Jing et al., 2007). Its family 
homologue SIRT1 represses myocyte differentiation (Fulco et al., 2003). 
 Blockade of HDAC activities by TSA and valproic acid (VPA) was found to 
delay oligodendroglial differentiation (Marin-Husstege et al., 2002; Liu et al., 2003; 
Hsieh et al., 2004; Shen et al., 2005). The results were confirmed by our experiments 
(data not shown). Since SIRT2, as a member of class III HDACs, is not inhibited by 
TSA (North et al., 2003), these results clearly indicate the involvement of other 
HDACs in regulating oligodendroglial differentiation. HDAC6, another known 
tubulin deacetylase, was coimmunoprecipitated with SIRT2 when overexpressed 
together with SIRT2 (Hubbert et al., 2002; North et al., 2003). But expression pattern 
study seemed against the possibility that HDAC6 is involved in oligodendrocyte 
differentiation because this molecular predominantly presents in neurons (Southwood 
et al., 2007). Future studies are necessary to understand which HDAC members 
 113
Discussion 
mediate the effect of such inhibition. 
Apart from regulating differentiation, the abundant SIRT2 immunoreactivity in 
adult oligodendrocytes (present results) entails functional roles of the protein in the 
mature CNS. Under the electron microscope, SIRT2 was mainly found in the 
non-compact outer and terminal loops of myelin sheath. This subcellular positioning 
and the tubulin deacetylation activity seemingly pointed to possible roles of the 
protein in subcytoarchitecture, molecular trafficking or myelin-axon signaling of 
oligodendroglia. Other cytoskeleton-related oligodendroglial proteins like CNP and 
JN have also been implicated in similar functions (Bifulco et al., 2002; Lappe-Siefke 
et al., 2003; Zhang et al., 2005). 
 
3. SIRT2 expression, tubulin deacetylation and oligodendroglial differentiation 
The present results demonstrated functional roles of tubulin acetylation in 
maturation of oligodendroglia, as well as SIRT2-mediated tubulin deacetylation in 
decelerating the differentiation/aging of the cell. Our data indicated that SIRT2 action 
in oligodendrocytes was most likely mediated through tubulin deacetylation. First, as 
revealed by our in vivo and cell culture results (Figs.3.6 and 3.11), SIRT2 was 
primarily an oligodendroglial cytoplasmic protein mainly localized to the cellular 
processes and non-compact cytoplasm-containing parts of myelin sheath, in 
agreement with previous data (Perrod et al., 2001; North et al., 2003; Vanrobaeys et 
al., 2005). Second, SIRT2 was colocalized with acetylated α-tubulin in cultured 
primary OLPs. Third, wildtype SIRT2 rather than SIRT2 mutants (SIRT2N131A and 
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SIRT2H150Y) simultaneously diminished its tubulin deacetylase activity and its 
inhibition of OLP morphological differentiation, and siRNA knockdown of SIRT2 
gave rise to similar effects (Figs. 3.9 and 3.15). Finally, comparison of Western 
blotting results from the anti-acetylated lysine and the anti-acetylated α-tubulin 
antibodies identified α-tubulin as the main substrate for SIRT2 among OLN-93 
cytoplasmic proteins (Figs. 3.9 and 3.10). In comparison to histones, tubulin has been 
demonstrated as a preferred substrate of SIRT2 (North et al., 2003). Our in vitro 
deacetylation test also indicated a NAD-dependent tubulin deacetylase activity of 
SIRT2. Hence tubulin deacetylation through SIRT2 probably represented yet another 
important mechanism in the complex cytoskeletal control of oligodendrogenesis and 
myelinogenesis, in parallel to those mediated through other cytoskeleton-related 
proteins such as MAP2, Tau, CNP and JN (LoPresti and Konat, 2001; 
Richter-Landsberg, 2001; Lee et al., 2005; Zhang et al., 2005). 
It remains unclear how tubulin deacetylation by SIRT2 was translated into altered 
cytoplasmic extensions and delayed differentiation of oligodendrocytes. A plausible 
hypothesis might be that deacetylation lowered microtubule stability, reduced tubulin 
polymerization, increased depolymerization, or altered the binding of tubulin to 
associated proteins, as previously suggested in other cell types (Piperno et al., 1987; 
Robson and Burgoyne, 1989; Hubbert et al., 2002). 
SIRT2 has also been shown to interact with histones H3, H4 (North et al., 2003; 
Vaquero et al., 2006) and transcription factor HoxA10 (Bae et al., 2004). Our electron 
microscopic observation also found SIRT2, albeit at lower levels than in the 
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cytoplasm, in the nuclei of a limited number of oligodendroglia. However, it seems 
that the acetylation levels of histone H3 (K14) and H4 (K16) were not altered in 
OLN-93 cells overexpressing SIRT2 (Fig. 3.9), suggesting the 
differentiation-inhibitory roles deciphered by the present data was not mediated 
through regulating histone acetylation. Future investigations are necessary to 
determine the circumstances/factors that govern the substrate selection (tubulin vs. 
histones, for example) and subcellular distribution (cytoplasmic vs. nuclear) of SIRT2. 
 
4. Overexpression of mutated forms of rSIRT2 differentially induce aggregate 
formation 
As illustrated by the current study and other reports, SIRT2 is an oligodendroglial 
protein in the CNS (Vanrobaeys et al., 2005; Li et al., 2007; Southwood et al., 2007). 
The current study identified that certain mutants of rSIRT2, when overexpressed, 
would trigger detergent solubility decreases of the proteins and cellular aggregates 
formation in a deacetylase activity-independent manner. At cellular level, similar 
characteristics could be found between rSIRT2 mutant aggregates as reported here and 
mutants aggregates of other proteins, such as parkin, α-synuclein, prion protein, 
peripheral myelin protein 22 (PMP22) and polyglutamine-containing proteins (Lee 
and Lee, 2002; Taylor et al., 2002; Ardley et al., 2003; Rajan and Kopito, 2005; 
Grenier et al., 2006). These similarities include that (1) formation of aggregates are 
related to solubility decreases of the protein mutants, and influenced by functions of 
MTs; (2) aggregates colocalized with ubiquitin; (3) affected cells exhibit 
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fragmentation of Golgi apparatus; and (4) aggregates appeared as either PAs dispersed 
throughout the cytoplasm or large IBs juxtanulearly localized. 
 
5. Deacetylase activity loss is not the cause of aggregate formation 
SIRT2 functions as NAD-dependent protein deacetylase using α-tubulin or 
histones as substrates (North et al., 2003; Li et al., 2007). Mutations of the enzyme 
cause variable loss of its deacetylase activity (Finnin et al., 2001; North et al., 2003). 
A possibility arises as whether the aggregation of SIRT2 mutants and endogenous 
oligodendroglial proteins (such as CNP in Fig. 3.17) was due to the loss of the 
deacetylase activity. Aggregation of the protein mutants would deplete availability and 
cause a further loss of the enzyme activity indirectly as has been suggested for 
mutants of other proteins, e.g., parkin (Sriram et al., 2005). Although theoretically 
conceivable, such a possibility was not supported by the present experimental data. 
siRNA knockdown of endogenous rSIRT2 in primary OLPs caused no obvious 
aggregates, and overexpression of other point-mutated deacetylase-defective rSIRT2 
also did not resulted in pronounced aggregates formation in transfected cells. Three of 
the 12 mutated residues examined (rN131A, rH150Y and rD133A) in the present 
study are in adjoining regions of rSIRT2 (Fig. 3.16; Finnin et al., 2001), and are 
known to be deacetylase-defective in vitro and in cultured cells (North et al., 2003). 
But the insolubility and aggregate-forming propensity of the three differed drastically. 
rSIRT2N131A and rH150Y were similar to wildtype rSIRT2 in these two aspects 




6. Determinant of aggregate formation 
6.1 Insolubility, cytoplasmic aggregate formation and cytotoxicity of rSIRT2 
mutants 
Rather than activity loss, mutation-induced detergent insolubility was 
demonstrated to be related to aggregates formation in our current system. It is striking 
to note that in comparison with wildtype rSIRT2, all 15 rSIRT2 mutants tested in the 
present study showed lower solubility in the presence of 0.1% SDS, and their 
propensity to form aggregates in transfected cells was inversely correlated with their 
detergent solubility. Furthermore, complex rSIRT2 mutants combining two or three 
point mutations exhibited not only lower solubility but also accordingly higher 
aggregate formation propensity as compared to mutants harboring any of the single 
mutations (Fig. 3.22).  
This conclusion is seemingly contradictory to our results that hSIRT2 mutants 
induced attenuated solubility in comparison to wildtype but no prominent aggregate 
formation (Fig. 3.23). We proposed that the reason for this discrepancy lay in the 
difference between rSIRT2 and hSIRT2. The 37aa hNter, as suggested by present data, 
protects hSIRT2 and its mutants from solubility decrease (see below). When this 
domain was deleted, the inverse correlation operates again (Fig. 3.25). Also, we 
proposed that the cell machinery might have different tolerance threshold to decreased 
solubility of different mutated proteins. For rSIRT2 proteins in OLN-93 cells, this 
threshold seemed to be somewhere between that of rSIRT2P182L (solubility 17±6.9%) 
 118
Discussion 
and rK302Δ (solubility 6.2±3.7%), because rSIRT2 mutants with solubility higher 
than ~17% only generated scarce aggregate-positive cells, but those lower than this 
threshold caused sharply increased number of aggregates (Fig. 3.22). In this regard, 
the difference between OLPs and OLN-93 cells in aggregate formation by some of the 
rSIRT2 mutants might also be partly attributed to the difference of the tolerance 
thresholds derived from variations in molecular trafficking, ubiquitin-proteasome 
system, binding partners and/or molecular chaperones across cell types. The 
microtubule-associated protein CNP, for example, is present in OLPs, but absent in 
OLN-93 cells (data not shown). 
Factors affecting rSIRT2 solubility have not been well elucidated. The crystal 
structure of hSIRT2, however, has been reported (Finnin et al., 2001). As all the 
rSIRT2 residues subjected to point mutations in the current study are conserved 
between rat and human, detailed analyses and comparison of human and rat SIRT2 
may provide some clues to the mutation-induced rSIRT2 solubility alterations. First, 
direct biophysical property change and conformational shifts may happen in response 
to point mutations (Garzon-Rodriguez et al., 2000; Ippel et al., 2002; Fasano et al., 
2006). Investigations have shown that biophysical properties such as solvent 
accessibility (SA) significantly differ between soluble and amyloid forms of prion 
protein (Nazabal et al., 2003) (SA: the ratio of the solvent accessible surface area of 
an amino acid residue in a folded protein structure to that in the unfolded structure, 
which would be generally lower for hydrophobic residues than hydrophilic ones (Lee 
and Richards, 1971). R126 of rSIRT2, for example, is a residue predicted with low SA 
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and buried from solvent (Finnin et al., 2001), the substitution of which might 
compromise the overall or partial solvent accessibility of rSIRT2 protein, and resulted 
in the decreased solubility. Property of the substitute amino acid may bring in new 
modifications of the protein mutants, as is the case with phosphorylation of tau 
(Sahara et al., 2002). Properties and functions SIRT2 are also influenced by 
phosphorylation (Dryden et al., 2003). 
Detergent insolubility has recently emerged as a common feature of many protein 
mutants involved in pathogenesis of diverse neurodegenerative diseases or in 
aggregation formation/cytotoxicity in cultured cells (Garcia-Mata et al., 1999; Wang 
et al., 1999; Johnston et al., 2000; Shinder et al., 2001; Sahara et al., 2002). Many 
studies connect aggregation of these disease-associated proteins to cell death or 
cellular toxicity in diseases. For example, the aggregation status of huntingtin protein 
is believed to determine neuronal loss in Huntingtin disease (Bates, 2003). Fibrillar 
α-synuclein aggregation into Lewy bodies is associated with nigrostriatral 
degeneration in PD (Lee and Trojanowski, 2006). One study suggested that, in protein 
misfolding diseases, the aggregates in host cells bearing them are inherently toxic 
(Bucciantini et al., 2002).A study on familial-associated mutations of parkin revealed 
that the aggregation of parkin might cause a sequestration of the enzymatic activity of 
this protein from its native substrates, which results in accumulation of toxic 
substrates of parkin and cellular toxicity (Sriram et al., 2005). On the contrary, 
inhibition of protein aggregation may prevent the cytotoxicity (Liu et al., 2004). 
In terms of cytotoxicity or pathogenecity, aggregates may not only present as 
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mechanical barriers of molecular trafficking or as reservoirs of toxic mutant 
molecules, but also trap endogenous proteins of the cell and affect their normal 
functions. Previous studies showed that disease-associated mutants of PLP and 
PMP22, two integral membrane proteins of the myelin sheath, promoted formation of 
not only homodimers or oligomers of the mutants themselves, but also heterodimers 
or oligomers of the mutant molecules together with the wildtype proteins that were 
thus prevented from reaching the cytoplasmic membrane to perform normal functions 
(Yool et al., 2000; Suter and Scherer, 2003). These dimers/oligomers may accumulate 
later on and was considered as the direct cause of oligodendrocyte death (Tobler et al., 
2002; Swanton et al., 2005).  
6.2 Factors in addition to solubility decrease contributed to rSIRT2 
mutation-induced aggregates formation 
However, the current study indicated that solubility does not act as the unique 
regulating factor of aggregate formation. The present results support the notion as in 
previous reports that structural and functional status of intracellular trafficking or 
degradation affects aggregate formation (Kopito, 2000; Johnston et al., 2002; Riley et 
al., 2003; Bauer and Richter-Landsberg, 2006). First, the overall aggregate-positive 
cell numbers increased in the presence of nocodazole and decreased in the presence of 
taxol (Fig. 3.26), indicating that the formation of aggregates could be influenced by 
functional status of the microtubule trafficking or misfolding-cleaning mechanisms. In 
this regard, it is noteworthy that both nocodazole and taxol treatment were reportedly 
inhibiting in tau aggregate formation in OLN-t40 cells (Bauer and Richter-Landsberg, 
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2006). Second, overexpression of rSIRT2R/N or rK302Δ also resulted in aggregation 
of the cytoskeleton-related endogenous CNP of OLPs (Fig. 3.17) which indicates 
disruption of normal trafficking of oligodendroglial proteins.  
Aggregation-inducing protein mutants have also been suggested to directly 
coaggregate with cytoskeleton (Refolo et al., 1991), or result in profound cytoskeletal 
elements reorganization or redistribution such as the intermediate filaments (IFs) 
protein, vimentin (Johnston et al., 1998). However, in oligodendrocytes which do not 
contain a cytoplasmic IF system, it is intriguing how the aggregates influence the 
cytoskeleton. Our current result showed no coaggregation between SIRT2 mutants 
and α-tubulin in both IBs and PAs (Figs. 3.17 and 3.18). Instead, the IBs were usually 
surrounded by bundles of tubulin staining (Fig. 3.18 C,F), which is consistent with a 
previous report about oligodendrocytic aggresomelike inclusions in cell line OLN-t40 
(Bauer and Richter-Landsberg, 2006). 
Another result from the current study is that HDAC6 activity influenced rSIRT2 
mutants-induced aggregates formation, similar to a previous report in other cell 
models (Kawaguchi et al., 2003). However, HDAC6 was not pivotal for the 
transformation between PAs and IBs in our model, partly in contradiction to a 
previous report in which HDAC inhibition impaired the microaggregates 
transportation to MTOC to form large aggresomes (Corcoran et al., 2004). Overall, 
the current results on roles of MT network and HDAC6 in aggregate formation were 
mostly consistent with previous studies. Some of the discrepancies may be expected 
considering the heterogeneous nature of aggregate formation. The biochemical 
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properties of the aggregation-prone proteins themselves, for examples, would be 
crucial determinants. The specific environments of the host cells may also exert 
significant influences. Also, other future investigations are necessary to figure out the 
molecules playing the role of HDAC6 in oligodendrocytes. 
 
Taken together, our current study suggested that solubility decrease was a direct 
result of protein mutations, which in turn only acts as a prerequisite for aggregate 
formation. The final extent to which aggregates formed are still determined by other 
factors, such as MT and HDAC6 mediated trafficking or degradation as implicated in 
current study (Figs. 3.26 and 3.27). But on the contrary, aggregate formation rooted 
from but was not solely determined by mutation-induced solubility attenuation. 
Aggregates to date almost invariably happened together with impaired protein 
solubility (Wang et al., 1999; Johnson, 2000; Shinder et al., 2001; Sahara et al., 2002;  
Sriram et al., 2005). 
 
7. The extra N terminus domain endows hSIRT2 protection from 
mutation-induced insolubility and aggregation 
Human SIRT2 is predicted to exist in two different isoforms as a result of 
alternative splicing (Voelter-Mahlknecht et al., 2005). But almost all studies about 
hSIRT2 are dedicated to the isoform bearing 389aa (hSIRT2_v1) rather than the other 
without the N-terminus 37-residue domain (352aa, hSIRT2_v2). The current study 
identified a role of this hNter domain in protecting the insolubilization and 
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aggregation of mutated SIRT2 proteins. The presence of hNter domain in hSIRT2 
largely prevents the formation of mutation-induced aggregates and increased the 
detergent solubility of mutants as compared to rSIRT2 counterparts. The deletion of 
this domain from both wildtype and mutated hSIRT2 proteins resulted in their 
solubility attenuation as well as increased propensity to form cellular aggregates (Fig. 
3.25). While the addition of this domain could help to prevent rSIRT2 from 
insolubilization and aggregation after being mutated or overexpression time was 
prolonged. These results raised a possibility that hNter domain plays a protective role 
against SIRT2 protein malformation and dysfunction.  
Though brain-specific genes in mammals are reported to exhibit a lower rate of 
evolution than genes expressed in other tissues, the trend seems to be reversed in the 
human lineage (Dorus et al., 2004; Wang et al., 2007b). It is interesting to note that 
the hNter domain seems not to be detected in lower mammals such as rat, yeast or 
fruit fly, though one recent study tended to propose the presence of a longer form of 
mouse SIRT2 containing this domain (Werner et al., 2007). Therefore, it might be an 
interesting to know what kind of evolutionary pressure generating the difference from 
rSIRT2 to hSIRT2.  
It is well-established that the age-dependent genomic instability and increase in 
protein mutations is an essential feature of aging, in which Sirtuins are important 
longevity regulators (Longo and Kennedy, 2006). Under the stress of SIRT2 mutations, 
this protective role the hNter may possibly represent an evolutionary improvement 
from rat to human, which at the molecular level guarantees more stable protein 
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properties in structure and function. This speculation is also supported by the greatly 
retarded insolubilization speed of rSIRT2 proteins adding with the hNter domain (Fig. 
3.25). An interesting question could be what if rSIRT2 be engineered to bear such an 
hNTer in vivo, whether mutation-induced insolubilization of rat proteins and 
aggregation would be inhibited or even life span would be extended? 
Further support of the crucial role of hNter came from a recent study which 
identified a disease-related mutated form of hSIRT2: SIRT2_v3mut (Lennerz et al., 
2005). This isoform was found in a human melanoma sample, and its N terminus 37aa 
domain was replaced by a completely different 18aa domain, in the meantime, this 
isoform possesses a P199L mutation, which corresponds to P219L of hSIRT2_v1 
(P182L of rSIRT2). These characters resulted in the recognition of the mutated protein 
by autologous T cells (Lennerz et al., 2005). This study suggested that in presence of 
mutations (i.e. P219L), hSIRT2 with deletion or substitution of the hNter domain 
could be particularly vulnerable to malfunction so that has to be cleared by immune 
system.   
The mechanisms underlying the protective effects of hNter have yet to be clearly 
defined. But the possibility may include that the biophysical properties of the mutated 
protein are affected by the presence of this domain (e.g. SA) or that this fragment acts 






8. SIRT2, Brain Aging and Neurodegeneration? 
SIR2 protein family extends lifespan or slows down aging in various species/cell 
types ranging from yeast, Drosophila, C. elegans to mouse and rat (Blander and 
Guarente, 2004). In view of the antagonistic effects of SIRT2 on oligodendrocyte 
differentiation, presence of the protein with normal functions in the adult CNS could 
presumably help prevent over-differentiation or premature senescence of 
oligodendrocytes or myelin sheaths. Alternatively, this negative influence of SIRT2 on 
oligodendroglial differentiation may help preserve an adequate pool of immature 
oligodendrocytes for remyelination or CNS self-repair when needed.  
Meanwhile, the abnormality of the protein will inversely affect the function of 
oligodendrocytes. The mutation-induced aggregates will deform the Golgi apparatus 
and cause cell apoptosis (data not shown). Indirectly, the SIRT2 effects on 
oligodendroglia and myelin could also presumably influence neuronal survival or 
aging. It is well documented that structural/functional abnormality of oligodendroglia 
or myelin sheath may cause axon degeneration or neuronal death (Bifulco et al., 2002). 
Essential roles are illustrated of glial dysfunction in non-cell-autonomous neuron 
degeneration (Gong et al., 2000; Clement et al., 2003; Custer et al., 2006).  
The results in this study that the mutated forms of SIRT2 are causing aggregates 
formation in both OLPs and cell lines make it intriguing to investigate the 
involvement of SIRT2 in CNS diseases or neurodegeneration. It remains unknown 
whether specific SIRT2 mutations in oligodendrocytes will affect normal functions 
and survival of neurons or through influencing myelin-axon interaction. We hope that 
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the present study could provide a cellular model to investigate aggregates formation 
related to myelinic or oligodendroglial diseases, and to help decipher the 
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1. Conclusions 
The present study comes to the following conclusions (Figure 5.1):  
1) SIRT2 is preferentially an oligodendroglia protein which shows juxtanodal 
enrichments adjacent to nodes of Ranvier in the myelin sheath.  
2) SIRT2 plays a role as NAD-dependent deacetylase with α-tubulin as its main 
substrate in oligodendrocytes. Also, this study established a correlation between CNP 
expression, α-tubulin acetylation levels and the degree of oligodendroglial 
differentiation.  
3) SIRT2 inhibits the differentiation of oligodendrocytes via deacetylating 
α-tubulin: overexpression of SIRT2 inhibiting the differentiation of oligodendrocytes, 
whereas siRNA knockdown of endogenous SIRT2 expression in primary OLPs has 
opposite effects. 
4) Overexpression of specific mutants of rat SIRT2 gene induces cellular 
aggregate formation in both OLPs and cell lines. The severity of aggregation 
formation is associated with the detergent insolubility of the mutants. 
5) Different from rat SIRT2, the human ortholog of SIRT2 contains a 37-residue 
N terminus fragment, which protects the protein from mutation-induced solubility 




Conclusions and future studies 
 
Figure 5.1 Summary of the conclusions reached in this thesis 
 
2. Future studies 
1) The current study revealed that the inhibitory role of SIRT2 on 
oligodendrocyte differentiation was mediated via deacetylating α-tubulin. However, 
there is still a lack of understanding about how the decrease of acetylation levels of 
α-tubulin is coupled to the morphological changes of the cell. Also, MBP expression 
is found to be upregulated when the endogenous SIRT2 expression was knockdown. 
This result seems to be consistent with other studies in which SIRT2 can translocate to 
nucleus or regulate transcription factors to modulate gene expression (North and 
Verdin, 2007; Jin et al., 2008), but the exact mechanisms behind such modulation in 
oligodendrocytes are still unclear.  
2) In the present study, SIRT2 is found to be enriched in the juxtanodal region 
adjacent to nodes of Ranvier. This region as well as paranodal region is 
well-established area where essential axon-glia interactions take place. The role of 
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SIRT2 with regard to myelination or axon-glia interaction could be an interesting 
issue for further investigation. 
3) Given the fact that several of the mutations examined in the current study (e.g. 
rS53CΔΔ, rA80S/hA117S, rK107Δ, hA198T, rP182L and rK302Δ) are either found in 
actual NCBI cDNA sequences or identified as single nucleotide polymorphism of 
Sirt2, our results imply potential involvement of SIRT2 mutations in certain CNS 
dys-/demyelinating or neurodegenerative diseases. Future studies are necessary to 
identify Sirt2 mutations in related diseases, and to establish animal models to test 
validity of this hypothesis.  
4) The difference of solubility and aggregation properties between hSIRT2 and 
rSIRT2 are attributed, as least in part, to the 37 residue N terminus domain of hSIRT2. 
How exactly this domain protects the protein from solubility decrease and aggregation 
will be a crucial direction for future work.  
5) HDAC6 and MT network are reported to be essential in forming aggresomes. 
Our present results indicated that the aggregates formed upon overexpression of 
SIRT2 mutants are affected by activity of HDAC6 and MT stability, but the exact 
pathways underlying these phenomena still await future investigations. 
 
The functions of SIRT2 and the pathways how it exerts those functions are 
summarized in Fig. 5.2. 
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Figure 5.2 A diagram showing the functions and pathways associated with SIRT2 
Solid lines represent pathways had been identified or reported by related studies. 
Dotted lines signify possible pathways implicated by previous studies or the current 
thesis. Question marks designate that the mechanisms or mediating molecules are not 
clear. “Æ” and “---|” are used to denote promotive and inhibitory pathways.  
 
1. Baumann and Pham-Dinh, 2001  
2. Bucciantini et al., 2002  
3. Dryden et al., 2003 
4. Gray and Ekstrom, 2001 
5. Grenier et al., 2006 
6. Jing et al., 2007 
7. Johnson et al., 1999 
8. Kristiansen et al., 2005 
9. Lee and Lee, 2002  
10. Matsuyama et al., 2002 
11. North et al., 2003 
12. Outeiro et al., 2007  
13. Richter-Landsberg, 2008 
14. Selkoe, 2003  
15. Sriram et al., 2005 
16. Suzuki and Koike, 2007  















Agrawal,H.C., Randle,C.L., and Agrawal,D. (1982). In vivo acylation of rat brain 
myelin proteolipid protein. J. Biol. Chem. 257, 4588-4592. 
Ahlgren,S.C., Wallace,H., Bishop,J., Neophytou,C., and Raff,M.C. (1997). Effects of 
thyroid hormone on embryonic oligodendrocyte precursor cell development in vivo 
and in vitro. Mol. Cell Neurosci. 9, 420-432. 
Ahuja,N., Schwer,B., Carobbio,S., Waltregny,D., North,B.J., Castronovo,V., 
Maechler,P., and Verdin,E. (2007). Regulation of insulin secretion by SIRT4, a 
mitochondrial ADP-ribosyltransferase. J. Biol. Chem. 282, 33583-33592. 
Allfrey, V. G., Faulkner, R., and Mirsky, A.E. (1964). Acetylation and methylation of 
histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. 
Sci. U. S. A 51, 786-794.  
Allison,S.J., and Milner,J. (2007). SIRT3 is pro-apoptotic and participates in distinct 
basal apoptotic pathways. Cell Cycle 6, 2669-2677. 
Altschul,S.F., Madden,T.L., Schaffer,A.A., Zhang,J., Zhang,Z., Miller,W., and 
Lipman,D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein 
database search programs. Nucleic Acids Res. 25, 3389-3402. 
Anastasiou,D., and Krek,W. (2006). SIRT1: linking adaptive cellular responses to 
aging-associated changes in organismal physiology. Physiology. (Bethesda. ) 21, 
404-410. 
Anekonda,T.S. (2006). Resveratrol--a boon for treating Alzheimer's disease? Brain 
Res. Rev. 52, 316-326. 
Anekonda,T.S., and Reddy,P.H. (2006). Neuronal protection by Sirtuins in 
Alzheimer's disease. J. Neurochem. 96, 305-313. 
Anitei,M., Ifrim,M., Ewart,M.A., Cowan,A.E., Carson,J.H., Bansal,R., and 
Pfeiffer,S.E. (2006). A role for Sec8 in oligodendrocyte morphological differentiation. 
J. Cell Sci. 119, 807-818. 
Araki,T., Sasaki,Y., and Milbrandt,J. (2004). Increased nuclear NAD biosynthesis and 
SIRT1 activation prevent axonal degeneration. Science 305, 1010-1013. 
Ardley,H.C., Scott,G.B., Rose,S.A., Tan,N.G., Markham,A.F., and Robinson,P.A. 
(2003). Inhibition of proteasomal activity causes inclusion formation in neuronal and 
non-neuronal cells overexpressing Parkin. Mol. Biol. Cell 14, 4541-4556. 
Armstrong,R.C. (1998). Isolation and characterization of immature oligodendrocyte 
lineage cells. Methods 16, 282-292. 
Arnett,H.A., Fancy,S.P., Alberta,J.A., Zhao,C., Plant,S.R., Kaing,S., Raine,C.S., 
 134
References 
Rowitch,D.H., Franklin,R.J., and Stiles,C.D. (2004). bHLH transcription factor Olig1 
is required to repair demyelinated lesions in the CNS. Science. 306, 2111-2115. 
Arroyo,E.J. and Scherer,S.S. (2000). On the molecular architecture of meylinated 
fibers. Histochem. Cell Biol. 113, 1-18. 
Ashburner,B.P., Westerheide,S.D., and Baldwin,A.S., Jr. (2001). The p65 (RelA) 
subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors 
HDAC1 and HDAC2 to negatively regulate gene expression. Mol. Cell Biol. 21, 
7065-7077. 
Bae,N.S., Swanson,M.J., Vassilev,A., and Howard,B.H. (2004). Human histone 
deacetylase SIRT2 interacts with the homeobox transcription factor HOXA10. J. 
Biochem. (Tokyo) 135, 695-700. 
Baker,M., Mackenzie,I.R., Pickering-Brown,S.M., Gass,J., Rademakers,R., 
Lindholm,C., Snowden,J., Adamson,J., Sadovnick,A.D., Rollinson,S., Cannon,A., 
Dwosh,E., Neary,D., Melquist,S., Richardson,A., Dickson,D., Berger,Z., Eriksen,J., 
Robinson,T., Zehr,C., Dickey,C.A., Crook,R., McGowan,E., Mann,D., Boeve,B., 
Feldman,H., and Hutton,M. (2006). Mutations in progranulin cause tau-negative 
frontotemporal dementia linked to chromosome 17. Nature 442, 916-919. 
Ballas,N., Battaglioli,E., Atouf,F., Andres,M.E., Chenoweth,J., Anderson,M.E., 
Burger,C., Moniwa,M., Davie,J.R., Bowers,W.J., Federoff,H.J., Rose,D.W., 
Rosenfeld,M.G., Brehm,P., and Mandel,G. (2001). Regulation of neuronal traits by a 
novel transcriptional complex. Neuron 31, 353-365. 
Ballas,N., Grunseich,C., Lu,D.D., Speh,J.C., and Mandel,G. (2005). REST and its 
corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. 
Cell 121, 645-657. 
Bardag-Gorce,F., Riley,N.E., Nan,L., Montgomery,R.O., Li,J., French,B.A., Lue,Y.H., 
and French,S.W. (2004). The proteasome inhibitor, PS-341, causes cytokeratin 
aggresome formation. Exp. Mol. Pathol. 76, 9-16. 
Barres,B.A., Lazar,M.A., and Raff,M.C. (1994). A novel role for thyroid hormone, 
glucocorticoids and retinoic acid in timing oligodendrocyte development. 
Development 120, 1097-1108. 
Barres,B.A., and Raff,M.C. (1994). Control of oligodendrocyte number in the 
developing rat optic nerve. Neuron 12, 935-942. 
Barry,C., Pearson,C., and Barbarese,E. (1996). Morphological organization of 
oligodendrocyte processes during development in culture and in vivo. Dev. Neurosci. 
18, 233-242. 




Bauer,N.G., and Richter-Landsberg,C. (2006). The dynamic instability of 
microtubules is required for aggresome formation in oligodendroglial cells after 
proteolytic stress. J. Mol. Neurosci. 29, 153-168. 
Baumann,N., and Pham-Dinh,D. (2001). Biology of Oligodendrocyte and Myelin in 
the Mammalian Central Nervous System. Physiol. Rev. 81, 871-927. 
Baur,J.A., Pearson,K.J., Price,N.L., Jamieson,H.A., Lerin,C., Kalra,A., Prabhu,V.V., 
Allard,J.S., Lopez-Lluch,G., Lewis,K., Pistell,P.J., Poosala,S., Becker,K.G., Boss,O., 
Gwinn,D., Wang,M., Ramaswamy,S., Fishbein,K.W., Spencer,R.G., Lakatta,E.G., 
Le,C.D., Shaw,R.J., Navas,P., Puigserver,P., Ingram,D.K., de,C.R., and Sinclair,D.A. 
(2006). Resveratrol improves health and survival of mice on a high-calorie diet. 
Nature 444, 337-342. 
Bence,N.F., Sampat,R.M., and Kopito,R.R. (2001). Impairment of the 
ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555. 
Bennett,E.J., Bence,N.F., Jayakumar,R., and Kopito,R.R. (2005). Global impairment 
of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates 
precedes inclusion body formation. Mol. Cell 17, 351-365. 
Benveniste,E.N., and Merrill,J.E. (1986). Stimulation of oligodendroglial proliferation 
and maturation by interleukin-2. Nature 321, 610-613. 
Berger,P., Niemann,A., and Suter,U. (2006). Schwann cells and the pathogenesis of 
inherited motor and sensory neuropathies (Charcot-Marie-Tooth disease). Glia 54, 
243-257. 
Bermingham,J.R.Jr., Scherer,S.S., O’Connell,S., Arroyo,E., Kalla,K.A., Powell,F.L., 
and Rosenfeld,M.G. (1996). Tst-1/Oct-6/SCIP regulates a unique step in peripheral 
myelinatio nand is required for normal respiration. Genes Dev. 10,1751-1762. 
Berry,R.W., Quinn,B., Johnson,N., Cochran,E.J., Ghoshal,N., and Binder,L.I. (2001). 
Pathological glial tau accumulations in neurodegenerative disease: review and case 
report. Neurochem. Int. 39, 469-479. 
Bifulco,M., Laezza,C., Stingo,S., and Wolff,J. (2002). 2',3'-Cyclic nucleotide 
3'-phosphodiesterase: a membrane-bound, microtubule-associated protein and 
membrane anchor for tubulin. Proc. Natl. Acad. Sci. U. S. A 99, 1807-1812. 
Billin,A.N., Thirlwell,H., and Ayer,D.E. (2000). Beta-catenin-histone deacetylase 
interactions regulate the transition of LEF1 from a transcriptional repressor to an 
activator. Mol. Cell Biol. 20, 6882-6890. 
Bjartmar,C., Karlsson,B., and Hildebrand,C. (1994). Cellular and extracellular 
 136
References 
components at nodes of Ranvier in rat white matter. Brain Res. 667, 111-114. 
Blander,G., and Guarente,L. (2004). The Sir2 family of protein deacetylases. Annu. 
Rev. Biochem. 73, 417-435. 
Bogler,O., Wren,D., Barnett,S.C., Land,H., and Noble,M. (1990). Cooperation 
between two growth factors promotes extended self-renewal and inhibits 
differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells. Proc. Natl. 
Acad. Sci. U. S. A 87, 6368-6372. 
Boiko,T., and Winckler,B. (2006). Myelin under construction -- teamwork required. J. 
Cell Biol. 172, 799-801. 
Bone,J.R., Lavender,J., Richman,R., Palmer,M.J., Turner,B.M., and Kuroda,M.I. 
(1994). Acetylated histone H4 on the male X chromosome is associated with dosage 
compensation in Drosophila. Genes Dev. 8, 96-104. 
Borra,M.T., O'Neill,F.J., Jackson,M.D., Marshall,B., Verdin,E., Foltz,K.R., and 
Denu,J.M. (2002). Conserved enzymatic production and biological effect of 
O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent 
deacetylases. J. Biol. Chem. 277, 12632-12641. 
Braun,N. (2005). Biochemical and molecular studies of the prion protein. Dissertation, 
University of Zurich. pp. 69. 
Brachmann,C.B., Sherman,J.M., Devine,S.E., Cameron,E.E., Pillus,L., and Boeke,J.D. 
(1995). The SIR2 gene family, conserved from bacteria to humans, functions in 
silencing, cell cycle progression, and chromosome stability. Genes Dev. 9, 2888-2902. 
Braunstein,M., Rose,A.B., Holmes,S.G., Allis,C.D., and Broach,J.R. (1993). 
Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. 
Genes Dev. 7, 592-604. 
Braunstein,M., Sobel,R.E., Allis,C.D., Turner,B.M., and Broach,J.R. (1996). Efficient 
transcriptional silencing in Saccharomyces cerevisiae requires a heterochromatin 
histone acetylation pattern. Mol. Cell Biol. 16, 4349-4356. 
Brehm,A., Miska,E.A., McCance,D.J., Reid,J.L., Bannister,A.J., and Kouzarides,T. 
(1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. 
Nature 391, 597-601. 
Brunet,A., Sweeney,L.B., Sturgill,J.F., Chua,K.F., Greer,P.L., Lin,Y., Tran,H., 
Ross,S.E., Mostoslavsky,R., Cohen,H.Y., Hu,L.S., Cheng,H.L., Jedrychowski,M.P., 
Gygi,S.P., Sinclair,D.A., Alt,F.W., and Greenberg,M.E. (2004). Stress-dependent 




Bucciantini,M., Giannoni,E., Chiti,F., Baroni,F., Formigli,L., Zurdo,J., Taddei,N., 
Ramponi,G., Dobson,C.M., and Stefani,M. (2002). Inherent toxicity of aggregates 
implies a common mechanism for protein misfolding diseases. Nature 416, 507-511. 
Bunge,R.P. (1968). Glial cells and the central myelin sheath. Physiol Rev. 48, 
197-251. 
Bunge,R.P. (1987). Tissue culture observations relevant to the study of axon-Schwann 
cell interactions during peripheral nerve development and repair. J. Exp. Biol. 132, 
21-34. 
Bunge,R.P., Bunge,M.B., and Eldridge,C.F. (1986). Linkage between axonal 
ensheathment and basal lamina production by Schwann cells. Annu. Rev. Neurosci. 9, 
305-328. 
Buss,A., and Schwab,M.E, (2003). Sequential loss of myelin proteins during 
Wallerian degeneration in the rat spinal cord. Glia. 42,424-432. 
Butt,A.M., Duncan,A., Hornby,M.F., Kirvell,S.L., Hunter,A., Levine,J.M., and 
Berry,M. (1999). Cells expressing the NG2 antigen contact nodes of Ranvier in adult 
CNS white matter. Glia. 26,84-91. 
Cai,R.L., Yan-Neale,Y., Cueto,M.A., Xu,H., and Cohen,D. (2000). HDAC1, a histone 
deacetylase, forms a complex with Hus1 and Rad9, two G2/M checkpoint Rad 
proteins. J. Biol. Chem. 275, 27909-27916. 
Canoll,P.D., Musacchio,J.M., Hardy,R., Reynolds,R., Marchionni,M.A., and 
Salzer,J.L. (1996). GGF/neuregulin is a neuronal signal that promotes the proliferation 
and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron 
17, 229-243. 
Casaccia-Bonnefil,P., and Liu,A. (2003). Relationship between cell cycle molecules 
and onset of oligodendrocyte differentiation. J. Neurosci. Res. 72, 1-11. 
Chakraborty,G., Drivas,A., and Ledeen,R. (1999). The phosphoinositide signaling 
cycle in myelin requires cooperative interaction with the axon. Neurochem.Res. 
24,249-254. 
Chandran,S., Svendsen,C., Compston,A., and Scolding,N. (1998). Regional potential 
for oligodendrocyte generation in the rodent embryonic spinal cord following 
exposure to EGF and FGF-2. Glia 24, 382-389. 
Chang,S., Young,B.D., Li,S., Qi,X., Richardson,J.A., and Olson,E.N. (2006). Histone 
deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10. 
Cell 126, 321-334. 
Chariot,A., van,L.C., Chapelier,M., Gielen,J., Merville,M.P., and Bours,V. (1999). 
 138
References 
CBP and histone deacetylase inhibition enhance the transactivation potential of the 
HOXB7 homeodomain-containing protein. Oncogene 18, 4007-4014. 
Chen,Z.J., and Tian,L. (2007). Roles of dynamic and reversible histone acetylation in 
plant development and polyploidy. Biochim. Biophys. Acta 1769, 295-307. 
Cheng,H.L., Mostoslavsky,R., Saito,S., Manis,J.P., Gu,Y., Patel,P., Bronson,R., 
Appella,E., Alt,F.W., and Chua,K.F. (2003). Developmental defects and p53 
hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U. S. 
A 100, 10794-10799. 
Chin,S.S., and Goldman,J.E. (1996). Glial inclusions in CNS degenerative diseases. J. 
Neuropathol. Exp. Neurol. 55, 499-508. 
Chinnadurai,G. (2002). CtBP, an unconventional transcriptional corepressor in 
development and oncogenesis. Mol. Cell 9, 213-224. 
Choi,C.Y., Kim,Y.H., Kwon,H.J., and Kim,Y. (1999). The homeodomain protein 
NK-3 recruits Groucho and a histone deacetylase complex to repress transcription. J. 
Biol. Chem. 274, 33194-33197. 
Chowdari,K.V., Northup,A., Pless,L., Wood,J., Joo,Y.H., Mirnics,K., Lewis,D.A., 
Levitt,P.R., Bacanu,S.A., and Nimgaonkar,V.L. (2007). DNA pooling: a 
comprehensive, multi-stage association analysis of ACSL6 and SIRT5 polymorphisms 
in schizophrenia. Genes Brain Behav. 6, 229-239. 
Clayton,A.L., Hazzalin,C.A., and Mahadevan,L.C. (2006). Enhanced histone 
acetylation and transcription: a dynamic perspective. Mol. Cell 23, 289-296. 
Clayton,A.L., Hebbes,T.R., Thorne,A.W., and Crane-Robinson,C. (1993). Histone 
acetylation and gene induction in human cells. FEBS Letters 336, 23-26. 
Clement,A.M., Nguyen,M.D., Roberts,E.A., Garcia,M.L., Boillee,S., Rule,M., 
McMahon,A.P., Doucette,W., Siwek,D., Ferrante,R.J., Brown,R.H., Jr., Julien,J.P., 
Goldstein,L.S., and Cleveland,D.W. (2003). Wild-type nonneuronal cells extend 
survival of SOD1 mutant motor neurons in ALS mice. Science 302, 113-117. 
Cohen,H.Y., Lavu,S., Bitterman,K.J., Hekking,B., Imahiyerobo,T.A., Miller,C., 
Frye,R., Ploegh,H., Kessler,B.M., and Sinclair,D.A. (2004). Acetylation of the C 
terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell 13, 
627-638. 
Corcoran,L.J., Mitchison,T.J., and Liu,Q. (2004). A novel action of histone 
deacetylase inhibitors in a protein aggresome disease model. Curr. Biol. 14, 488-492. 
Cunningham,J.J., and Roussel,M.F. (2001). Cyclin-dependent kinase inhibitors in the 
development of the central nervous system. Cell Growth Differ. 12, 387-396. 
 139
References 
Custer,S.K., Garden,G.A., Gill,N., Rueb,U., Libby,R.T., Schultz,C., Guyenet,S.J., 
Deller,T., Westrum,L.E., Sopher,B.L., and La Spada,A.R. (2006). Bergmann glia 
expression of polyglutamine-expanded ataxin-7 produces neurodegeneration by 
impairing glutamate transport. Nat. Neurosci. 9, 1302-1311. 
Davis,T., Kennedy,C., Chiew,Y.E., Clarke,C.L., and deFazio,A. (2000). Histone 
deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression 
in normal mammary epithelial cells. Clin. Cancer Res. 6, 4334-4342. 
Dorus,S., Vallender,E.J., Evans,P.D., Anderson,J.R., Gilbert,S.L., Mahowald,M., 
Wyckoff,G.J., Malcom,C.M., and Lahn,B.T. (2004). Accelerated evolution of nervous 
system genes in the origin of Homo sapiens. Cell 119, 1027-1040. 
Dryden,S.C., Nahhas,F.A., Nowak,J.E., Goustin,A.S., and Tainsky,M.A. (2003). Role 
for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the 
cell cycle. Mol. Cell Biol. 23, 3173-3185. 
Dryja,T.P., McGee,T.L., Reichel,E., Hahn,L.B., Cowley,G.S., Yandell,D.W., 
Sandberg,M.A., and Berson,E.L. (1990). A point mutation of the rhodopsin gene in 
one form of retinitis pigmentosa. Nature 343, 364-366. 
Duan,W., and Mattson,M.P. (1999). Dietary restriction and 2-deoxyglucose 
administration improve behavioral outcome and reduce degeneration of dopaminergic 
neurons in models of Parkinson's disease. J. Neurosci. Res. 57, 195-206. 
Dugas,J.C., Ibrahim,A., and Barres,B.A. (2007). A crucial role for p57(Kip2) in the 
intracellular timer that controls oligodendrocyte differentiation. J. Neurosci. 27, 
6185-6196. 
Edgar,J.M., McLaughlin,M., Yool,D., Zhang,S.C., Fowler,J.H., Montague,P., 
Barrie,J.A., McCulloh,M.C., Duncan,I.D., Garbern,J., Nave,K.A., Griffiths,I.R. 
(2004). Oligodendroglial modulation of fast axonal transport in a mouse model of 
hereditary spastic paraplegia. J. Cell. Biol. 166, 121-131 
MclEisenbarth,G.S., Walsh,F.S., and Nirenberg,M. (1979). Monoclonal antibody to a 
plasma membrane antigen of neurons. Proc. Natl. Acad. Sci. U. S. A 76, 4913-4917. 
Fasano,C., Campana,V., and Zurzolo,C. (2006). Prions: protein only or something 
more? Overview of potential prion cofactors. J. Mol. Neurosci. 29, 195-214. 
Finnin,M.S., Donigian,J.R., and Pavletich,N.P. (2001). Structure of the histone 
deacetylase SIRT2. Nat. Struct. Biol. 8, 621-625. 
Finzer,P., Kuntzen,C., Soto,U., zur,H.H., and Rosl,F. (2001). Inhibitors of histone 
deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells 
circumventing human papillomavirus oncogene expression. Oncogene 20, 4768-4776. 
 140
References 
Folch,J., and Lees,M. (1951). Proteolipides, a new type of tissue lipoproteins; their 
isolation from brain. J. Biol. Chem. 191, 807-817. 
Ford,E., Voit,R., Liszt,G., Magin,C., Grummt,I., and Guarente,L. (2006). Mammalian 
Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 
20, 1075-1080. 
Franklin,R.J. (2002). Why does remyelination fail in multiple sclerosis? Nat. Rev. 
Neurosci. 3, 705-714. 
Fratta,P., Engel,W.K., McFerrin,J., Davies,K.J., Lin,S.W., and Askanas,V. (2005). 
Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis 
and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. 
Am. J. Pathol. 167, 517-526. 
Fredman,P., Magnani,J.L., Nirenberg,M., and Ginsburg,V. (1984). Monoclonal 
antibody A2B5 reacts with many gangliosides in neuronal tissue. Arch. Biochem. 
Biophys. 233, 661-666. 
Friedrich,V.L.Jr, and Mugnaini,E. (1983). Myelin sheath thickness in the CNS is 
regulated near the axon. Brain Res. 274, 329-331 
Frye,R.A. (1999). Characterization of five human cDNAs with homology to the yeast 
SIR2 gene: Sir2-like proteins (Sirtuins) metabolize NAD and may have protein 
ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260, 273-279. 
Frye,R.A. (2000). Phylogenetic classification of prokaryotic and eukaryotic Sir2-like 
proteins. Biochem. Biophys. Res. Commun. 273, 793-798. 
Fuchs,J., Demidov,D., Houben,A., and Schubert,I. (2006). Chromosomal histone 
modification patterns--from conservation to diversity. Trends Plant Sci. 11, 199-208. 
Fujita,Y., Okamoto,K., Sakurai,A., Kusaka,H., Aizawa,H., Mihara,B., and 
Gonatas,N.K. (2002). The Golgi apparatus is fragmented in spinal cord motor neurons 
of amyotrophic lateral sclerosis with basophilic inclusions. Acta Neuropathol. (Berl) 
103, 243-247. 
Fulco,M., Schiltz,R.L., Iezzi,S., King,M.T., Zhao,P., Kashiwaya,Y., Hoffman,E., 
Veech,R.L., and Sartorelli,V. (2003). Sir2 Regulates Skeletal Muscle Differentiation 
as a Potential Sensor of the Redox State. Molecular Cell 12, 51-62. 
Gao,L., Cueto,M.A., Asselbergs,F., and Atadja,P. (2002). Cloning and functional 
characterization of HDAC11, a novel member of the human histone deacetylase 
family. J. Biol. Chem. 277, 25748-25755. 
Garcia-Mata,R., Bebok,Z., Sorscher,E.J., and Sztul,E.S. (1999). Characterization and 




Garzon-Rodriguez,W., Vega,A., Sepulveda-Becerra,M., Milton,S., Johnson,D.A., 
Yatsimirsky,A.K., and Glabe,C.G. (2000). A conformation change in the carboxyl 
terminus of Alzheimer's Abeta (1-40) accompanies the transition from dimer to fibril 
as revealed by fluorescence quenching analysis. J. Biol. Chem. 275, 22645-22649. 
Ghazvini,M., Mandemakers,W., Jaegle,M., Piirsoo,M., Driegen,S., Koutsourakis,M., 
Smit,X., Grosveld,F., and Meijer,D. (2002). A cell type-specific allele of the POU 
gene Oct-6 reveals Schwann cell autonomous function in nerve development and 
regeneration. EMBO J. 21, 4162-4120. 
Ghiani,C., and Gallo,V. (2001). Inhibition of cyclin E-cyclin-dependent kinase 2 
complex formation and activity is associated with cell cycle arrest and withdrawal in 
oligodendrocyte progenitor cells. J. Neurosci. 21, 1274-1282. 
Ghiani,C.A., Eisen,A.M., Yuan,X., DePinho,R.A., McBain,C.J., and Gallo,V. (1999). 
Neurotransmitter receptor activation triggers p27(Kip1 )and p21(CIP1) accumulation 
and G1 cell cycle arrest in oligodendrocyte progenitors. Development 126, 
1077-1090. 
Ghosh,A.K., Steele,R., and Ray,R.B. (1999). MBP-1 physically associates with 
histone deacetylase for transcriptional repression. Biochem. Biophys. Res. Commun. 
260, 405-409. 
Girault,J.A. and Peles,E. (2002). Development of nodes of Ranvier. Curr. Opin. 
Neurobiol. 12, 476-485. 
Goedert,M., Spillantini,M.G., and Davies,S.W. (1998). Filamentous nerve cell 
inclusions in neurodegenerative diseases. Curr. Opin. Neurobiol. 8, 619-632. 
Gong,Y.H., Parsadanian,A.S., Andreeva,A., Snider,W.D., and Elliott,J.L. (2000). 
Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in 
astrocytosis but does not cause motoneuron degeneration. J. Neurosci. 20, 660-665. 
Gosavi,N., Lee,H.J., Lee,J.S., Patel,S., and Lee,S.J. (2002). Golgi fragmentation 
occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the 
formation of fibrillar inclusion. J. Biol. Chem. 277, 48984-48992. 
Gray,S.G., and Ekstrom,T.J. (2001). The human histone deacetylase family. Exp. Cell 
Res. 262, 75-83. 
Grenier,C., Bissonnette,C., Volkov,L., and Roucou,X. (2006). Molecular morphology 
and toxicity of cytoplasmic prion protein aggregates in neuronal and non-neuronal 
cells. J. Neurochem. 97, 1456-1466. 
Grewal,S.I., and Elgin,S.C. (2002). Heterochromatin: new possibilities for the 
 142
References 
inheritance of structure. Curr. Opin. Genet. Dev. 12, 178-187. 
Grubisha,O., Rafty,L.A., Takanishi,C.L., Xu,X., Tong,L., Perraud,A.L., 
Scharenberg,A.M., and Denu,J.M. (2006). Metabolite of SIR2 reaction modulates 
TRPM2 ion channel. J. Biol. Chem. 281, 14057-14065. 
Haigis,M.C., and Guarente,L.P. (2006). Mammalian Sirtuins--emerging roles in 
physiology, aging, and calorie restriction. Genes Dev. 20, 2913-2921. 
Haigis,M.C., Mostoslavsky,R., Haigis,K.M., Fahie,K., Christodoulou,D.C., 
Murphy,A.J., Valenzuela,D.M., Yancopoulos,G.D., Karow,M., Blander,G., 
Wolberger,C., Prolla,T.A., Weindruch,R., Alt,F.W., and Guarente,L. (2006). SIRT4 
inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in 
pancreatic beta cells. Cell 126, 941-954. 
Hall,A., Giese,N.A., and Richardson,W.D. (1996). Spinal cord oligodendrocytes 
develop from ventrally derived progenitor cells that express PDGF alpha-receptors. 
Development 122, 4085-4094. 
Hallows,W.C., Lee,S., and Denu,J.M. (2006). Sirtuins deacetylate and activate 
mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. U. S. A 103, 10230-10235. 
Hebbes,T.R., Thorne,A.W., Clayton,A.L., and Crane-Robinson,C. (1992). Histone 
acetylation and globin gene switching. Nucleic Acids Res. 20, 1017-1022. 
Hiratsuka,M., Inoue,T., Toda,T., Kimura,N., Shirayoshi,Y., Kamitani,H., Watanabe,T., 
Ohama,E., Tahimic,C.G., Kurimasa,A., and Oshimura,M. (2003). Proteomics-based 
identification of differentially expressed genes in human gliomas: down-regulation of 
SIRT2 gene. Biochem. Biophys. Res. Commun. 309, 558-566. 
Hsieh,J., Nakashima,K., Kuwabara,T., Mejia,E., and Gage,F.H. (2004). Histone 
deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural 
progenitor cells. Proc. Natl. Acad. Sci. U. S. A 101, 16659-16664. 
Hu,E., Chen,Z., Fredrickson,T., Zhu,Y., Kirkpatrick,R., Zhang,G.F., Johanson,K., 
Sung,C.M., Liu,R., and Winkler,J. (2000). Cloning and characterization of a novel 
human class I histone deacetylase that functions as a transcription repressor. J. Biol. 
Chem. 275, 15254-15264. 
Hu,Q.D., Ang,B.T., Karsak,M., Hu,W.P., Cui,X.Y., Duka,T., Takeda,Y., Chia,W., 
Sankar,N., Ng,Y.K., Ling,E.A., Maciag,T., Small,D., Trifonova,R., Kopan,R., 
Okano,H., Nakafuku,M., Chiba,S., Hirai,H., Aster,J.C., Schachner,M., Pallen,C.J., 
Watanabe,K., and Xiao,Z.C. (2003). F3/contactin acts as a functional ligand for Notch 
during oligodendrocyte maturation. Cell 115, 163-175. 
Hubbert,C., Guardiola,A., Shao,R., Kawaguchi,Y., Ito,A., Nixon,A., Yoshida,M., 
Wang,X.F., and Yao,T.P. (2002). HDAC6 is a microtubule-associated deacetylase. 
 143
References 
Nature 417, 455-458. 
Huynh,K.D., and Bardwell,V.J. (1998). The BCL-6 POZ domain and other POZ 
domains interact with the co-repressors N-CoR and SMRT. Oncogene 17, 2473-2484. 
Imai,S., Armstrong,C.M., Kaeberlein,M., and Guarente,L. (2000). Transcriptional 
silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 
403, 795-800. 
Ippel,J.H., Olofsson,A., Schleucher,J., Lundgren,E., and Wijmenga,S.S. (2002). 
Probing solvent accessibility of amyloid fibrils by solution NMR spectroscopy. Proc. 
Natl. Acad. Sci. U. S. A 99, 8648-8653. 
Ito,K., Barnes,P.J., and Adcock,I.M. (2000). Glucocorticoid receptor recruitment of 
histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on 
lysines 8 and 12. Mol. Cell Biol. 20, 6891-6903. 
Iwata,A., Riley,B.E., Johnston,J.A., and Kopito,R.R. (2005). HDAC6 and 
microtubules are required for autophagic degradation of aggregated huntingtin. J. Biol. 
Chem. 280, 40282-40292. 
Jeppesen,P., and Turner,B.M. (1993). The inactive X chromosome in female mammals 
is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene 
expression. Cell 74, 281-289. 
Jiang,S., Avraham,H.K., Park,S.Y., Kim,T.A., Bu,X., Seng,S., and Avraham,S. (2005). 
Process elongation of oligodendrocytes is promoted by the Kelch-related 
actin-binding protein Mayven. J. Neurochem. 92, 1191-1203. 
Jin,Y.H., Kim,Y.J., Kim,D.W., Baek,K.H., Kang,B.Y., Yeo,C.Y., and Lee,K.Y. (2008). 
Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. 
Biochem. Biophys. Res. Commun. 368, 690-695. 
Jing,E., Gesta,S., and Kahn,C.R. (2007). SIRT2 Regulates Adipocyte Differentiation 
through FoxO1 Acetylation/Deacetylation. Cell Metab 6, 105-114. 
Johnston,J.A., Dalton,M.J., Gurney,M.E., and Kopito,R.R. (2000). Formation of high 
molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse 
model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A 97, 
12571-12576. 
Johnston,J.A., Illing,M.E., and Kopito,R.R. (2002). Cytoplasmic dynein/dynactin 
mediates the assembly of aggresomes. Cell Motil. Cytoskeleton 53, 26-38. 
Johnston,J.A., Ward,C.L., and Kopito,R.R. (1998). Aggresomes: a cellular response to 
misfolded proteins. J. Cell Biol. 143, 1883-1898. 
 144
References 
Junn,E., Lee,S.S., Suhr,U.T., and Mouradian,M.M. (2002). Parkin accumulation in 
aggresomes due to proteasome impairment. J. Biol. Chem. 277, 47870-47877. 
Kandel,E.R. (2001a) Nerve cells and behavior. In: Principles of Neural Science, 4th 
edition, edited by Kandel,E.R., Schwartz,J.H., and Jessell,T.M. New York: 
McGraw-Hill, pp. 19-35. 
Kawaguchi,Y., Kovacs,J.J., McLaurin,A., Vance,J.M., Ito,A., and Yao,T.P. (2003). The 
deacetylase HDAC6 regulates aggresome formation and cell viability in response to 
misfolded protein stress. Cell 115, 727-738. 
Kies,M.W., Murphy, J.B., and Alvord, E.C. (1965) Fractionation of guinea-pig 
proteins with encephalitogenic activity (Abstract). Federation Proc. 19, 207.  
Kim,D., Nguyen,M.D., Dobbin,M.M., Fischer,A., Sananbenesi,F., Rodgers,J.T., 
Delalle,I., Baur,J.A., Sui,G., Armour,S.M., Puigserver,P., Sinclair,D.A., and Tsai,L.H. 
(2007). SIRT1 deacetylase protects against neurodegeneration in models for 
Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 26, 3169-3179. 
Kim,T.Y., Bang,Y.J., and Robertson,K.D. (2006). Histone deacetylase inhibitors for 
cancer therapy. Epigenetics. 1, 14-23. 
Kirsh,O., Seeler,J.S., Pichler,A., Gast,A., Muller,S., Miska,E., Mathieu,M., 
Harel-Bellan,A., Kouzarides,T., Melchior,F., and Dejean,A. (2002). The SUMO E3 
ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 21, 
2682-2691. 
Kitamura,Y.I., Kitamura,T., Kruse,J.P., Raum,J.C., Stein,R., Gu,W., and Accili,D. 
(2005). FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA 
induction. Cell Metab 2, 153-163. 
Knoepfler,P.S., and Eisenman,R.N. (1999). Sin meets NuRD and other tails of 
repression. Cell 99, 447-450. 
Komori,T. (1999). Tau-positive glial inclusions in progressive supranuclear palsy, 
corticobasal degeneration and Pick's disease. Brain Pathol. 9, 663-679. 
Kopito,R.R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends 
Cell Biol. 10, 524-530. 
Kornberg,R.D. (1977). Structure of chromatin. Annu. Rev. Biochem. 46, 931-954. 
Kristiansen, M., Messenger, M.J., Klohn, P., Brandner, S., et al. (2005). isease-related 
prion protein forms aggresomes in neuronal cells leading to caspase activation and 
apoptosis. J. Biol. Chem. 280 (46), 38851–38861. 
Kuhlbrodt,K., Herbarth,B., Sock,E., Hermans-Borgmeyer,I., and Wegner,M. (1998). 
 145
References 
Sox10, a novel transcriptional modulator in glial cells. J. Neurosci. 18, 237-250. 
Kuo,M.H., and Allis,C.D. (1998). Roles of histone acetyltransferases and deacetylases 
in gene regulation. Bioessays 20, 615-626. 
Lagace,D.C., and Nachtigal,M.W. (2004). Inhibition of histone deacetylase activity by 
valproic acid blocks adipogenesis. J. Biol. Chem. 279, 18851-18860. 
Lagouge,M., Argmann,C., Gerhart-Hines,Z., Meziane,H., Lerin,C., Daussin,F., 
Messadeq,N., Milne,J., Lambert,P., Elliott,P., Geny,B., Laakso,M., Puigserver,P., and 
Auwerx,J. (2006). Resveratrol improves mitochondrial function and protects against 
metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122. 
Landry,J., Sutton,A., Tafrov,S.T., Heller,R.C., Stebbins,J., Pillus,L., and Sternglanz,R. 
(2000). The silencing protein SIR2 and its homologs are NAD-dependent protein 
deacetylases. PNAS 97, 5807-5811. 
Langley,E., Pearson,M., Faretta,M., Bauer,U.M., Frye,R.A., Minucci,S., Pelicci,P.G., 
and Kouzarides,T. (2002). Human SIR2 deacetylates p53 and antagonizes 
PML/p53-induced cellular senescence. EMBO J. 21, 2383-2396. 
Lappe-Siefke,C., Goebbels,S., Gravel,M., Nicksch,E., Lee,J., Braun,P.E., 
Griffiths,I.R., and Nave,K.A. (2003). Disruption of Cnp1 uncouples oligodendroglial 
functions in axonal support and myelination. Nat. Genet. 33, 366-374. 
Lee,B., and Richards,F.M. (1971). The interpretation of protein structures: estimation 
of static accessibility. J. Mol. Biol. 55, 379-400. 
Lee,H.J., and Lee,S.J. (2002). Characterization of cytoplasmic alpha-synuclein 
aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. 
J. Biol. Chem. 277, 48976-48983. 
Lee,J., Gravel,M., Zhang,R., Thibault,P., and Braun,P.E. (2005). Process outgrowth in 
oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J. 
Cell Biol. 170, 661-673. 
Lee,V.M., and Trojanowski,J.Q. (2006). Mechanisms of Parkinson's disease linked to 
pathological alpha-synuclein: new targets for drug discovery. Neuron 52, 33-38. 
Lelouard,H., Ferrand,V., Marguet,D., Bania,J., Camosseto,V., David,A., Gatti,E., and 
Pierre,P. (2004). Dendritic cell aggresome-like induced structures are dedicated areas 
for ubiquitination and storage of newly synthesized defective proteins. J. Cell Biol. 
164, 667-675. 
Lelouard,H., Gatti,E., Cappello,F., Gresser,O., Camosseto,V., and Pierre,P. (2002). 
Transient aggregation of ubiquitinated proteins during dendritic cell maturation. 
Nature 417, 177-182. 
 146
References 
Lennerz,V., Fatho,M., Gentilini,C., Frye,R.A., Lifke,A., Ferel,D., Wolfel,C., Huber,C., 
and Wolfel,T. (2005). The response of autologous T cells to a human melanoma is 
dominated by mutated neoantigens. Proc. Natl. Acad. Sci. U. S. A 102, 16013-16018. 
Li,J., Wang,J., Wang,J., Nawaz,Z., Liu,J.M., Qin,J., and Wong,J. (2000). Both 
corepressor proteins SMRT and N-CoR exist in large protein complexes containing 
HDAC3. EMBO J. 19, 4342-4350. 
Li,W., Zhang,B., Tang,J., Cao,Q., Wu,Y., Wu,C., Guo,J., Ling,E.A., and Liang,F. 
(2007). Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 
longevity regulator, is an oligodendroglial protein that decelerates cell differentiation 
through deacetylating alpha-tubulin. J. Neurosci. 27, 2606-2616. 
li-Youcef,N., Lagouge,M., Froelich,S., Koehl,C., Schoonjans,K., and Auwerx,J. 
(2007). Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann. 
Med. 39, 335-345. 
Liang,F., Hatanaka,Y., Saito,H., Yamamori,T., and Hashikawa,T. (2000). Differential 
expression of gamma-aminobutyric acid type B receptor-1a and -1b mRNA variants in 
GABA and non-GABAergic neurons of the rat brain. J. Comp Neurol. 416, 475-495. 
Lin,S.J., Kaeberlein,M., Andalis,A.A., Sturtz,L.A., Defossez,P.A., Culotta,V.C., 
Fink,G.R., and Guarente,L. (2002). Calorie restriction extends Saccharomyces 
cerevisiae lifespan by increasing respiration. Nature 418, 344-348. 
Ling,E.A., Kaur,C., and Wong,W.C. (1992). Expression of major histocompatibility 
complex antigens and CR3 complement receptors in activated microglia following an 
injection of ricin into the sciatic nerve in rats. Histol. Histopathol. 7, 93-100. 
Liszt,G., Ford,E., Kurtev,M., and Guarente,L. (2005). Mouse Sir2 homolog SIRT6 is a 
nuclear ADP-ribosyltransferase. J. Biol. Chem. 280, 21313-21320. 
Liu,A., Muggironi,M., Marin-Husstege,M., and Casaccia-Bonnefil,P. (2003). 
Oligodendrocyte process outgrowth in vitro is modulated by epigenetic regulation of 
cytoskeletal severing proteins. Glia 44, 264-274. 
Liu,R., McAllister,C., Lyubchenko,Y., and Sierks,M.R. (2004). Proteolytic antibody 
light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry 43, 
9999-10007. 
Longo,V.D., and Kennedy,B.K. (2006). Sirtuins in aging and age-related disease. Cell 
126, 257-268. 
LoPresti,P., and Konat,G.W. (2001). Hydrogen peroxide induces transient 




LoPrestic,P., Muma,N.A., and De Vries,G.H. (2001). Neu differentiation factor 
regulaters tau protein and mRNA in cultured neonatal oligodendrocytes. Glia. 35, 
147-155 
Lu,Q.R., Sun,T., Zhu,Z., Ma,N., Garcia,M., Stiles,C.D., and Rowitch,D.H. (2002). 
Common developmental requirement for Olig function indicates a motor 
neuron/oligodendrocyte connection. Cell 109, 75-86. 
Luo,J., Nikolaev,A.Y., Imai,S., Chen,D., Su,F., Shiloh,A., Guarente,L., and Gu,W. 
(2001). Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 
107, 137-148. 
Lusser,A., Brosch,G., Loidl,A., Haas,H., and Loidl,P. (1997). Identification of maize 
histone deacetylase HD2 as an acidic nucleolar phosphoprotein. Science 277, 88-91. 
Manser,E., Huang,H.Y., Loo,T.H., Chen,X.Q., Dong,J.M., Leung,T., and Lim,L. 
(1997). Expression of constitutively active alpha-PAK reveals effects of the kinase on 
actin and focal complexes. Mol. Cell Biol. 17, 1129-1143. 
Marin-Husstege,M., Muggironi,M., Liu,A., and Casaccia-Bonnefil,P. (2002). Histone 
deacetylase activity is necessary for oligodendrocyte lineage progression. J. Neurosci. 
22, 10333-10345. 
Matsuyama,A., Shimazu,T., Sumida,Y., Saito,A., Yoshimatsu,Y., Seigneurin-Berny,D., 
Osada,H., Komatsu,Y., Nishino,N., Khochbin,S., Horinouchi,S., and Yoshida,M. 
(2002). In vivo destabilization of dynamic microtubules by HDAC6-mediated 
deacetylation. EMBO J. 21, 6820-6831. 
Mattson,M.P., and Cheng,A. (2006). Neurohormetic phytochemicals: Low-dose toxins 
that induce adaptive neuronal stress responses. Trends Neurosci. 29, 632-639. 
Melendez-Vasquez,C.V., Einheber,S., and Salzer,J.L. (2004). Rho kinase regulates 
schwann cell myelination and formation of associaterd axonal domains. J. Neurosci. 
24,3953-3963. 
McCarthy,K.D., and de,V.J. (1980). Preparation of separate astroglial and 
oligodendroglial cell cultures from rat cerebral tissue. J. Cell Biol. 85, 890-902. 
McKinnon,R.D., Matsui,T., Dubois-Dalcq,M., and Aaronson,S.A. (1990). FGF 
modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 5, 
603-614. 
McKinnon,R.D., Piras,G., Ida,J.A., Jr., and Dubois-Dalcq,M. (1993). A role for 
TGF-beta in oligodendrocyte differentiation. J. Cell Biol. 121, 1397-1407. 
McKinsey,T.A., Zhang,C.L., and Olson,E.N. (2001). Control of muscle development 
by dueling HATs and HDACs. Curr. Opin. Genet. Dev. 11, 497-504. 
 148
References 
McNaught,K.S., Shashidharan,P., Perl,D.P., Jenner,P., and Olanow,C.W. (2002). 
Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 16, 2136-2148. 
Mi,S., Miller,R.H., Lee,X., Scott,M.L., Shulag-Morskaya,S., Shao,Z., Chang,J., 
Thill,G., Levesque,M., Zhang,M., Hession,C., Sah,D., Trapp,B., He,Z., Jung,V., 
McCoy,J.M., and Pepinsky,R.B. (2005). LINGO-1 negatively regulates myelination 
by oligodendrocytes. Nat. Neurosci. 8, 745-751. 
Michailov,G.V., Sereda,M.W., Brinkmann,B.G., Fischer,T.M., Haug,B., Birchmeier,C., 
Role,L., Lai,C., Schwab,M.H. and Nave,K.A. (2004). Axonal neuregulin-1 regulates 
myelin sheath thickness. Science. 304, 700-703. 
Milne,J.C., Lambert,P.D., Schenk,S., Carney,D.P., Smith,J.J., Gagne,D.J., Jin,L., 
Boss,O., Perni,R.B., Vu,C.B., Bemis,J.E., Xie,R., Disch,J.S., Ng,P.Y., Nunes,J.J., 
Lynch,A.V., Yang,H., Galonek,H., Israelian,K., Choy,W., Iffland,A., Lavu,S., 
Medvedik,O., Sinclair,D.A., Olefsky,J.M., Jirousek,M.R., Elliott,P.J., and 
Westphal,C.H. (2007). Small molecule activators of SIRT1 as therapeutics for the 
treatment of type 2 diabetes. Nature 450, 712-716. 
Montgomery,R.L., Davis,C.A., Potthoff,M.J., Haberland,M., Fielitz,J., Qi,X., Hill,J.A., 
Richardson,J.A., and Olson,E.N. (2007). Histone deacetylases 1 and 2 redundantly 
regulate cardiac morphogenesis, growth, and contractility. Genes Dev. 21, 1790-1802. 
Morell,P., Quarles,R.H., and Norton,W.T. (1994). Myelin formation, structure and 
biochemistry. In: Basic Neurochemistry, edited by Siegel,G.J., Agranoff, B.W., Albers, 
R.W., and Molinoff, P.B. New York: Raven, pp.117-143. 
Mostoslavsky,R., Chua,K.F., Lombard,D.B., Pang,W.W., Fischer,M.R., Gellon,L., 
Liu,P., Mostoslavsky,G., Franco,S., Murphy,M.M., Mills,K.D., Patel,P., Hsu,J.T., 
Hong,A.L., Ford,E., Cheng,H.L., Kennedy,C., Nunez,N., Bronson,R., Frendewey,D., 
Auerbach,W., Valenzuela,D., Karow,M., Hottiger,M.O., Hursting,S., Barrett,J.C., 
Guarente,L., Mulligan,R., Demple,B., Yancopoulos,G.D., and Alt,F.W. (2006). 
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. 
Cell 124, 315-329. 
Motta,M.C., Divecha,N., Lemieux,M., Kamel,C., Chen,D., Gu,W., Bultsma,Y., 
McBurney,M., and Guarente,L. (2004). Mammalian SIRT1 represses forkhead 
transcription factors. Cell 116, 551-563. 
Moynihan,K.A., Grimm,A.A., Plueger,M.M., Bernal-Mizrachi,E., Ford,E., 
Cras-Meneur,C., Permutt,M.A., and Imai,S. (2005). Increased dosage of mammalian 
Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. 
Cell Metab 2, 105-117. 
Nakamura,Y., Ogura,M., Tanaka,D., and Inagaki,N. (2008). Localization of mouse 
mitochondrial SIRT proteins: Shift of SIRT3 to nucleus by co-expression with SIRT5. 
 149
References 
Biochem. Biophys. Res. Commun. 366, 174-179. 
Nawrocki,S.T., Carew,J.S., Pino,M.S., Highshaw,R.A., Andtbacka,R.H., Dunner,K., 
Jr., Pal,A., Bornmann,W.G., Chiao,P.J., Huang,P., Xiong,H., Abbruzzese,J.L., and 
McConkey,D.J. (2006). Aggresome disruption: a novel strategy to enhance 
bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66, 3773-3781. 
Nazabal,A., Dos,R.S., Bonneu,M., Saupe,S.J., and Schmitter,J.M. (2003). 
Conformational transition occurring upon amyloid aggregation of the HET-s prion 
protein of Podospora anserina analyzed by hydrogen/deuterium exchange and mass 
spectrometry. Biochemistry 42, 8852-8861. 
Nishiyama,A., Lin,X.H., Giese,N., Heldin,C.H., and Stallcup,W.B. (1996). 
Co-localization of NG2 proteoglycan and PDGF alpha-receptor on O2A progenitor 
cells in the developing rat brain. J. Neurosci. Res. 43, 299-314. 
North,B.J., and Verdin,E. (2007). Interphase nucleo-cytoplasmic shuttling and 
localization of SIRT2 during mitosis. PLoS. ONE. 2, e784. 
North,B.J., Marshall,B.L., Borra,M.T., Denu,J.M., and Verdin,E. (2003). The Human 
Sir2 Ortholog, SIRT2, Is an NAD+-Dependent Tubulin Deacetylase. Molecular Cell 
11, 437-444. 
Oh,L.Y., Larsen,P.H., Krekoski,C.A., Edwards,D.R., Donovan,F., Werb,Z., and 
Yong,V.W. (1999). Matrix metalloproteinase-9/gelatinase B is required for process 
outgrowth by oligodendrocytes. J. Neurosci. 19, 8464-8475. 
Onyango,P., Celic,I., McCaffery,J.M., Boeke,J.D., and Feinberg,A.P. (2002). SIRT3, a 
human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. 
Proc. Natl. Acad. Sci. U. S. A 99, 13653-13658. 
Osterhout,D.J., Wolven,A., Wolf,R.M., Resh,M.D., and Chao,M.V. (1999). 
Morphological Differentiation of Oligodendrocytes Requires Activation of Fyn 
Tyrosine Kinase. J. Cell Biol. 145, 1209-1218. 
Outeiro,T.F., Kontopoulos,E., Altmann,S.M., Kufareva,I., Strathearn,K.E., 
Amore,A.M., Volk,C.B., Maxwell,M.M., Rochet,J.C., McLean,P.J., Young,A.B., 
Abagyan,R., Feany,M.B., Hyman,B.T., and Kazantsev,A.G. (2007). Sirtuin 2 
inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. 
Science 317, 516-519. 
Park,B.L., Kim,Y.J., Cheong,H.S., Lee,S.O., Han,C.S., Yoon,J.H., Park,J.H., 
Chang,H.S., Park,C.S., Lee,H.S., and Shin,H.D. (2007). HDAC10 promoter 
polymorphism associated with development of HCC among chronic HBV patients. 
Biochem. Biophys. Res. Commun. 363, 776-781. 
Parker,J.A., Arango,M., Abderrahmane,S., Lambert,E., Tourette,C., Catoire,H., and 
 150
References 
Neri,C. (2005). Resveratrol rescues mutant polyglutamine cytotoxicity in nematode 
and mammalian neurons. Nat. Genet. 37, 349-350. 
Patel,N.V., Gordon,M.N., Connor,K.E., Good,R.A., Engelman,R.W., Mason,J., 
Morgan,D.G., Morgan,T.E., and Finch,C.E. (2005). Caloric restriction attenuates 
Abeta-deposition in Alzheimer transgenic models. Neurobiol. Aging 26, 995-1000. 
Peinado,H., Ballestar,E., Esteller,M., and Cano,A. (2004). Snail mediates E-cadherin 
repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 
complex. Mol. Cell Biol. 24, 306-319. 
Peles,E. and Salzer,J.L. (2000). Molecular domains of myelinated axons. Curr. Opin. 
Neurobiol. 10, 558-565. 
Perrod,S., Cockell,M.M., Laroche,T., Renauld,H., Ducrest,A.L., Bonnard,C., and 
Gasser,S.M. (2001). A cytosolic NAD-dependent deacetylase, Hst2p, can modulate 
nucleolar and telomeric silencing in yeast. EMBO J. 20, 197-209. 
Pfeiffer,S.E., Warrington,A.E., and Bansal,R. (1993). The oligodendrocyte and its 
many cellular processes. Trends in Cell Biology 3, 191-197. 
Piperno,G., LeDizet,M., and Chang,X.J. (1987). Microtubules containing acetylated 
alpha-tubulin in mammalian cells in culture. J. Cell Biol. 104, 289-302. 
Poncet,C., Soula,C., Trousse,F., Kan,P., Hirsinger,E., Pourquie,O., Duprat,A.M., and 
Cochard,P. (1996). Induction of oligodendrocyte progenitors in the trunk neural tube 
by ventralizing signals: effects of notochord and floor plate grafts, and of sonic 
hedgehog. Mech. Dev. 60, 13-32. 
Pringle,N.P., Yu,W.P., Guthrie,S., Roelink,H., Lumsden,A., Peterson,A.C., and 
Richardson,W.D. (1996). Determination of neuroepithelial cell fate: induction of the 
oligodendrocyte lineage by ventral midline cells and sonic hedgehog. Dev. Biol. 177, 
30-42. 
Qi,Y., Cai,J., Wu,Y., Wu,R., Lee,J., Fu,H., Rao,M., Sussel,L., Rubenstein,J., and 
Qiu,M. (2001). Control of oligodendrocyte differentiation by the Nkx2.2 
homeodomain transcription factor. Development 128, 2723-2733. 
Qin,W., Yang,T., Ho,L., Zhao,Z., Wang,J., Chen,L., Zhao,W., Thiyagarajan,M., 
MacGrogan,D., Rodgers,J.T., Puigserver,P., Sadoshima,J., Deng,H., Pedrini,S., 
Gandy,S., Sauve,A.A., and Pasinetti,G.M. (2006). Neuronal SIRT1 activation as a 
novel mechanism underlying the prevention of Alzheimer disease amyloid 
neuropathology by calorie restriction. J. Biol. Chem. 281, 21745-21754. 
Quarles,R.H. (1997). Glycoproteins of myelin sheaths. J. Mol. Neurosci. 8, 1-12. 
Raff,M., Apperly,J., Kondo,T., Tokumoto,Y., and Tang,D. (2001). Timing cell-cycle 
 151
References 
exit and differentiation in oligodendrocyte development. Novartis. Found. Symp. 237, 
100-107. 
Rajan,R.S., and Kopito,R.R. (2005). Suppression of wild-type rhodopsin maturation 
by mutants linked to autosomal dominant retinitis pigmentosa. J. Biol. Chem. 280, 
1284-1291. 
Rasband,M.N., and Trimmer,J.S. (2001). Developmental clustering of ion channels at 
and near the node of Ranvier. Dev. Biol. 236, 5-16. 
Rasouri,S., Lagouge,M., and Auwerx,J. (2007). [SIRT1/PGC-1: a neuroprotective 
axis?]. Med. Sci. (Paris) 23, 840-844. 
Refolo,L.M., Wittenberg,I.S., Friedrich,V.L., Jr., and Robakis,N.K. (1991). The 
Alzheimer amyloid precursor is associated with the detergent-insoluble cytoskeleton. 
J. Neurosci. 11, 3888-3897. 
Richter-Landsberg,C. (2001). Organization and functional roles of the cytoskeleton in 
oligodendrocytes. Microsc. Res. Tech. 52, 628-636. 
Richter-Landsberg,C. (2008). The cytoskeleton in oligodendrocytes. Microtubule 
dynamics in health and disease. J. Mol. Neurosci. 35, 55-63. 
Richter-Landsberg,C., and Heinrich,M. (1996). OLN-93: a new permanent 
oligodendroglia cell line derived from primary rat brain glial cultures. J. Neurosci. 
Res. 45, 161-173. 
Riley,N.E., Bardag-Gorce,F., Montgomery,R.O., Li,J., Lungo,W., Lue,Y.H., and 
French,S.W. (2003). Microtubules are required for cytokeratin aggresome (Mallory 
body) formation in hepatocytes: an in vitro study. Exp. Mol. Pathol. 74, 173-179.  
Rio Hortega, D.P. (1921). Histogenesis y evolucion normal; exodo y distribucion 
sregional de la microglia. Memor. Real. Soc. Esp. Hist. Nat. 11, 213-268.  
Robertson,K.D., it-Si-Ali,S., Yokochi,T., Wade,P.A., Jones,P.L., and Wolffe,A.P. 
(2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses 
transcription from E2F-responsive promoters. Nat. Genet. 25, 338-342. 
Robinson,S., Tani,M., Strieter,R.M., Ransohoff,R.M., and Miller,R.H. (1998). The 
chemokine growth-regulated oncogene-alpha promotes spinal cord oligodendrocyte 
precursor proliferation. J. Neurosci. 18, 10457-10463. 
Robson,S.J., and Burgoyne,R.D. (1989). Differential localisation of tyrosinated, 
detyrosinated, and acetylated alpha-tubulins in neurites and growth cones of dorsal 
root ganglion neurons. Cell Motil. Cytoskeleton 12, 273-282. 
Rodgers,J.T., Lerin,C., Haas,W., Gygi,S.P., Spiegelman,B.M., and Puigserver,P. 
 152
References 
(2005). Nutrient control of glucose homeostasis through a complex of PGC-1alpha 
and SIRT1. Nature 434, 113-118. 
Rundlett,S.E., Carmen,A.A., Kobayashi,R., Bavykin,S., Turner,B.M., and 
Grunstein,M. (1996). HDA1 and RPD3 are members of distinct yeast histone 
deacetylase complexes that regulate silencing and transcription. Proc. Natl. Acad. Sci. 
U. S. A 93, 14503-14508. 
Ryan,M.C., Shooter,E.M., and Notterpek,L. (2002). Aggresome formation in 
neuropathy models based on peripheral myelin protein 22 mutations. Neurobiol. Dis. 
10, 109-118. 
Ryu,J.K., Lee,W.J., Lee,K.H., Hwang,J.H., Kim,Y.T., Yoon,Y.B., and Kim,C.Y. (2006). 
SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and 
apoptosis in pancreatic cancer cell lines. Cancer Lett. 237, 143-154. 
Sahara,N., Lewis,J., DeTure,M., McGowan,E., Dickson,D.W., Hutton,M., and 
Yen,S.H. (2002). Assembly of tau in transgenic animals expressing P301L tau: 
alteration of phosphorylation and solubility. J. Neurochem. 83, 1498-1508. 
Sakurai,A., Okamoto,K., Fujita,Y., Nakazato,Y., Wakabayashi,K., Takahashi,H., and 
Gonatas,N.K. (2000). Fragmentation of the Golgi apparatus of the ballooned neurons 
in patients with corticobasal degeneration and Creutzfeldt-Jakob disease. Acta 
Neuropathol. (Berl) 100, 270-274. 
Salzer,J.L. (1995). Mechanisms of adhesion between axons and glial cells. In The 
Axon, Waxman,S., Kocsis,J., and Stys,P, eds. New York: Oxford University press, 
pp.164-184. 
Salzer,J.L. (2003). Polarized domains of myelinated axons. Neuron. 40, 297-318. 
Sanchez,I., Hassinger,L., Paskevich,P.A., Shine,H.D., and Nixon,R.A. (1996). 
Oligodendroglia regulate the regional expansion of axon caliber and local 
accumulation of neurofilaments during development independently of myelin 
formation. J. Neurosci. 16, 5095-5105. 
Scher,M.B., Vaquero,A., and Reinberg,D. (2007). SirT3 is a nuclear NAD+-dependent 
histone deacetylase that translocates to the mitochondria upon cellular stress. Genes 
Dev. 21, 920-928. 
Schlierf,B., Werner,T., Glaser,G., Wegner,M.(2006). Expression of connexin47 in 
oligodendrocytes is regulated by the Sox10 transcription factor. J. Mol. Biol. 
361:11-21.  
Schnell,R., and Rine,J. (1986). A position effect on the expression of a tRNA gene 
mediated by the SIR genes in Saccharomyces cerevisiae. Mol. Cell Biol. 6, 494-501. 
 153
References 
Schuetz,A., Min,J., Antoshenko,T., Wang,C.L., lali-Hassani,A., Dong,A., Loppnau,P., 
Vedadi,M., Bochkarev,A., Sternglanz,R., and Plotnikov,A.N. (2007). Structural basis 
of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure. 
15, 377-389. 
Seeler,J.S., and Dejean,A. (1999). The PML nuclear bodies: actors or extras? Curr. 
Opin. Genet. Dev. 9, 362-367. 
Seigneurin-Berny,D., Verdel,A., Curtet,S., Lemercier,C., Garin,J., Rousseaux,S., and 
Khochbin,S. (2001). Identification of components of the murine histone deacetylase 6 
complex: link between acetylation and ubiquitination signaling pathways. Mol. Cell 
Biol. 21, 8035-8044. 
Selkoe,D.J. (2003). Folding proteins in fatal ways. Nature 426, 900-904. 
Shahbazian,M.D., and Grunstein,M. (2007). Functions of site-specific histone 
acetylation and deacetylation. Annu. Rev. Biochem. 76, 75-100. 
Shen,S., Li,J., and Casaccia-Bonnefil,P. (2005). Histone modifications affect timing of 
oligodendrocyte progenitor differentiation in the developing rat brain. J. Cell Biol. 
169, 577-589. 
Shi,T., Wang,F., Stieren,E., and Tong,Q. (2005). SIRT3, a mitochondrial Sirtuin 
deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. 
J. Biol. Chem. 280, 13560-13567. 
Shimazu,T., Horinouchi,S., and Yoshida,M. (2007). Multiple histone deacetylases and 
the CREB-binding protein regulate pre-mRNA 3'-end processing. J. Biol. Chem. 282, 
4470-4478. 
Shinder,G.A., Lacourse,M.C., Minotti,S., and Durham,H.D. (2001). Mutant 
Cu/Zn-superoxide dismutase proteins have altered solubility and interact with heat 
shock/stress proteins in models of amyotrophic lateral sclerosis. J. Biol. Chem. 276, 
12791-12796. 
Shindler,K.S., Ventura,E., Rex,T.S., Elliott,P., and Rostami,A. (2007). SIRT1 
activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol. 
Vis. Sci. 48, 3602-3609. 
Shogren-Knaak,M., Ishii,H., Sun,J.M., Pazin,M.J., Davie,J.R., and Peterson,C.L. 
(2006). Histone H4-K16 acetylation controls chromatin structure and protein 
interactions. Science 311, 844-847. 
Shore,D., Squire,M., and Nasmyth,K.A. (1984). Characterization of two genes 




Sinclair,D.A., and Guarente,L. (1997). Extrachromosomal rDNA circles--a cause of 
aging in yeast. Cell 91, 1033-1042. 
Smith,J.S., and Boeke,J.D. (1997). An unusual form of transcriptional silencing in 
yeast ribosomal DNA. Genes Dev. 11, 241-254.  
Smith,J.S., Brachmann,C.B., Celic,I., Kenna,M.A., Muhammad,S., Starai,V.J., 
Avalos,J.L., Escalante-Semerena,J.C., Grubmeyer,C., Wolberger,C., and Boeke,J.D. 
(2000). A phylogenetically conserved NAD+-dependent protein deacetylase activity 
in the Sir2 protein family. Proc. Natl. Acad. Sci. U. S. A 97, 6658-6663.  
Smith,K.J., Blakemore,W.F., Murray,J.A., and Patterson,R.C. (1982). Internodal 
myelin volume and axon surface area: A relationship determining myelin thickness? J. 
Neurol. Sci. 55, 231-246. 
Sohn,J., Natale,J., Chew,L.J., Belachew,S., Cheng,Y., Aguirre,A., Lytle,J., 
Nait-Oumesmar,B., Kerninon,C., Kanai-Azuma,M., Kanai,Y., and Gallo,V. (2006). 
Identification of Sox17 as a transcription factor that regulates oligodendrocyte 
development. J. Neurosci. 26, 9722-9735. 
 
Sommer,I., and Schachner,M. (1981). Monoclonal antibodies (O1 to O4) to 
oligodendrocyte cell surfaces: an immunocytological study in the central nervous 
system. Dev. Biol. 83, 311-327. 
Southwood,C.M., Garbern,J., Jiang,W., and Gow,A. (2002). The unfolded protein 
response modulates disease severity in Pelizaeus-Merzbacher disease. Neuron 36, 
585-596. 
Southwood,C.M., He,C., Garbern,J., Kamholz,J., Arroyo,E., and Gow,A. (2004). CNS 
myelin paranodes require Nkx6-2 homeoprotein transcriptional activity for normal 
structure. J. Neurosci. 24, 11215-11225. 
Southwood,C.M., Peppi,M., Dryden,S., Tainsky,M.A., and Gow,A. (2007). 
Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem. Res. 
32, 187-195. 
Sprinkle,T.J. (1989). 2',3'-cyclic nucleotide 3'-phosphodiesterase, an 
oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. 
Crit Rev. Neurobiol. 4, 235-301. 
Sriram,S.R., Li,X., Ko,H.S., Chung,K.K., Wong,E., Lim,K.L., Dawson,V.L., and 
Dawson,T.M. (2005). Familial-associated mutations differentially disrupt the 
solubility, localization, binding and ubiquitination properties of parkin. Hum. Mol. 
Genet. 14, 2571-2586. 
Stolt,C.C., Rehberg,S., Ader,M., Lommes,P., Riethmacher,D., Schachner,M., 
Bartsch,U., Wegner,M.(2002). Terminal differentiation of myelin-forming 
 155
References 
oligodendrocytes depends on the transcription factor Sox10.Genes Dev. 16,165-70. 
Stolt,C.C., Lommes,P., Sock,E., Chaboissier,M.C., Schedl,A., and Wegner,M. (2003). 
The Sox9 transcription factor determines glial fate choice in the developing spinal 
cord. Genes Dev. 17, 1677-1689. 
Stolt,C.C., Lommes,P., Friedrich,R.P., and Wegner,M. (2004). Transcription factors 
Sox8 and Sox10 perform non-equivalent roles during oligodendrocyte development 
despite functional redundancy. Development 131, 2349-2358. 
Stolt,C.C., Schmitt,S., Lommes,P., Sock,E., Wegner, M. (2005). Impact of 
transcription factor Sox8 on oligodendrocyte specification in the mouse embryonic 
spinal cord. Dev Biol. 15, 309-17. 
Strahl,B.D., and Allis,C.D. (2000). The language of covalent histone modifications. 
Nature 403, 41-45. 
Suter,U., and Scherer,S.S. (2003). Disease mechanisms in inherited neuropathies. Nat. 
Rev. Neurosci. 4, 714-726. 
Suzuki,K., and Koike,T. (2007). Resveratrol abolishes resistance to axonal 
degeneration in slow Wallerian degeneration (WldS) mice: activation of SIRT2, an 
NAD-dependent tubulin deacetylase. Biochem. Biophys. Res. Commun. 359, 
665-671. 
Swanton,E., Holland,A., High,S., and Woodman,P. (2005). Disease-associated 
mutations cause premature oligomerization of myelin proteolipid protein in the 
endoplasmic reticulum. Proc. Natl. Acad. Sci. U. S. A 102, 4342-4347. 
Tanaka,M., Kim,Y.M., Lee,G., Junn,E., Iwatsubo,T., and Mouradian,M.M. (2004). 
Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective. J. Biol. 
Chem. 279, 4625-4631. 
Tang,D.G., Tokumoto,Y.M., Apperly,J.A., Lloyd,A.C., and Raff,M.C. (2001). Lack of 
replicative senescence in cultured rat oligodendrocyte precursor cells. Science 291, 
868-871. 
Tanner,K.G., Landry,J., Sternglanz,R., and Denu,J.M. (2000). Silent information 
regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique 
product, 1-O-acetyl-ADP-ribose. Proc. Natl. Acad. Sci. U. S. A 97, 14178-14182. 
Tanny,J.C., Dowd,G.J., Huang,J., Hilz,H., and Moazed,D. (1999). An enzymatic 
activity in the yeast Sir2 protein that is essential for gene silencing. Cell 99, 735-745. 
Taunton,J., Hassig,C.A., and Schreiber,S.L. (1996). A mammalian histone deacetylase 
related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411. 
 156
References 
Taylor,J.P., Hardy,J., and Fischbeck,K.H. (2002). Toxic proteins in neurodegenerative 
disease. Science 296, 1991-1995. 
Temple,S., and Raff,M.C. (1986). Clonal analysis of oligodendrocyte development in 
culture: evidence for a developmental clock that counts cell divisions. Cell 44, 
773-779. 
Thompson,J.S., Ling,X., and Grunstein,M. (1994). Histone H3 amino terminus is 
required for telomeric and silent mating locus repression in yeast. Nature 369, 
245-247. 
Timsit,S., Martinez,S., Allinquant,B., Peyron,F., Puelles,L., and Zalc,B. (1995). 
Oligodendrocytes originate in a restricted zone of the embryonic ventral neural tube 
defined by DM-20 mRNA expression. J. Neurosci. 15, 1012-1024. 
Tissenbaum,H.A., and Guarente,L. (2001). Increased dosage of a sir-2 gene extends 
lifespan in Caenorhabditis elegans. Nature 410, 227-230. 
Tobler,A.R., Liu,N., Mueller,L., and Shooter,E.M. (2002). Differential aggregation of 
the Trembler and Trembler J mutants of peripheral myelin protein 22. Proc. Natl. 
Acad. Sci. U. S. A 99, 483-488. 
Trousse,F., Giess,M.C., Soula,C., Ghandour,S., Duprat,A.M., and Cochard,P. (1995). 
Notochord and floor plate stimulate oligodendrocyte differentiation in cultures of the 
chick dorsal neural tube. J. Neurosci. Res. 41, 552-560. 
Turner,B.M., Birley,A.J., and Lavender,J. (1992). Histone H4 isoforms acetylated at 
specific lysine residues define individual chromosomes and chromatin domains in 
Drosophila polytene nuclei. Cell 69, 375-384. 
Uhm,J.H., Dooley,N.P., Oh,L.Y., and Yong,V.W. (1998). Oligodendrocytes utilize a 
matrix metalloproteinase, MMP-9, to extend processes along an astrocyte 
extracellular matrix. Glia 22, 53-63. 
Ursell,M.R., McLaurin,J., Wood,D.D., Ackerley,C.A., and Moscarello,M.A. (1995). 
Localization and partial characterization of a 60 kDa citrulline-containing transport 
form of myelin basic protein from MO3-13 cells and human white matter. J. Neurosci. 
Res. 42, 41-53. 
Umemori,H., Sato,S., Yagi,T., Aizawa,S., and Yamamoto,T. (1994). Initial events of 
myelination involve Fyn tyrosine kinase signaling. Nature. 367, 572-576. 
Vanrobaeys,F., Van,C.R., Dhondt,G., Devreese,B., and Van,B.J. (2005). Profiling of 
myelin proteins by 2D-gel electrophoresis and multidimensional liquid 




Vaquero,A., Scher,M.B., Lee,D.H., Sutton,A., Cheng,H.L., Alt,F.W., Serrano,L., 
Sternglanz,R., and Reinberg,D. (2006). SirT2 is a histone deacetylase with preference 
for histone H4 Lys 16 during mitosis. Genes Dev. 20, 1256-1261. 
Vaziri,H., Dessain,S.K., Ng,E.E., Imai,S.I., Frye,R.A., Pandita,T.K., Guarente,L., and 
Weinberg,R.A. (2001). hSIR2(SIRT1) functions as an NAD-dependent p53 
deacetylase. Cell 107, 149-159. 
Verdin,E., Dequiedt,F., and Kasler,H. (2004). HDAC7 regulates apoptosis in 
developing thymocytes. Novartis. Found. Symp. 259, 115-129. 
Verdin,E., Dequiedt,F., and Kasler,H.G. (2003). Class II histone deacetylases: versatile 
regulators. Trends Genet. 19, 286-293. 
Vidal,M., and Gaber,R.F. (1991). RPD3 encodes a second factor required to achieve 
maximum positive and negative transcriptional states in Saccharomyces cerevisiae. 
Mol. Cell Biol. 11, 6317-6327. 
Vidal,M., Strich,R., Esposito,R.E., and Gaber,R.F. (1991). RPD1 (SIN3/UME4) is 
required for maximal activation and repression of diverse yeast genes. Mol. Cell Biol. 
11, 6306-6316. 
Voelter-Mahlknecht,S., Ho,A.D., and Mahlknecht,U. (2005). FISH-mapping and 
genomic organization of the NAD-dependent histone deacetylase gene, Sirtuin 2 
(Sirt2). Int. J. Oncol. 27, 1187-1196. 
Wang,A.H., Kruhlak,M.J., Wu,J., Bertos,N.R., Vezmar,M., Posner,B.I., 
Bazett-Jones,D.P., and Yang,X.J. (2000). Regulation of histone deacetylase 4 by 
binding of 14-3-3 proteins. Mol. Cell Biol. 20, 6904-6912. 
Wang,F., Nguyen,M., Qin,F.X., and Tong,Q. (2007a). SIRT2 deacetylates FOXO3a in 
response to oxidative stress and caloric restriction. Aging Cell 6, 505-514. 
Wang,H.Y., Chien,H.C., Osada,N., Hashimoto,K., Sugano,S., Gojobori,T., Chou,C.K., 
Tsai,S.F., Wu,C.I., and Shen,C.K. (2007b). Rate of evolution in brain-expressed genes 
in humans and other primates. PLoS. Biol. 5, e13. 
Wang,J., Dickson,D.W., Trojanowski,J.Q., and Lee,V.M. (1999). The levels of soluble 
versus insoluble brain Abeta distinguish Alzheimer's disease from normal and 
pathologic aging. Exp. Neurol. 158, 328-337. 
Wang,J., Zhai,Q., Chen,Y., Lin,E., Gu,W., McBurney,M.W., and He,Z. (2005). A local 
mechanism mediates NAD-dependent protection of axon degeneration. J. Cell Biol. 
170, 349-355. 
Ward,C.L., Omura,S., and Kopito,R.R. (1995). Degradation of CFTR by the 
ubiquitin-proteasome pathway. Cell 83, 121-127. 
 158
References 
Wegner,M. (2000). Transcriptional control in myelinating glia: the basic recipe. Glia. 
29,118-123. 
Weindruch,R. (1996). The retardation of aging by caloric restriction: studies in 
rodents and primates. Toxicol. Pathol. 24, 742-745. 
Werner,H.B., Kuhlmann,K., Shen,S., Uecker,M., Schardt,A., Dimova,K., 
Orfaniotou,F., Dhaunchak,A., Brinkmann,B.G., Mobius,W., Guarente,L., 
Casaccia-Bonnefil,P., Jahn,O., and Nave,K.A. (2007). Proteolipid protein is required 
for transport of Sirtuin 2 into CNS myelin. J. Neurosci. 27, 7717-7730. 
Wilson,A.J., Byun,D.S., Popova,N., Murray,L.B., L'Italien,K., Sowa,Y., Arango,D., 
Velcich,A., Augenlicht,L.H., and Mariadason,J.M. (2006). Histone deacetylase 3 
(HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression 
and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548-13558. 
Wiper-Bergeron,N., Wu,D., Pope,L., Schild-Poulter,C., and Hache,R.J. (2003). 
Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 
complex. EMBO J. 22, 2135-2145. 
Wotton,D., Lo,R.S., Lee,S., and Massague,J. (1999). A Smad transcriptional 
corepressor. Cell 97, 29-39. 
Yamashita,Y., Shimada,M., Harimoto,N., Rikimaru,T., Shirabe,K., Tanaka,S., and 
Sugimachi,K. (2003). Histone deacetylase inhibitor trichostatin A induces cell-cycle 
arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int. J. Cancer 
103, 572-576. 
Yang,W.M., Yao,Y.L., Sun,J.M., Davie,J.R., and Seto,E. (1997). Isolation and 
characterization of cDNAs corresponding to an additional member of the human 
histone deacetylase gene family. J. Biol. Chem. 272, 28001-28007. 
Yang,X.J. (2004). Lysine acetylation and the bromodomain: a new partnership for 
signaling. Bioessays 26, 1076-1087. 
Yeung,F., Hoberg,J.E., Ramsey,C.S., Keller,M.D., Jones,D.R., Frye,R.A., and 
Mayo,M.W. (2004). Modulation of NF-kappaB-dependent transcription and cell 
survival by the SIRT1 deacetylase. EMBO J. 23, 2369-2380. 
Yool,D.A., Edgar,J.M., Montague,P., and Malcolm,S. (2000). The proteolipid protein 
gene and myelin disorders in man and animal models. Hum. Mol. Genet. 9, 987-992. 
Youn,H.D., Grozinger,C.M., and Liu,J.O. (2000). Calcium regulates transcriptional 
repression of myocyte enhancer factor 2 by histone deacetylase 4. J. Biol. Chem. 275, 
22563-22567. 
Zeng,L., and Zhou,M.M. (2002). Bromodomain: an acetyl-lysine binding domain. 
 159
References 
FEBS Lett. 513, 124-128. 
Zeng,Y., Tang,C.M., Yao,Y.L., Yang,W.M., and Seto,E. (1998). Cloning and 
characterization of the mouse histone deacetylase-2 gene. J. Biol. Chem. 273, 
28921-28930. 
Zhang,B., Cao,Q., Guo,A., Chu,H., Chan,Y.G., Buschdorf,J.P., Low,B.C., Ling,E.A., 
and Liang,F. (2005). Juxtanodin: An oligodendroglial protein that promotes cellular 
arborization and 2',3'-cyclic nucleotide-3'-phosphodiesterase trafficking. PNAS 102, 
11527-11532. 
Zhang,C.L., McKinsey,T.A., and Olson,E.N. (2002). Association of class II histone 
deacetylases with heterochromatin protein 1: potential role for histone methylation in 
control of muscle differentiation. Mol. Cell Biol. 22, 7302-7312. 
Zhao,X.H., Jin,W.L., and Ju,G. (2007). An in vitro study on the involvement of 
LINGO-1 and Rho GTPases in Nogo-A regulated differentiation of oligodendrocyte 
precursor cells. Mol. Cell Neurosci. 36, 260-269. 
Zhou,Q., Choi,G., and Anderson,D.J. (2001). The bHLH transcription factor Olig2 
promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron. 
31,791-807. 
Zhou,Q., and Anderson,D.J. (2002). The bHLH transcription factors OLIG2 and 
OLIG1 couple neuronal and glial subtype specification. Cell 109, 61-73. 
Zhu,H., Guo,Q., and Mattson,M.P. (1999). Dietary restriction protects hippocampal 
neurons against the death-promoting action of a presenilin-1 mutation. Brain Res. 842, 
224-229. 
Zhuang,H., Kim,Y.S., Koehler,R.C., and Dore,S. (2003). Potential mechanism by 
which resveratrol, a red wine constituent, protects neurons. Ann. N. Y. Acad. Sci. 993, 
276-286.  
 
 
 
 
 
 160
